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Summary 
Sub-Saharan Africa is the region of the world with the highest burden of malaria (WHO, 
2014), as well as some of the fastest growing cities. The 2011 United Nations report (UN, 
2014a) estimated that by 2013 40% of the population of sub-Saharan Africa would live in 
urban areas, projected to become a total urbanised population of 760 million by 2030. 
Urbanisation has a significant impact on the economy, lifestyles, ecosystems and disease 
patterns (Omumbo et al., 2005). 
Although historically considered a rural disease, malaria transmission does occur in urban 
Africa, causing specific challenges for inhabitants, notably the heterogeneous spatial 
distribution of risk and the low level of acquired immunity of citizens, who are therefore 
exposed to higher risk of severe disease (Robert et al., 2003). Kinshasa, the capital of the 
Democratic Republic of the Congo (DRC) and the third largest city in Africa, has undergone 
rapid urbanisation during the past decades, presenting today a heterogeneous pattern of land 
use. However, there is a paucity of information on the geographic distribution of malaria 
prevalence in urban Kinshasa and on the risk factors linked to its distribution.  
The overall aim of the first part of this thesis was to update the distribution map of malaria in 
Kinshasa, since the latest epidemiological study was conducted in 2000 (Kazadi et al., 2004), 
and to update information on malaria control activities. Field research was initially conducted 
in 2009 by the School of Public Health of Kinshasa (KSPH), which sampled nine out of the 
32 non-rural health zones (HZs); the remaining 23 were sampled during fieldwork conducted 
in 2011 by the Swiss Tropical and Public Health Institute (Swiss TPH) in collaboration with 
the KSPH. Two HZs already sampled in 2009 were resampled in the 2011 survey, bringing 
the total of HZs sampled in 2011 to 25.  
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In the first step (detailed in Chapter 3), which took place at the end of the 2011 rainy season, 
we undertook a cross-sectional survey to complete those urban and peri-urban HZs of 
Kinshasa that had not been sampled during the 2009 survey to assess the prevalence of 
malaria by Rapid Diagnostic Test (RDT) among children aged six to 59 months, anaemia and 
history of fever, and to obtain a comprehensive report on the state of key preventive malaria 
indicators. Point-referenced prevalence data from the two surveys and seasons were combined 
by indirect standardisation and mapped at the level of the health areas (HAs) by means of a 
geographic information system (GIS). The overall standardised malaria prevalence was found 
to be 11.7%, showing a decline over the previous two decades, with higher risk in the peri-
urban areas compared to the more central urban areas. We observed considerable progress in 
key malaria indicators compared to the Demographic and Health Survey 2007 (DHS-DRC, 
2007). Age groups with the highest prevalence were five to nine years and 15 to 19 years, an 
indication that malaria occurs more frequently in late childhood. This study presents the first 
comprehensive map of malaria risk in Kinshasa.  
In the second step (discussed in Chapter 4), logistic regression with random effects was used 
to investigate predictors for malaria and anaemia among children aged six to 59 months and 
for malaria in individuals older than five years across zones in Kinshasa with a prevalence of 
malaria of less than 10% and 10% or greater. Accordingly, evidence was found of a different 
age pattern in the two transmission settings. The peak prevalence of malaria in children under 
five years was observed in the 48 to 59 months group in both transmission settings, but it 
increased more gradually for the lower transmission setting. In a separate analysis, in children 
over the age of five in two selected HZs, the peak prevalence was found to be in five to nine 
year-olds in the higher transmission setting and in 15 to 19 year-olds in the lower 
transmission setting. Reported fever in the last two weeks was associated with the risk of 
having malaria in all age groups in both transmission settings, with no evidence of a 
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difference in these associations; in children older than five years however, there was a 
significant interaction with a stronger association in the low transmission HZ. Insecticide-
treated net (ITN) use was associated with a lower risk of malaria infection among children 
aged six to 59 months in the high transmission settings. Similar estimates were found in 
children over five years and the lower transmission HZ but the associations there were not 
significant. No evidence was found of a difference in these associations by strata. The risk of 
anaemia was found to decrease with increasing age, and to increase with malaria infection and 
reported fever among children aged six to 59 months. However, ITN usage did not show 
evidence of protection against anaemia. Low socioeconomic status was associated with 
malaria in high transmission settings in children aged six to 59 months and anaemia in low 
transmission settings. 
The aim of the second part of this thesis was to demonstrate the operational feasibility of 
introducing injectable artesunate in the DRC as the preferred treatment for severe malaria, to 
provide a national cost estimate and to assess the acceptability of the new drug among health-
care providers and patients. Furthermore, to assess the potential risk of delayed anaemia in 
patients, haemoglobin (hb) measurement was included at follow-up visits scheduled at days 
14, 21 and 28 after treatment with injectable artesunate had been received. 
In Chapter 5 we compare the implementation of injectable quinine and injectable artesunate in 
patients aged two months and older, through the evaluation of key components before (IV 
quinine) and after (IV/IM artesunate) the introduction of the new regimen. The time to 
discharge was lower in the artesunate compared to the quinine group. Similarly, the interval 
between admission and the start of intravenous treatment and the parasite clearance time were 
lower in the artesunate group. The overall staff pre-administration time and the personnel time 
spent on patient management were also lower in the artesunate group. In hospitals and health 
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centres, the mean total cost per patient treated for severe malaria was also found to be lower 
with injectable artesunate.  
Chapter 6 discusses a sub-study, conducted within the MATIAS study, to assess the potential 
risk of delayed anaemia secondary to injectable artesunate in patients two months and older, 
through the measurement of hb levels at follow-up visits at days 7, 14, 21 and 28. Although 
the study was limited in its design (lack of follow-up information, no additional markers of 
haemolysis), we observed a decrease in hb levels in 23 (11.4%) out of 201 patients (out of 
350, 57.4%) with complete hb measurements, from days 7 to 21. Of these 23 patients, five 
(2.5%) experienced a decrease in hb levels below 5 g/dl at at least one of the follow-up visits. 
At the day 28 clinical assessment, hb had recovered in all patients. These results point to the 
need for additional research to better understand the magnitude of delayed anaemia in African 
children. 
In the last step (Chapter 7), qualitative methods were used to investigate the feasibility of 
implementing injectable artesunate from the perspective of health-care providers, as well as 
the acceptability of the new versus the old treatment from the perspective of both health-care 
providers and patients/caretakers. It was subsequently found that the use of artesunate was 
perceived to be easier by the health-care providers, with 75% of them reporting greater ease 
of use and preparation compared to quinine. Satisfaction with the injectable artesunate was 
high among both health-care providers (61.3%) and patients/caretakers (96.7%). Altogether, 
our work documented the feasibility, acceptability, greater operational simplicity and lower 
cost of injectable artesunate in the DRC, hence supporting its national deployment. 
In conclusion, this thesis provides the first comprehensive map of malaria risk in Kinshasa 
and an overview of the state of malaria control activities. At the same time it allows for the 
identification of the health areas where malaria control interventions should be prioritised.  
Summary 
xiii 
 
Furthermore, this thesis shows that introducing injectable artesunate in the routine care in the 
DRC is feasible and highly accepted by both health-care providers and patients/caretakers, 
thus providing the basis for practical recommendations for its rapid deployment within the 
country.  
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Résumé 
L'Afrique subsaharienne est la région du monde qui supporte le fardeau le plus lourd en terme 
de cas de paludisme et de décès dus au paludisme (OMS, 2014) et avec quelques-unes des 
villes à croissance très rapide. Selon le rapport de 2011 des Nations Unies (ONU, 2014A), on 
estime que 40% de la population en Afrique subsaharienne vivaient dans des zones urbaines 
en 2013; c’est prévu qu'ils deviendront 760 millions d'ici 2030. L'urbanisation a un impact 
significatif sur l'économie, les modes de vie, les écosystèmes et les types de maladies 
(Omumbo et al., 2005). 
Bien que historiquement considérée comme une maladie rurale, le paludisme en Afrique se 
transmet aussi dans les zones urbaines et qui cause des défis pour leurs habitants, notamment 
la distribution spatiale hétérogène du risque et le faible niveau de l'immunité acquise des 
citoyens donc exposés à un risque plus élevé de complications graves de la maladie (Robert et 
al., 2003). Kinshasa, capitale de la République Démocratique du Congo (RDC) et troisième 
plus grande ville d'Afrique a connu une urbanisation rapide au cours des dernières décennies, 
et elle présente aujourd'hui un pattern d’utilisation des terres très hétérogènes. Cependant, il y 
a pénurie d'informations sur la répartition géographique de la prévalence du paludisme dans la 
ville de Kinshasa et sur les facteurs de risque liés à sa distribution. 
L'objectif de la première partie de cette thèse est de mettre à jour la carte de distribution du 
paludisme à Kinshasa, puisque la dernière étude épidémiologique a été menée en 2000 
(Kazadi et al., 2004) et aussi les informations sur les activités de lutte contre le paludisme. La 
recherche sur le terrain a été initialement réalisée en 2009 par l'Ecole de Santé Publique de 
Kinshasa (KSPH), qui a échantillonné 9 zones de santé (ZS) sur 32 non rurales, alors que les 
23 autres ont été échantillonnées au cours de l’enquête menée en 2011 par le Swiss TPH en 
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collaboration avec le KSPH. Deux ZS déjà enquêtées en 2009 ont été reéchantillonnées en 
2011, pour un totale de 25 ZS échantillonnées en 2011. 
Dans une première étape (chapitre 3), à la fin de la saison des pluies 2011, nous avons conduit 
une enquête transversale pour compléter ces ZS urbaines et péri-urbaines de Kinshasa qui 
n’ont pas été échantillonnées au cours de l'enquête 2009, afin d'évaluer la prévalence du 
paludisme (par TDR) chez les enfants de 6 à 59 mois, l'anémie et l'histoire de la fièvre, et 
d'obtenir un rapport complet sur l'état des indicateurs clés de prévention du paludisme. Les 
données sur la prévalence du paludisme des deux enquêtes et de deux saisons ont été 
combinées par standardisation indirecte et cartographiées au niveau des zones de santé (HA) 
au moyen d'un système d'information géographique (SIG). La prévalence du paludisme 
standardisé était de 11,7% montrant une baisse au cours des deux dernières décennies, et avec 
un risque plus élevé dans les zones péri-urbaines par rapport aux zones centrales plus 
urbanisées. Nous avons observé des progrès considérables dans les indicateurs clés du 
paludisme par rapport à l'Enquête Démographique et de Santé 2007 (EDS-RDC, 2007). Les 
groupes d'âge avec la plus forte prévalence étaient les 5-9 et 15-19 ans, une indication que le 
paludisme survient de plus en plus à la fin de l'enfance. Cette étude présente la première carte 
du risque de paludisme à Kinshasa. 
Dans une deuxième étape, (chapitre 4) une régression logistique avec des effets aléatoires a 
été utilisée pour étudier les facteurs de risque du paludisme chez les enfants de 6 à 59 mois et 
chez les individus âgés de plus de cinq ans et de l'anémie chez les enfants de 6 à 59 mois dans 
des zones à Kinshasa avec une prévalence du paludisme de moins de 10% et de plus de 10%. 
Il y avait des preuves d'un profil d’âge différent dans les deux zones de transmission. Le pic 
de prévalence du paludisme chez les enfants de moins de cinq ans a été observé dans le 
groupe d’âge 48 à 59 mois dans les deux zones de transmission, mais il a augmenté plus 
doucement pour les zones à transmission plus faible. Dans une analyse séparée chez les 
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enfants de plus de cinq ans dans deux ZS sélectionnées, la prévalence la plus élevée était chez 
le groupe d’âge 5-9 ans dans la ZS à transmission plus élevée et chez le 15-19 ans dans la ZS 
à transmission moins élevée. La fièvre rapportée au cours des deux dernières semaines a été 
associée au risque du paludisme dans tous les groupes d'âge dans les deux zones de 
transmission avec aucune évidence d'une différence de ces associations; par contre, chez les 
enfants âgés de plus de cinq ans il y avait une interaction significative avec une association 
plus forte dans la ZS à transmission plus faible. L'utilisation de la moustiquaire imprégnée 
d'insecticide (ITN) a été associée à un risque d'infection du paludisme inférieure chez les 
enfants de 6 à 59 mois dans les zones de forte transmission. Des estimations similaires ont été 
trouvées chez les enfants de plus de cinq ans dans les ZS à transmission plus faible, mais ces 
associations ne sont pas significatives. Il n'y avait aucune preuve d'une différence de ces 
associations par strates. Le risque d'anémie diminue avec l'âge, et augmente avec l'infection 
du paludisme et la fièvre rapporté chez les enfants de 6-59 mois. L’utilisation des MII n'a pas 
mis en évidence de la protection contre l'anémie. Le faible statut socio-économique a été 
associé à la malaria dans dans le ZS à forte transmission chez les enfants de 6-59 mois et à 
l'anémie dans les ZS à transmission plus faible. 
L'objectif de la deuxième partie de cette thèse est de démontrer la faisabilité opérationnelle de 
l'introduction de l'artésunate injectable en RDC comme traitement privilégié pour le 
paludisme sévère, de fournir une estimation nationale des coûts, et d'évaluer l'acceptabilité du 
nouveau médicament chez les prestataires de soins de santé et les patients. En outre, pour 
évaluer le risque potentiel de l'anémie retardée chez les patients, la mesure de l’hémoglobine 
(hb) a été incluse lors de la visite de suivi aux jours 14, 21, 28 après le traitement par 
artésunate injectable. 
Dans le chapitre 5, nous avons comparé la mise en œuvre de la quinine injectable avec 
l'artésunate injectable chez les patients de deux mois et plus, par l'évaluation des éléments clés 
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avant (quinine IV) et après (IV / IM artésunate) l'introduction du nouveau régime. Le temps 
de décharge était inférieur dans le groupe traité avec l’artésunate par rapport au groupe traité 
avec la quinine. De même, l'intervalle entre l'admission et le début du traitement par voie 
intraveineuse et le temps de clairance parasitaire était inférieure dans le groupe artésunate. Le 
temps total de pré-administration et le temps du personnel consacré à la gestion des patients 
étaient inférieurs dans le groupe artésunate. Dans les hôpitaux et les centres de santé, le coût 
total moyen par patient traité pour le paludisme sévère avec l'artésunate injectable était 
également inférieur avec l'artésunate injectable. 
Le chapitre 6 est une sous-étude de l'étude MATIAS pour évaluer le risque potentiel de 
l'anémie retardée secondaire à l’artésunate injectable chez les patients de deux mois et plus, 
grâce à la mesure du taux d'hémoglobine lors des visites de suivi aux jours 7, 14, 21 et 28. 
Bien que l'étude ait été limitée dans la conception (manque des informations de suivi, aucun 
des marqueurs supplémentaires d'hémolyse), nous avons observé une diminution des niveaux 
d’hémoglobine dans 23 (11,4%) patients sur 201 (sur 350, 57,4%) chez les patients qui 
avaient complété toutes les mesures de l’hb à chaque visite de suivi, pendant les jours 7-21. 
Sur ces 23 patients, cinq (2,5%) ont connu une diminution des taux d'hb en-dessous de 5g / dl 
au moins une des visites de suivi. Chez tous les patients le taux d’hb avait récupéré à 
l’évaluation clinique au jour 28. Ces résultats soulignent la nécessité de recherches 
supplémentaires pour mieux comprendre l'ampleur de l'anémie retardée chez les enfants 
africains. 
Dans une dernière étape (Chapitre 7), des méthodes qualitatives ont été utilisées pour étudier 
la faisabilité de la mise en œuvre de l'artésunate injectable du point de vue des prestataires de 
soins de santé ainsi que l'acceptabilité du nouveau traitement par rapport à l'ancien du point de 
vue des prestataires de soins de santé et patients/ gardiens. L'utilisation de l'artésunate était 
perçue comme plus facile par les prestataires de soins de santé, avec 75% d'entre eux 
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rapportant une plus grande facilité d'utilisation et préparation par rapport à la quinine. Le 
niveau de satisfaction avec l'artésunate injectable était élevé chez les prestataires de soins de 
santé (61,3%) et chez les patients/ gardians (96,7%). Au total, notre travail a documenté la 
faisabilité, l'acceptabilité, une plus grande simplicité d'utilisation et un coût moindre de 
l'artésunate injectable en RDC, d'où l'appui de son déploiement national. 
En conclusion cette thèse fournit la première carte complète du risque de paludisme à 
Kinshasa et un aperçu de l'état des activités de lutte contre le paludisme. Dans le même temps, 
elle permet d'identifier les aires de santé où prioriser les interventions de lutte contre le 
paludisme. 
En outre, cette thèse montre que l'introduction de l'artésunate injectable dans les soins de 
routine en RDC est réalisable et hautement acceptée par les prestataires de soins de santé et 
les patients/ gardians, en apportant la base pour des recommandations pratiques pour son 
déploiement rapide dans le pays. 
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1. Introduction 
1.1 Global malaria distribution 
Malaria is recognised as one of the most prevalent and deadly parasitic diseases affecting 
humans worldwide. It is a major cause of morbidity and death in large areas of the developing 
world. According to the World Health Organization (WHO, 2014), at the end of 2013 there 
were 97 malaria-endemic countries (Figure 1.1) and 3.2 billion people were at risk of malaria. 
Guerra et al. (2008) reported that more than 70% of these people lived in areas at risk of P. 
falciparum transmission in 2007. Also according to the WHO, 198 million clinical cases of 
malaria were recorded globally in 2013 and 584,000 people died of the disease, representing a 
decrease in malaria case incidence and mortality rates of 30% and 47% respectively since 
2000. Nevertheless, the African region alone still accounts for 81% of reported cases and 90% 
of all malaria deaths, primarily in children under the age of five (WHO, 2014).  
 
Figure 1-1: World malaria distribution in 2014 
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1.2 Malaria disease and transmission 
Malaria is an infectious disease caused by the single-celled parasite of the genus Plasmodium, 
of which four species have been identified that regularly cause disease in humans: P. 
falciparum, P vivax, P ovale and P. malariae. The general life cycle requires two separate 
cycles of asexual reproduction in the human host (one in the liver, called the exo-erythrocytic 
cycle, and one inside the red blood cells, known as the erythrocytic cycle) and a sexual 
reproductive stage inside the mosquito definitive host (“the vector”).  
When a human is bitten by an Anopheles mosquito infected with malaria, the parasite 
(sporozoite) is introduced into the body. Within 30 minutes, the sporozoites pass into the liver 
where they reproduce asexually (schizogony) in the liver cells (exo-erythrocytic cycle). The 
sporozoites mature into schizonts and release thousands of small offspring (merozoites) into 
the bloodstream. Merozoites invade the red blood cells in which they reproduce asexually. In 
the red blood cell the form of the parasite is now known as trophozoite. The trophozoite 
subsequently undergoes asexual reproduction leading to the formation of schizonts, which 
divide to form merozoites. The infected blood cell bursts and more merozoites are released in 
the blood from where they will penetrate new red blood cells and the cycle will continue. The 
lysis of the red blood cells is accompanied by fever, triggering the onset of symptoms. After 
some time, some of the merozoites transform into male or female gametocytes, necessary for 
the sexual reproduction of the parasite. If the gametocytes are ingested during a bite from an 
Anopheles mosquito, they will undergo sexual reproduction in the mosquito and will form a 
zygote. The zygote then matures into new sporozoites, which migrate to the salivary glands 
where they will be ready to be injected into a new human host to perpetrate the malaria life 
cycle.  
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1.3 The Anopheles vector 
Malaria is transmitted by Anopheles mosquitoes. There are some 400 Anopheles species, 40 
of which are major vectors thought to be of public health importance, while 28 are poor 
vectors. The Anopheles gambiae complex in Africa includes seven species of which 
Anopheles gambiae sensu strictu, Anopheles arabiensis and Anopheles funestus are excellent 
vectors. An. gambiae sensu strictu is generally anthropophagic (prefers feeding on humans) 
and endophilic (prefers to rest indoor). An. Funestus prefers permanent water bodies, feeds 
preferably on humans, both indoors and outdoors, and rests indoors. An. arabiensis is found in 
dry savannah, feeds on animals (zoophilic) and rests outdoors (Gillies & De Meillon, 1968).   
 
1.4 Epidemiological measures of malaria risk 
The risk of acquiring malaria depends on the interaction between the host, the parasite, the 
vector and the environment. When planning malaria control activities, governments need to 
quantify the risk of infection and the endemicity levels, which can be done by using either 
indirect or direct measures of malaria transmission.  
Indirect methods measure the risk of malaria through surrogate markers of risk, such as 
rainfall, temperature, spleen rate and antibody titres. Direct methods measure the risk of 
malaria either clinically/microscopically or entomologically (Baird et al., 2002).  
The first indirect method used to quantify malaria endemicity involves determining the spleen 
rate (percentage of people in a given population with an enlarged spleen) (Dempster, 1848), 
while the parasite rate is the most common direct measure. Malaria prevalence estimates 
obtained by measuring the spleen rate and the parasite rate have been used to classify 
endemicity levels as either holoendemic, hyperendemic, mesoendemic or hypoendemic 
(Metselaar & Van Thiel, 1959).  
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Another commonly used direct measure of malaria transmission intensity is the entomological 
inoculation rate (EIR), that is, the number of infective mosquito bites received per person per 
unit of time, usually one year (Macdonald, 1957). The EIR is expressed as the product of the 
“human biting rate” (the product of the anopheles mosquito density and the average number 
of persons bitten by one mosquito in a day) and the “sporozoite rate” (the proportion of 
mosquitoes with sporozoites in their salivary glands). Africa can support a wide range of 
EIRs, with mean annual EIRs of 121 infective bites, ranging from a maximum of 884 in 
Sierra Leone to close to 0 in Burkina Faso, the Gambia and Senegal (Hay et al., 2000). 
Although it can be challenging to measure the EIR, it remains the most effective method for 
assessing the effect of anti-vector control activities (Shaukat et al., 2010).  
Incidence of malaria is the most direct measure of malarial disease. It measures the number of 
new malaria cases diagnosed during a specific period of time among all those who are 
susceptible to the disease. Incidence of malaria is useful in areas of low to moderate 
transmission rather than high transmission, where virtually everyone is infected to some 
extent at all times. Owing to the lack of laboratory confirmation of malaria, incidence of fever 
is often used as a proxy measure for incidence of malaria.  
1.5 Vector control measures  
Vector control methods can be grouped into measures directed against the parasite in the 
human host, measures against the vector and measures directed at preventing human–
mosquito contact. The use of anti-malarial agents to treat clinical malaria or as 
chemoprophylaxis for the more vulnerable groups has proven to be difficult as a result of low 
compliance with self-medication and the inability to afford a full treatment, thus encouraging 
drug resistance.  
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The two currently most common and by far the most effective ways of controlling malaria 
transmission are indoor residual spraying (IRS) and insecticide treated nets (ITNs). Together 
they account for almost 60% of global investment in malaria control (WHO, 2012a), as they 
both reduce mosquito–human contact, mosquito density and longevity. In specific settings 
and under specific circumstances, they can be used in combination or complemented by other 
methods such as larval source management. Evidence of the effectiveness of ITNs comes 
from 22 randomised controlled trials conducted on ITN campaigns, reviewed by two 
Cochrane reviews (Lengeler, 2004; Ter Kuile et al., 2003), and showing a substantial impact 
on child morbidity and mortality. Although in principle IRS and ITNs could be considered 
suitable everywhere, there are essential differences between the two. ITNs provide individual 
personal protection, even at low population coverage, while in order to be effective IRS 
requires high coverage of all potential resting places.  
 
Use of malaria control tools depends on the local malaria epidemiology and the availability of 
resources. In this context, risk maps of malaria are increasingly being recognised as a 
powerful tool to identify geographical areas for priority allocation of resources and to evaluate 
the progress of malaria intervention programmes. 
 
1.6 Mapping malaria risk 
The Pan-African Mapping Malaria Risk in Africa collaboration (MARA/ARMA, 1998) is 
based on 10,000 historical malaria parasite prevalence data collected from geographically 
positioned surveys in both published and unpublished sources, providing the first continental 
maps of malaria distribution and the first evidence-based burden of disease estimate.  
The Malaria Atlas Project (MAP) represents the most advanced attempt to map the global 
endemicity of malaria. By gathering parasite rate surveys from historical data, the MAP 
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database was able to assemble close to 3,500 estimates of parasite prevalence from a 
multitude of sources, providing a substantial basis for global malaria endemicity mapping 
within defined spatial limits (Guerra et al., 2007).  
Parasite prevalence data derived from nationally representative surveys such as the 
Demographic and Health Surveys (DHS), the Multiple Indicator Cluster Surveys (MICS) and 
Malaria Indicator Surveys (MIS) are often used to build maps for the period 2000 onwards.  
An additional source of data for risk mapping is routine case statistics. Using clinical 
incidence data is particularly appropriate in areas of low transmission, where people will be 
more likely to develop symptoms. Such data must be based on a reliable disease surveillance 
system but unfortunately such systems are weak in many sub-Saharan countries. In addition, 
many new malaria cases are diagnosed solely on clinical signs and symptoms, with no 
parasitological confirmation.  
As stated above, the EIR provides a direct measure of transmission, and hence a reflection of 
anti-vector control actions, by quantifying the parasite-infected mosquito pool to the human 
population (Shaukat et al., 2010). However, measurement of the EIR is based on protocols 
that are non-standardised and difficult to execute, making comparison among studies difficult. 
 
1.7 A brief overview of the Democratic Republic of the Congo and its 
administrative and health system organisation  
The Democratic Republic of the Congo (DRC) (Figure 1–2) is the second largest country in 
Africa (after Nigeria) with a surface area of 2,345,000 km
2
, spanning the equivalent of two-
thirds of the European Union. With an estimated population of 65 million people (National 
Statistics Institute, DRC), the majority of whom live in rural areas, the DRC is the third most 
populated country in Africa. Located in the central Africa, the DRC shares its borders with 
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nine countries and the Atlantic Ocean to the west. Administratively, the country is divided 
into 11 provinces, which are expected soon to become 26. The city province of Kinshasa is 
divided into 24 municipalities.  
Since 2001, the DRC has been recovering from a long period of regional, inter-ethnic conflict, 
particularly in the eastern provinces where tensions and insecurity still continue. This has 
generated a vast humanitarian crisis resulting in the death of about five million people. The 
DRC continues to be a fragile country, characterised by political uncertainty and military 
instability.  
The DRC is also one of the poorest countries in the world. It is estimated that 80% of 
Congolese live on less than USD 1 a day. In 2012, the DRC had the lowest human 
development index (HDI) value out of 187 countries (UNDP, 2014) and its per capita income 
stood at USD450 in 2013, among the lowest in the world (World Bank, 2013). Mortality rates 
are still high; out of every 1000 children born, 104 die, although this represents a considerable 
reduction on the previous rate of 158/1000 in 2010 (UNICEF, 2010).  
The country is divided into 515 health zones (HZs). An HZ is the main operational unit of the 
health system, covering an average population of 150,000 in rural health zones and 250,000 in 
urban health areas. Conventionally, an HZ includes a general hospital of reference, some 
health centres, and dispensaries. An HZ is led by a team comprising the Central Board of 
Health Zone (CBHZ) which is responsible for the planning and management, implementation 
and reporting of health activities. It is split on average into 15 health areas (HAs) with 
between 5000 and 10,000 inhabitants. Kinshasa, the capital, has six health districts (Nsele, 
Funa, Lukunga, Kalamu, Gombe and Tshangu) and 35 HZs, including one rural (Maluku 2), 
four urban–rural (Maluku 1, Nsele, Mont Ngafula 1 and 2, Kisenso) and 30 urban.  
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Figure 1-2: Administrative map of the Democratic Republic of the Congo 
 
1.8 Epidemiological situation and parasite distribution in the Democratic 
Republic of the Congo  
The DRC is second only to Nigeria in terms of burden of malaria in the world. The WHO 
estimates that of the 128 million infections that occurred in 18 countries in sub-Saharan 
Africa in 2013, 14 million occurred in the DRC alone – 11% of all cases of malaria in sub-
Saharan Africa. The preliminary findings of the Demographic and Health Survey 2013–2014 
(DHS-DRC, 2013) indicate that 29.5% of Congolese children under the age of five had had a 
fever during the two weeks prior to the survey. Of these, 29.2% had received an antimalarial 
of which only 5% were artemisinin-based combination therapies (ACTs).  
The Ministry of Health reports malaria as the first cause of mortality and morbidity in the 
country. Most of the DRC territory is very suitable for malaria transmission, with 97% of the 
population living in high transmission areas where P. falciparum is the prevalent species. 
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These include 1) the equatorial area where the transmission of malaria is intense and perennial 
with an EIR of up to 1000 infected bites per person per year. This allows for the early 
acquisition of natural immunity. In children under five years, 30 to 50% of fevers are 
attributed to malaria. Severe malaria in the form of cerebral malaria is found in children but 
only rarely in adults; and 2) the tropical area where transmission is seasonal with a rise in the 
rainy season which lasts five to eight months (EIR of 60 to 400). Semi-immunity appears 
later, morbidity is higher in the rainy season and severe malaria is described until early 
adulthood. Ninety-seven per cent of the Congolese population is exposed to these two 
epidemiological ecotypes, while 3% of the Congolese population is exposed to marginal 
malaria transmission in mountainous areas (between 1000 and 1500 m). In these areas, the 
transmission period is very short and there may even be years without transmission. Semi-
immunity is low or even absent; severe malaria therefore occurs in the general population.  
Messina et al. (2011) generated the first estimate of malaria prevalence among individuals 
aged 15 to 59 years across the DRC by employing high-throughput polymerase chain reaction 
(PCR) malaria analysis of dried blood spots left over from the 2007 DRC Demographic and 
Health Survey (DHS-DRC, 2007). Low prevalence was recorded in the central and east-
central regions and near the urban areas of Kinshasa and Lubumbashi, whereas high 
prevalence was recorded in the northern regions of the country, and in the rural areas close to 
Kinshasa and Lubumbashi. Previously, the MAP identified very few parasite rate surveys in 
the DRC, highlighting the paucity of available epidemiological data (Guerra et al., 2007) for 
this region. 
 
1.9 Malaria control interventions in the Democratic Republic of the Congo 
The DRC has made considerable progress in the coverage of key interventions over the last 
five years. Malaria control activities are coordinated by the National Malaria Control Program 
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(NMCP), created in 1998. In 1999, the country endorsed the Roll Back Malaria (RBM) 
strategy, resuming and coordinating malaria control activities based on a National Malaria 
Strategic Plan (NMSP). The Strategic Plan is continuously updated to follow WHO and RBM 
recommendations, and the latest is the 2013–2015 strategic plan, which is aimed at reducing 
malaria morbidity and mortality by 75% by 2015. The current focus is to strengthen key 
interventions such as ITNs and IRS, the treatment of mosquito breeding sites, the prevention 
of malaria during pregnancy through intermittent preventive treatment (IPTp) and the 
improvement of early case management at all levels of the health system. In addition to these 
interventions, some major revisions of the 2013 strategic plan include 1) a change in the IPTp 
policy to add sulfadoxine-pyrimethamine (SP) at every antenatal care (ANC) clinic after the 
first trimester; 2) the introduction of artemether-lumefantrine (AL) as a second-line treatment 
for uncomplicated malaria; 3) the introduction of rectal artesunate for pre-referral treatment at 
community level; and 4) the introduction of injectable artesunate for all cases of severe 
malaria, consequently replacing quinine during a transition phase of three years (PMI, 2015; 
PNLP, 2013a).  
Several donors contribute to malaria control efforts in the DRC: the Global Fund, the World 
Bank, the US President’s Malaria Initiative (PMI), the UK Department for International 
Development (DfID), and a series of additional donors (UNICEF, KOJCA etc.). Each donor 
is covering a number of HZs, and soon the entire country will be covered with a minimum 
package of malaria services.  
Following massive ITN distribution campaigns, national health indicators have improved 
steadily over the past decade. This increase has been further confirmed by the results of the 
MICS 2010 and DHS 2013. For example, in 2007 the use of insecticide-treated mosquito nets 
at national level was at 6% and 7% among children and women respectively; this has now 
risen to 56% and 60% respectively. 
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1.10 Urbanisation and health 
The UN predicts that the world urban population will increase from 3,6 billion in 2011 to 6,3 
billion in 2050 (UN, 2014c). Almost all of this growth will be concentrated in the cities and 
towns of the less developed regions. Africa in particular is experiencing a massive expansion 
of its urban population, which is projected to increase from 400 million in 2010 to 1,26 billion 
in 2050 (UN, 2014a).  
The current urban planning of African cities has no resources to cope with the exceptionally 
high growth and the increased influx of migrants. In 2001, 924 million people lived in slums 
and informal settlements, with sub-Saharan Africa having the largest proportion of urban 
population residents in slums (91.7%) (UN-HABITAT, 2003). The epidemiology of 
individual diseases can differ according to specific urban dynamics and contexts. In 
industrialised countries, urbanisation and consequent improved health conditions have 
contributed to a change in disease patterns, with a rise in chronic diseases. In African cities, 
despite the increasing importance of non-communicable diseases, infectious diseases are still 
the leading cause of morbidity and mortality. The emergence of important socioeconomic 
disparities in urban areas also contributes to profound health inequalities (Alirol et al., 2011).  
 
1.11 Epidemiology of urban malaria  
The urban environment has been shown to be an unfavourable place for the proliferation of 
most species of Anopheles, owing to the lack of clean water collection pools, although some 
species have adapted to polluted waste water (Awolola et al., 2007; Barbazan et al., 1998; 
Batra et al., 2001; Sattler et al., 2005; Trape & Zoulani, 1987). Evidence of malaria 
transmission has been found in many African cities, although the levels were found to be 
generally lower than rural areas (Pond, 2013; Robert et al., 2003). It is estimated that of the 
600 million people in Africa who are at risk of malaria, about 200 million are urban 
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inhabitants (Alirol et al., 2011; Keiser et al., 2004). Pond et al. (2013) documented a 
substantially lower prevalence of malaria in large African cities by analysing data from 
malaria indicator surveys, while Robert et al. (2003) found an inverse relationship between 
EIR and the level of urbanisation from a meta-analysis of malaria transmission in sub-Saharan 
Africa (from 7.1 infective bites per person per year in urban centres to 45.8 in peri-urban 
areas and 167.7 in rural areas). This is largely due to the fact that African cities tend to grow 
outwards with perimeters consisting of relatively underdeveloped settlements and often 
harbouring urban agriculture (Byrne, 2007). The most complete set of investigations on the 
effects of urbanisation on malaria transmission was conducted by Trape et al. (1987) in 
Brazzaville. They showed how the citizens living in different parts of the city were subjected 
to differences in malaria prevalence, from 3% in central areas to 81% in peripheral areas, 
reflecting in annual EIRs that varied from 1 to 100 (Robert et al., 2003; Trape, 1987).  
In the middle of African cities it is common to find rice fields, market gardens, and large 
areas where urban agriculture is practised. Land use may influence malaria transmission in 
several ways. For example, larval habitats are gradually eliminated through the construction 
of new buildings and roads, although they may persist in areas where vegetation remains or 
where agriculture is practised. Urban agriculture provides optimal conditions for vector 
breeding and several studies have highlighted the increased malaria risk of citizens living 
nearby (Afrane et al., 2004). In addition, human influence such as tyre tracks and construction 
activities can contribute to the creation of artificial water collection reservoirs. Hence, vector 
density, sporozoite rate and EIR are influenced by the complex interplay between several 
biological and environmental factors, as well as socioeconomic status and coverage of malaria 
control measures. In addition, malaria transmission is continually changing in response to 
urbanisation and to environmental modifications.  
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The EIR is also affected by increased human population density. It is thought that high human 
density coupled with a low mosquito population reduces overall biting rates per person 
(Robert et al., 2003). High population density also limits the vector dispersal from breeding 
sites, thus localising bites, compared to areas of low population densities where female 
mosquitoes disperse over longer distances in search for a blood meal. In addition, the 
longevity of infective vectors appears to be reduced in the less favourable urban environment 
compared to rural areas (Coene, 1993).  
The uneven distribution of malaria risk in urban areas leads to delayed acquisition of semi-
immunity (Robert et al., 2003; Sattler et al., 2005; Trape et al., 1992; Trape & Zoulani, 1987). 
The first malaria infection often occurs late in childhood, exposing a much wider age range to 
severe forms of the disease (Lindsay & Martens, 1998; Modiano et al., 1998, 1999; Watts et 
al., 1990). Therefore, a large segment of the adult population in cities has no significant 
malaria immunity, representing a potential epidemic risk of great public health significance 
(Robert et al., 2003). Citizens with reduced immunity also have a higher risk of contracting 
malaria when travelling to rural areas, increasing demands on urban health services (Knudsen 
& Slooff, 1992; Martens & Hall, 2000).  
An important operational parameter is that the risk of overtreatment is increased in urban 
areas. The reported history of fever in the last two weeks for predicting current or recent 
history of malaria has lower positive predictive value in most urban areas (Pond, 2013; Wang 
et al., 2006).  
 
1.12 Anaemia 
It is estimated that about 28% of the 260 million children suffering from anaemia are from 
sub-Saharan Africa (De Benoist et al., 2007), largely from malaria endemic countries. Besides 
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the contribution of malaria, anaemia can be caused by many additional factors. These include 
nutritional (iron deficiency) and non-nutritional ones (host factors, socio-cultural or 
comorbities) (Brooker et al., 2007; Ekvall, 2003; Hotez & Molyneux, 2008; Ong'echa et al., 
2006; Owusu-Agyei et al., 2002). Important consequences of anaemia involve the slower 
physical and cognitive development of children (Biemba et al., 2000; Brabin et al., 2001; 
Marsh et al., 1995; Slutsker et al., 1994). Therefore it is important to determine the prevalence 
of anaemia in African cities and to untangle the fraction of anaemia caused by malaria. This 
will in turn guide the efficient and appropriate allocation of interventions such as nutrient 
supplements and fortified food in the most affected communities.  
 
1.13 Urban malaria control in Kinshasa  
Malaria in Kinshasa has been a known public health problem since colonial times (Kazadi et 
al., 2004; Mulumba et al., 1990; Ngimbi et al., 1982; Nguyen-Dinh et al., 1985; Peel & Van 
Hoof, 1948; Ward, 1977). The Program de Lutte Antipaludique was initially created as a pilot 
malaria project in 1976, in agreement with the United States Agency for International 
Development (USAID) and the government of Zaire, to implement malaria control activities 
in four HZs and in one rural area of Kinshasa. DDT was adopted as the primary measure of 
vector control followed by semi-annual blood surveys conducted in primary school children 
aged five to 15 years. The mean malaria prevalence found was 17% during the early school 
surveys conducted in 1981–1983. At the same time, a survey of infants at two hospitals 
confirmed ongoing malaria transmission in the city. Additional school surveys were then 
extended to other HZs. Mulumba et al. (1990) found the prevalence of malaria in six districts 
of Kinshasa to be 50% during 1986 and 1987, and higher in the peripheral districts. In 1998, 
the Program National de Lutte Contre le Paludisme [National Malaria Control Programme], 
was set up by the Ministry of Health and, in 1999, the DRC started implementing the RBM 
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strategy. The latest epidemiological survey, conducted in Kinshasa in 2000 among children 
aged five to nine, revealed a mean parasite prevalence of 34%, with much lower transmission 
in the city centre (parasite rate 4%) compared to the peri-urban area (46%) (Kazadi et al., 
2004). Consequently, additional surveys to update prevalence figures in Kinshasa are urgently 
required.  
 
1.14 Epidemiology of severe malaria  
Uncomplicated malaria can lead to severe malaria and death. Several factors influence this 
progression including the species of the infecting parasite, the level of the innate and acquired 
immunity, and the timing of the treatment. Almost all severe forms of and deaths from 
malaria are largely but not entirely due to P. falciparum infections. Obtaining accurate 
incidence and distribution data of severe malaria is often problematic as a result of weak 
reporting by the health system and the fact that a large proportion of deaths occurs at home. It 
is estimated that 90% of deaths from severe malaria in children under five occur at home in 
the Gambia (Greenwood et al., 1987), and 47% in Zambia (Mudenda et al., 2011). In addition, 
severe malaria can be misdiagnosed (Reyburn et al., 2004; Taylor et al., 2004). Accounting 
for these considerations, the WHO estimated that the global annual incidence of severe 
malaria was approximately two million cases in 2012.  
The risk of prognosis varies with age and according to the level of malaria transmission, and 
is associated with changes in the dominant clinical manifestation (Griffin et al., 2015; Idro et 
al., 2006; Okiro et al., 2013; Reyburn et al., 2005; Snow et al., 1994; Snow et al., 1997). In 
areas of high transmission, severe malaria is concentrated in young children over the age of 
six months and severe anaemia is the most common complication, while in areas of less 
intense or seasonal transmission, older children and adults are affected and cerebral malaria 
may predominate with higher case fatality rates (Griffin et al., 2015).  
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1.15 A new treatment of severe malaria 
For many decades the mainstay for the treatment of severe malaria was quinine. Recently, two 
large open-label randomised controlled trials have been conducted to compare intravenous 
quinine with artesunate in malaria-endemic countries in Southeast Asia (SEAQUAMAT) and 
in Africa (AQUAMAT) (Dondorp et al., 2005; Dondorp et al., 2010). The evidence of the 
benefits of injectable artesunate versus quinine from these and additional small trials have led 
to a rapid change in the policy for the treatment of severe malaria. The WHO now 
recommends injectable artesunate for the treatment of severe malaria in children and adults 
and individual countries are adopting the new policy. Artesunate has been proven to reduce 
mortality and it is a fast-acting drug against several parasite stages, including gametocytes 
(Dondorp et al., 2005; Dondorp et al., 2010). However, the long-term safety profile is still of 
concern because of reported delayed severe anaemia (CDC, 2013).  
In early 2012, the DRC changed its policy and injectable artesunate will be used in 
conjunction with quinine infusion for a transition period of three years. In this context, 
operational research is needed to support the policy change in order to establish the feasibility 
and acceptability of the new drug in the context of routine care.  
 
1.16 Cost of severe malaria 
Despite the clinical superiority of artesunate over quinine, concerns have been raised that 
artesunate could be costlier than quinine and that this might place a substantial economic 
burden on the healthcare system (Kyaw et al., 2014). However, modelling studies have shown 
that artesunate is highly cost-effective in the management of severe malaria, with an 
incremental cost per death averted of approximately USD150 (Lubell et al., 2010; Lubell et 
al., 2011). Cost estimates for the DRC are lacking and studies are required to establish 
procurement and operational costs.  
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2 Aims and objectives 
The aims of this thesis were twofold: 1) to estimate the malaria risk and associated risk 
factors among different subgroups of the population of greater Kinshasa by means of a series 
of cross-sectional studies; and 2) to investigate through limited scope implementation studies 
how injectable artesunate may be best implemented as the preferred treatment for severe 
malaria in the DRC. 
Specific objectives: 
Part 1 
(1) To establish a comprehensive and representative risk map of malaria transmission in the 
greater Kinshasa area on the basis of a malariometric survey in 25 health zones in 
children aged six to 59 months of age  
(2) To assess the age profile of malaria risk in two health zones (one presumed low risk, 
one presumed high risk) 
(3) To obtain a comprehensive report on the current malaria control activities in greater 
Kinshasa 
 
Part 2 
(4) To quantify the time from registration at the hospital to discharge for severe malaria 
patients and from initiation of injectable malaria treatment to initiation of oral treatment 
(5) To evaluate the cost difference between the two treatment regimens (IV quinine vs 
IV/IM artesunate) from a provider perspective 
(6) To quantify the cumulative staff time required for all steps of management of patients 
with severe malaria, including drug administration (quinine and artesunate) and material 
needed 
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(7) To evaluate the feasibility and acceptability of new treatment by administering a 
provider and patient/caretaker questionnaire. 
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3.1 Abstract 
Background 
In Kinshasa, malaria remains a major public health problem but its spatial epidemiology has 
not been assessed for decades now. The city’s growth and transformation, as well as recent 
control measures, call for an update. To identify highly exposed communities and areas 
where control measures are less critically needed, detailed risk maps are required to target 
control and optimise resource allocation.  
 
Methods 
In 2009 (end of the dry season) and 2011 (end of the rainy season), two cross-sectional 
surveys were conducted in Kinshasa to determine malaria prevalence, anaemia, history of 
fever, bed net ownership and use among children 6–59 months. Geo-referenced data for key 
parameters were mapped at the level of the health area (HA) by means of a geographic 
information system (GIS). 
 
Results  
Among 7,517 children aged 6–59 months from 33 health zones (HZs), 6,661 (3,319 in 2009 
and 3,342 in 2011) were tested for both malaria (by Rapid Diagnostic Tests) and anaemia, 
and 856 (845 in 2009 and 11 in 2011) were tested for anaemia only. Fifteen HZs were 
sampled in 2009, 25 in 2011, with seven HZs sampled in both surveys. Mean prevalence for 
malaria and anaemia was 6.4% (5.6–7.4) and 65.1% (63.7–66.6) in 2009, and 17.0% (15.7–
18.3) and 64.2% (62.6–65.9) in 2011. In two HZs sampled in both surveys, malaria 
prevalence was 14.1% and 26.8% in Selembao (peri-urban), in the 2009 dry season and 2011 
rainy season respectively, and it was 1.0% and 0.8% in Ngiri Ngiri (urban). History of fever 
during the preceding two weeks was 13.2% (12.5–14.3) and 22.3% (20.8–23.4) in 2009 and 
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2011. Household ownership of at least one insecticide treated net (ITN) was 78.7% (77.4–
80.0) and 65.0% (63.7–66.3) at both time points, while use was 57.7% (56.0–59.9) and 
45.0% (43.6–46.8), respectively.  
 
Conclusions 
This study presents the first malaria risk map of Kinshasa, a mega city of roughly 10 million 
inhabitants and located in a highly endemic malaria zone. Prevalence of malaria, anaemia and 
reported fever was lower in urban areas, whereas low coverage of ITN and sub-optimal net 
use were frequent in peri-urban areas. 
 
 
 
 
 
 
 
 
Keywords: Malaria, Anaemia, mosquito nets, DRC, Democratic Republic of Congo, 
Kinshasa  
 
A malaria risk map in Kinshasa 
22 
 
3.2 Background 
Malaria is the leading cause of morbidity and death in children under five years in the 
Democratic Republic of Congo (DRC), accounting for an estimated 40% of outpatient visits 
and 40% of overall mortality {Roll Back Malaria, 2014 #457}. Malaria is also a major public 
health issue in the capital city Kinshasa; an issue that has been studied since colonial times 
(Ngimbi et al., 1982). After Cairo and Lagos, Kinshasa is Africa’s third largest city, with an 
estimated population of more than 10 million (Nations). In 1979–1980, the average malaria 
parasite rate in a representative sample of children was 33% (Ngimbi et al., 1982). Around 
the same time, malaria admissions comprised 29.5% of consultations in 1983, then 38.2% in 
1985–86 (Greenberg et al., 1989). In 1986–1987, the mean prevalence rate of malaria in six 
districts of Kinshasa was 50%, with a higher prevalence in the peripheral districts (Mulumba 
et al., 1990). This reflected the distribution pattern of the main vector Anopheles gambiae, 
which was less present in the city centre than in the periphery (Karch et al., 1992; Coene, 
1993). The latest study in 2000 confirmed the general prevalence distribution pattern, with 
lower prevalence in the city centre (parasite rate 4%) than in peri-urban areas (46%) (Kazadi 
et al., 2004).  
 
A first insecticide treated net (ITN) distribution campaign in 2007 achieved a 15.9% rate of 
ITN ownership and a 12.6% rate of use among children under five (DHS-DRC, 2007). In 
2008, the World Bank financed the acquisition and distribution of two million ITNs in 
Kinshasa through the PURUS project (Programme d’Urgence de Réhabilitation Urbaine et 
Sociale). The National Malaria Control Programme (NMCP), along with technical and 
logistic support from Population Services International (PSI), distributed two ITNs per 
household. Eight months after that distribution, the Kinshasa School of Public Health (KSPH) 
conducted a survey on basic malaria indicators to assess the impact of the intervention in 15 
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health zones (HZs) of the city. In 2011, the Swiss Tropical and Public Health Institute (Swiss 
TPH), in collaboration with the KSPH, conducted a second survey to evaluate the coverage 
and use of key malaria indicators, parasitaemia, anaemia and fever in the 23 HZs excluded 
from the 2009 survey. Kinshasa has expanded very rapidly in the past 20 years, thus updating 
and consolidating these data was urgently required for general malaria control purposes and 
for planning specific further research projects. Using geo-referenced prevalence data, this 
study aimed to generate the first map of malaria risk among children 6–59 months in Greater 
Kinshasa, down to the lowest level of the health system in DRC, the health area (HA). These 
maps will enable researchers and implementers to identify HZs of high priority for malaria 
control in Kinshasa.  
  
3.3 Method 
Study area 
The study was conducted in Kinshasa, the capital of the DRC. The city is located along the 
southern bank of the Congo River, directly opposite the city of Brazzaville, capital of the 
Republic of the Congo. The climate is hot and humid (AW4 according to the Koppen 
classification), with a rainy season lasting from October to May (Kottek M, 2006). 
Characterised in the north by the Pool Malebo and by a marshy area in the north east along 
the river Congo, Kinshasa extends across a plain delimited to the south by hills with heights 
varying between 350 and 750 meters. The plain is crossed by three rivers (Ndjili, Nsele and 
Mai-Ndombe) and many smaller streams (D’Ascenzo, 2010; de Maximy, 1975). The northern 
and central parts of the city include the old colonial neighbourhoods (ville), some of which 
represent the most industrialised and commercial areas. To the south lies the cité, consisting 
of more recent, large, residential districts. The land use pattern is heterogeneous, with densely 
populated areas separated by large semi-rural areas where urban agriculture is practiced. The 
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most heavily inhabited area of Kinshasa covers 583 square km (Demographia, 2014), of which 
80% is actually semi-rural. Administratively, Kinshasa has the status of a province, divided 
into four districts, which are further divided into 24 communes (municipalities). The 
organisation of the health system differs from the administrative system and comprises six 
health districts, divided into 35 health zones (HZs). These represent the primary operational 
units of the health system in DRC. An HZ usually covers a population of 100,000 to 150,000 
inhabitants in rural areas and 200,000 to 250,000 in urban centres. They include a general 
referral hospital, some health centres and a dozen lower-level health facilities. Each HZ is 
further divided into 15 health areas (HAs), on average, which represent the lowest level of the 
health system. Each HA is clearly delimited and defined by the Ministry of Health and 
usually includes a population of 10,000 to 15,000 inhabitants. In Kinshasa Province, the three 
most eastern HZs are completely rural in nature, while the remaining 32 HZs are semi-rural 
or urbanised (http://www.kinshasa.cd). The study area only consisted of the 32 non-rural HZs 
because of the practical issues involved in including the three eastern HZs. Details of the 
sampled HZs can be found in Table 3.1.  
 
Study design and sampling procedure 
Two cross-sectional household surveys were conducted. The first survey was carried out at 
the end of the dry season between mid-September and end of October 2009 in 15 HZs, eight 
months after the first large ITN distribution campaign. The second survey was conducted at 
the end of the rainy season from mid-April to early June 2011 and covered 25 non-rural HZs. 
Seven HZs were sampled in both studies, including five HZs for which malaria prevalence 
was not measured in 2009 and two HZs for which prevalence was measured previously in 
2009. The detailed list of HZs surveyed in 2009 and 2011 is presented in Table 3.1. For both 
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surveys, a multi-stage cluster sampling design was adopted to select households for inclusion, 
using the HZ as a primary sampling stage and the HA as a secondary sampling stage. 
 
2009 survey 
Fifteen HZs were selected using a probability proportional to size (PPS) sampling method, so 
that more populated HZs had a higher probability of being selected. Of these 15 HZs, 10 were 
selected by simple random sampling for the determination of malaria by rapid diagnostic test 
(RDT). In the remaining five HZs, only haemoglobin (Hb) was measured and malaria 
preventive measures were investigated using a pre-tested, structured questionnaire. In each 
HZ, data collection took place in half of the HAs, selected again with PPS. In case of an odd 
number of HAs per HZ, (n +1)/ 2 HAs were selected. In a third stage, a list of all streets with 
their approximate population number was obtained for each selected HA. Streets with fewer 
than 200 inhabitants were excluded and three streets were selected by simple random 
sampling. Households with at least one child aged 6–59 months were listed by community 
health workers (CHW) for each of the three streets. From this list, 25 eligible households 
were randomly selected, proportional to the size of each street. The target sample size of 325 
children was calculated based on an estimated prevalence of anaemia of 69.2% in children 
aged 6–59 months. Assuming 1.3 children aged 6–59 months per household, a sample size of 
260 households was set as the target per health zone (DHS-DRC, 2007).  
 
2011 survey 
From mid-April to early June 2011, the remaining 23 HZs were sampled, including the five 
HZs for which malaria prevalence had not been measured in the 2009 survey. In all 23 HZs, a 
questionnaire was administered to households and malaria parasite prevalence and the Hb 
concentration were measured in children aged 6–59 months. Two additional HZs already 
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investigated in 2009 were re-sampled in 2011 among children 6-59 months for both malaria 
and anaemia. To obtain the epidemiological age profile for all age groups in these latter HZs 
only, all individuals older than five were also included. In all, 25 HZs were sampled in the 
2011 survey. The primary outcome measure was documented malaria in study children, as 
measured by RDT. The sample size was calculated based on the prevalence estimate for 2009 
survey (6.4%) during the dry season, and increased to 10% to take into account the seasonal 
variation. In each HZ, the aim was to measure children’s malaria with a precision of ± 8 
absolute percent. The sample size calculation indicated the need for 55 children in each HZ. 
With a design effect accounting for clustering of two, this number increased to 110. With an 
average 1.3 children under five years in households in Kinshasa, 87 households needed to be 
selected (DHS-DRC, 2007). To account for losses in the study process, we aimed for 100 
households in each of the 25 HZs. Hence, the total number of households sampled in 
Kinshasa in 2011 was 2,500, including 3,250 children aged 6–59 months. HA and household 
selection followed the same methodology applied in the 2009 survey (described above). An 
average of 25 households was set per HA. 
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Table 3-1: List of the Health Zones in Greater Kinshasa surveyed in 2009 and 2011 and their 
corresponding populations. 
 
Health zone Environment Population Year survey 
Bandalungwa Urban 147.252 2011 
Barumbu Urban 115.780 2011 
Binza Meteo Urban 325.446 2009†/2011 
Binza Ozone Urban 317.731 2011 
Biyela Urban 174.232 2009†/2011 
Bumbu Urban 316.188 2009 
Gombe Urban 22.732 2011 
Kalamu I Urban 112.915 2011 
Kalamu II Urban 100.782 2011 
Kasa-Vubu Urban 102.856 2009 
Kikimi Urban 198.997 2011 
Kimbanseke Urban 217.772 2011 
Kingabwa Urban 162.323 2009 
Kingasani Urban 171.538 2011 
Kinshasa Urban 135.665 2011 
Kintambo Urban 81.026 2011 
Kisenso Urban-rural 335.265 2009 
Kokolo Urban 336.086 2009 
Lemba Urban 249.292 2009†/2011 
Limete Urban 145.331 2009†/2011 
Lingwala Urban 66.595 2011 
Makala Urban 238.088 2011 
Maluku I Urban 149.040 Excluded 
Maluku II Rural 54.158 2009 
Masina I Urban 258.687 2011 
Masina II Urban 214.401 2009†/2011 
Matete Urban 223.248 2009 
Mont Ngafula I Urban-rural 196.810 2011 
Mont Ngafula II Urban-rural 111.921 2011 
N’djili Urban 249.310 2009 
Ngaba Urban 140.861 2011 
Ngiri Ngiri§ Urban 125.634 2009/2011 
Nsele Rural 387.486 Excluded 
Police Urban 93.910 2011 
Selembao§ Urban 269.498 2009/2011 
 
* KSPH/ NMCP 2009, KSPH/ Swiss TPH 2011; † Surveyed for malaria preventive indicators and prevalence of 
anaemia; § surveyed for malaria prevalence in both years and for all age groups in 2011. 
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Data collection  
Household survey questionnaire  
In 2009, survey data were collected using a paper-based questionnaire. In 2011, survey data 
were collected using smartphone technology. For the 2011 survey, a validated electronic 
semi-quantitative questionnaire was developed on an HTC smartphone running Google’s 
Android operating system. Eight teams of three field workers (one interviewer, one 
laboratory technician, one community liaison person) were trained in using the electronic 
questionnaire, in general interviewing skills and in administering informed consent during 
simulated interviews sessions. Each of the eight teams visited, on average, 25 households per 
day in each selected HA. The 2011 questionnaire was a simplified version of the one used in 
2009, which was adapted from the standard Malaria Indicator Survey Household 
Questionnaire from the Roll Back Malaria Partnership (www.RBM.org). All questions 
retained from the 2009 survey form were kept as they were in 2011 to ensure comparability 
between both surveys. The questionnaire was developed in French with oral translation into 
Lingala (the second lingua franca in Kinshasa) and field tested prior to the survey.  
 
Prior to administering the questionnaire, a signed informed consent form was obtained from 
the head of the household or his/her representative. Participation was entirely voluntary. 
Respondents were asked about demographic information of usual residents, educational level, 
factors indicating the household’s socio-economic status, household construction material, 
presence and type of mosquito bed net (verified by direct observation), use of mosquito bed 
net and ITN in the night prior to the survey, history of fever (past 2 weeks), whether fever 
was present on the day of the survey and health seeking behaviour in case of a fever episode. 
During the 2011 survey, the coordinates (longitude and latitude) of all investigated 
households were recorded on-site using the integrated Global Positioning System (GPS) of 
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the data collection devices. Households were revisited if no one was available for interview 
on the first attempt; if no one was available after two attempts, the interviewer continued to 
the next randomly selected household on the list until the desired number of households was 
obtained.  
 
Blood testing  
For each selected participant who gave signed informed consent, the same laboratory 
procedures as in 2009 were adopted during the 2011 survey. They included measuring 
axillary temperature with a digital thermometer, collecting peripheral blood by standard 
finger prick to test for malaria parasites with an RDT for Plasmodium falciparum-specific 
histidine rich protein 2 (HRP2) and other Plasmodium species (Pan pLDH for P. vivax, P. 
malariae and P. ovale) (Paracheck pf in 2009 and SD Bioline Malaria Antigen P.f/Pan in 
2011) and assessing Hb level using a blood haemoglobin photometer (HemoCue 201 plus, 
Ängelholm, Sweden). In two HZs in 2011, Selembao and Ngiri Ngiri, individuals of all ages 
(not only children) were surveyed. RDTs were used for on–site diagnosis of malaria and 
treatment with artesunate-amodiaquine, the official first-line malaria treatment at the time of 
the survey, was offered as needed. The HemoCue was validated by running a weekly high 
and low Hb liquid control (HemoCue – HemoTrol).  
 
Statistical analysis 
To ensure consistency and integrity of data collected during the 2009 survey, all paper forms 
were rechecked by team supervisors in the field at the end of each day. Incomplete entries 
were sent back to be filled the next day. Questionnaires were first checked for completeness, 
and the information was manually coded and entered using EpiData and crosschecked using 
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EpiInfo (v. 6.04). Statistical analyses were performed using SPSS software for Windows 
(version 16.0), NCSS, and STATA (version 10).  
Data collection devices used in the 2011 survey (HTC phones) were equipped with Open 
Data Kit (ODK) software (University of Washington & Google Foundation) to allow for data 
entry in the field. ODK programming also allowed for systematic range and consistency 
checks. Data in xml format were downloaded every evening from the HTC smartphones and 
then converted on the ODK Aggregate Server into tabular format (ODK aggregate).  
Statistical analyses were performed using Stata version 12.1 (Stata Corp, College Station, Tx, 
USA). Analysis and mapping for the 2011 survey were based on geo-referenced prevalence 
data at the level of the HA. Since households could not be georeferenced in 2009, HA spatial 
coordinates were assigned to the HA’s mean malaria prevalence. Maps were produced using 
ArcGIS version 10.0 (Environmental Systems Research Institute Inc. Redlands, USA). A 
centroid for every HA was first generated (for 2009 the centroid was generated at the centre 
of the HZ, since GPS coordinates of the households were not collected). The standardized 
prevalence data were then assigned to the centroids of the surveyed health zone. The next 
step involved using the IDW interpolation to get prevalence estimates at un-surveyed HZs. 
Lastly, the interpolated prevalence estimates were extracted using the centroids (points data) 
of the HZs. These estimates were subsequently used map out the prevalence at HZs level 
(polygons data). Boundaries (shape files) were initially available at the level of the HZ only, 
from the Health Monitoring Information System Unit of the Ministry of Health (MoH). By 
using images developed by the Japan International Cooperation Agency (JICA) and through 
collaborating with a team of experts from the Institut géographique du Congo (IGC), it was 
possible to develop shape files at the level of the HA. The most eastern rural HZs (Maluku I 
and II and Nsele) were excluded from the final map due to the great effort that drawing 
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boundaries in remote HAs would have entailed. This was beyond the means and the scope of 
this study.  
 
Ethical consideration 
For both surveys, ethical clearance was obtained from the Ethics Committee of the KSPH, at 
the University of Kinshasa. In addition, the 2011 survey received authorization from the 
ethical committees in Basel (Ethikkommission beider Basel, Basel-Stadt) as well as clearance 
from Swiss TPH’s internal research commission. 
Signed informed consent to participate was obtained from parents or guardians on behalf of 
the enrolled children or by the adult participants themselves. Precautions to minimise the risk 
of secondary infection during blood collection were taken. All tested participants with a 
positive RDT but no evidence of severe illness were diagnosed as having uncomplicated 
malaria and given a voucher for treatment, free of charge, as per the DRC national malaria 
treatment policy (artesunate-amodiaquine or artemether-lumefantrine), at the nearest health 
facility. Drugs were provided to the relevant facilities one day before the household visits 
started in the area, to ensure drug availability for treatment. Participants diagnosed with 
severe anaemia and those with severe illnesses were excluded from the study and 
immediately referred to the nearest health facility for diagnosis and management, as 
recommended by national guidelines.  
 
 
3.4 Results  
Characteristics of the study population 
Household and individual characteristics of the study populations in 2009 and 2011 are 
shown in Table 3.2. A total of 3,896 households distributed throughout 15 HZs were included 
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in the 2009 survey, while 2,512 household in 25 HZs were sampled in 2011. The age 
distribution of individuals was similar between surveys, as were the proportions of men and 
women. Overall, 27,371 people were surveyed in 2009, including 12,761 men and 14,610 
women. Of these, 47.1% were under 15 years of age, while the percentage of children 6–59 
months was 24%. In addition, 302 pregnant women also participated. The 2011 survey 
included 15,005 people; 6,770 men and 8,235 women. Of these, 44.7% were under 15 years 
of age, while the percentage of children 6–59 months was 24.9%.  
 
Table 3-2: Characteristics of study households and individuals in the 2009 and 2011 surveys, 
Kinshasa, Democratic Republic of Congo 
 Survey 
2009 
Survey 
2011 
Household characteristics   
Number of households sampled 3896 2512 
Mean (SD) household size 7.1  5.9 (2.1) 
Individual characteristics    
Number of persons in sampled households 27371 15005 
Median Age years (90% central range) - 17 
Age groups   
     < 6 months - 0.9 
        6-59 months (%) 24.0 24.9 
        5-9 years (%) 13.1 10.9 
        10-14 years (%) 10.0 8.9 
        15-19 years (%) 9.2 8.1 
     ≥ 20 years (%) 43.7 46.2 
Proportion of females (%) 53.4 54.9 
 
Prevalence of P. falciparum by health zone  
Table 3 gives the proportion of children 6–59 months who tested positive for malaria with 
RDT, by sampled HZs. A total of 3,319 children 6–59 months in 10 HZs were tested for 
malaria by RDT in the 2009 survey, whereas 3,342 were tested in 25 HZs in 2011. 
Prevalence of confirmed malaria was 6.4% (5.6–7.4) at the end of the 2009 dry season, 
ranging from 1.0% (0.3–2.6) in Ngiri Ngiri (urban centre) to 14.1% (10.6–18.2) in Selembao 
(peri-urban). At the end of the 2011 wet season, malaria prevalence was 17.0% (15.7–18.3), 
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ranging from 0.7% (0.0–4.1) in Kinshasa and Lingwala (urban centre) to 46.0% (37.1–55.1) 
in Biyela (peri-urban). P. falciparum accounted for 52% (95% CI: 47.4-55.8) of infections in 
2011 survey, non-falciparum infections for 0.3% (95% CI: 0.0-1.3) while mixed infection 
(were not distinguished) prevalence was 48% (95% CI: 43.9-52.3).  
In the two HZs sampled in both 2009 and 2011, prevalence of malaria in children aged 6–59 
months was 1.0% (0.3–2.6) and 0.8% (0.0–4.2) in Ngiri Ngiri, and 14.1% (10.6–18.2) and 
26.8% (19.9–34.7) in Selembao. Age-specific rates (Figure 3.1) show that prevalence in Ngiri 
Ngiri in 2011 was highest among individuals aged 15–19 years (14.0%), followed by the 
groups aged 5–9 years (4.8%), > 20 (4.2%), 10–14 (1.4%) and 6–59 months (0.0%). In 
Selembao, malaria prevalence was highest among the groups aged 5–9 (34.2%) and 15–19 
(28.3%) years, followed by those 6–59 months (26.2%), 10–14 years (25.0%) and over 20 
years (17.6%). All-ages malaria prevalence was 3.8% (2.4–5.8) in Ngiri Ngiri and 23.8% 
(20.4–27.6) in Selembao.  
 
To prepare the data for mapping, direct standardisation was used to make prevalence rates of 
malaria comparable between surveys, accounting for the two different years and seasons. The 
standardisation was done according to the following formula:  
 
 
 
 
where, Ps is the overall standardized prevalence for surveys 2009 and 2011, p1 is the 
prevalence rate in survey 1 (2009), p2 is the prevalence rate in survey 2 (2011), n1 is the 
number of study participants in survey 1, n2 is the number of study participants in survey 2, 
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p¯1 is the overall prevalence rate for survey 1, p¯2 is the overall prevalence rate for survey 2 
and ∑ is the total number of study participants (per survey). 
 
Figure 3-1: Plasmodium falciparum malaria prevalence (RDT positivity) by age group for 
the health zones of Selembao and Ngiri Ngiri 
 
 
 
 
 
 
 
 
 
 
 
 
 
Geographical distribution of P. falciparum malaria 
Results from the two surveys were used to produce a representative and standardised map of 
risk for malaria in children aged 6–59 months. Figure 3.2 shows the spatial distribution of the 
standardised prevalence rates of P. falciparum from the 2009 and 2011 surveys, at the level 
of the HA. Interpolated standardised prevalence rates are presented in Figure 3.3. Based on 
this risk map, three zones could be approximately defined; low risk in the central north part 
of the city, where prevalence rates were generally low (≤ 5%); intermediate risk in the central 
southern part of the city, where prevalence rates were between  >5% and  ≤30%; and high 
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risk in the south western and eastern zones, where prevalence rates were higher (>30%) and, 
in general, more homogeneously distributed. 
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Figure 3-2: Standardized Plasmodium falciparum malaria prevalence in children aged 6-59 months, by health area  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The 2009 data for the health zones of Bumbu, Kingabwa, Kisenso, Kokolo and Ndjili were only available at the level of the health zones. 
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Figure 3-3: Interpolation results for standardized Plasmodium falciparum malaria prevalence in children aged 6-59 months, by health area 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: The data of Figure 3.2 were used for an inverse distance weighting (IDW) interpolation and then a mean prevalence value was calculated for every health area.  
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Geographical distribution of anaemia  
A total of 4,164 and 3,353 children aged 6–59 months were tested for anaemia in the 2009 
and 2011 surveys, respectively. The mean prevalence of anaemia (Hb < 11g/dl) was similar 
between surveys: 65.1% (63.7–66.6) in 2009 and 64.2% (62.6–65.9) in 2011. Results also 
show that the prevalence of moderate (7.0-9.9 g/dl) and severe (< 7.0 g/dl) anaemia was 
34.2% and 1.9% in 2009, and 30.1% and 1.9% in 2011 (Table 3.3).  
The formula given above was used to standardise the prevalence of anaemia and of severe 
anaemia. The spatial distribution of the standardised prevalence of anaemia for both surveys 
is shown in Figure 4. The risk of anaemia was consistently high across the entire study area, 
with maximal mean prevalence rates (> 70%) in the HZs of Kingabwa, Matete and Biyela. A 
map showing the standardised prevalence of severe anaemia is presented in Figure 5.  
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Figure 3-4: Standardized prevalence of anaemia (Hb<11g/dl) in children aged 6-59 months, by health area, surveys 2009 and 2011. 
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Figure 3-5: Standardized prevalence of severe anaemia (Hb<7g/dl) in children aged 6-59 months, by health area, surveys 2009 and 2011. 
A malaria risk map in Kinshasa 
41 
 
History of fever 
The proportion of children aged 6–59 months reporting a history of fever in the two weeks 
preceding the survey was 13.2% (12.5–14.3) in 2009 and 22.3% (20.8–23.4) in 2011. On the 
day of the 2011 survey (data not available for 2009), 3.2% (106/3348) were febrile (defined 
as temperature > 37.5 C). The positive predictive value (PPV) of history of fever among 
children with a positive RDT was 29.7% (26.3–32.7) in 2011. Health seeking behaviour in 
case of fever was high in 2011 (data not available for 2009): overall, 91.4% (770/842) of 
children sought some type of care. In all, 53.9% sought modern treatment at home by a 
family member, whereas 36.1% were taken to a health facility. Very few (0.5%) made use of 
traditional medicine. Private facilities were the most common provider of treatment among 
those who sought care outside the home, covering 65.4% of the cases, whereas 22.9% 
consulted a public facility and 11.8% consulted a confessional structure. In case of home 
treatment, drug outlets represented the principal source of treatment (96.3%). Unfortunately, 
only 4.3% of the antimalarials purchased were the recommended combination of artesunate-
amodiaquine. As a result, only 3.6% received the recommended treatment at home within the 
24 hours. In 66.5% of fever cases, treatment was sought within 24 hours regardless of 
whether treatment was recommended or not. 
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Table 3-3: Clinical outcomes, by health zone 
 
Health zone Malaria prevalence in children aged 6-59 months  
 
Anaemia prevalence in children aged 6-59 months Children <5 years with a fever episode in 
the 2 weeks before the survey 
Survey 2009  
(dry season) 
Survey 2011  
(wet season 2011) 
Standardised 
prevalence 
Survey 2009 
(dry season) 
Survey 2011 
(wet season 2011) 
Survey 2009 
(dry season) 
Survey 2011 
(wet season 2011) 
% [95% CI] N % [95% CI] N % 
 
%  
severe 
(<7g/dl) 
%  
any 
(<11g/dl) 
N %  
severe 
(<7g/dl) 
%  
any 
(<11g/dl) 
N % N % N 
Bandalungwa    1.5 [0.2-5.3] 134 1.0    0.7 51.5 134   22.8 149 
Barumbu    2.4 [0.5-6.9] 125 1.7    0.8 57.8 128   19.6 143 
Binza Météo    24.8 [17.0-34.0] 109 17.1 1.3 70.6 238 1.7 65.3 118 20.4 339 24.4 131 
Binza Ozone    19.1 [12.9-26.7] 136 13.2    1.5 66.2 136   19.0 158 
Biyela    46.0 [37.1-55.1] 126 31.7 4.5 64.9 313 2.4 78.6 126 9.5 422 24.7 150 
Bumbu 7.4 [4.7-10.9] 299    13.6 3.6 69.2 308    9.3 407   
Gombe    11.5 [6.7-18.0] 139 7.9    3.6 65.5 139   29.6 159 
Kalamu I    16.2 [8.4-27.1] 68 11.2    0.0 73.5 68   28.8 73 
Kalamu II    2.5 [0.8-5.7] 200 1.7    1.5 56.7 203   19.5 221 
Kasa Vubu 2.8 [1.2-5.4] 286    5.1 1.6 55.4 242    10.2 352   
Kikimi    32.8 [24.9-41.6] 131 22.6    2.3 64.9 131   18.5 151 
Kimbanseke    36.1 [27.9-44.9] 133 24.9    2.3 75.9 133   22.7 154 
Kingabwa 2.6 [1.2-4.9] 345    4.8 1.5 74.3 315    9.8 386   
Kingasani    25.0 [18.3-32.7] 152 17.2    3.3 76.2 151   24.6 175 
Kinshasa    0.7 [0.0-4.0] 136 0.5    1.5 61.2 134   30.7 150 
Kintambo    11.7 [7.0-18.1] 145 8.1    1.5 68.2 132   24.8 165 
Kisenso 11.2 [8.0-15.1] 331    20.5 1.0 69.3 267    8.3 348   
Kokolo§ 9.3 [6.5-12.9] 353    17.0 0.6 66.7 36    10.3 39   
Lemba    7.7 [3.8-13.7] 130 5.3 1.8 59.4 276 3.1 53.8 130 25.8 357 15.3 150 
Limete    17.3 [11.3-24.8] 133 11.9 1.8 69.5 334 3.0 72.2 133 14.3 399 29.1 148 
Lingwala    0.7 [0.0-4.1] 135 0.5    0.7 63.0 135   27.3 154 
Makala    17.9 [11.8-25.5] 134 12.3    4.5 69.4 134   20.6 155 
Maluku II* 8.0 [5.0-12.0] 261    14.7 1.2 54.2 260    11.1 342   
Masina I    12.3 [7.3-19.0] 138 8.5    0.7 66.7 138   20.2 163 
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* The HZ of Maluku II although surveyed in 2009 was excluded from the final risk map since the choice was to map only HZs of non-rural character. § The HZs Kokolo and 
Police consist of military and police camps scattered in the city. 
 
 
 
 
 
 
 
 
Masina II    24.8 [17.7-33.0] 133 17.1 2.5 57.6 321 2.3 60.9 133 15.6 458 21.7 161 
Matete 3.5 [1.8-6.0] 344    6.4 2.1 74.0 334    6.6 394   
Mont Ngafula I    33.6 [25.7-42.2] 134 23.2    3.7 69.4 134   20.8 154 
Mont Ngafula II    35.3 [27.3-44.1] 133 24.4    3.0 68.4 133   19.0 158 
Ndjili 6.3 [4.0-9.3] 366    11.5 2.4 61.3 287    16.7 412   
Ngaba    7.5 [3.6-13.3] 134 5.2    1.5 50.7 134   28.8 153 
Ngiri Ngiri 1.0 [0.3-2.6] 387 0.8 [0.0-4.2] 124 1.5 1.3 62.4 314 0.8 58.8 131 15.3 428 12.9 140 
Police§    17.0 [11.1-24.5] 135 11.7    0.7 53.3 135   13.4 164 
Selembao 14.1 [10.6-18.2] 347 26.8 [19.9-34.7] 145 23.6 1.9 67.1 319 1.3 65.3 150 15.2 387 19.1 162 
TOTAL 6.4 [5.6-7.4] 3319 17.0 [15.7-18.3] 3342 11.7 1.9 65.1 4164 1.9 64.2 3353 13.2 5470 22.3 3841 
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Coverage of malaria control measures 
Eight months after the 2009 distribution campaign, ITN coverage (measured by the 
possession of at least one ITN per household) reached 78.7% (77.4–80.0). In 2011, it was 
57.7% (56.0–59.9). In 2009, coverage ranged from 51.7% in Biyela (peri-urban) to 92.7% in 
Maluku II (peri-urban) (Table 3.4), with a mean number of 2.0 ITNs per household. In 2011, 
ITN coverage ranged from 34.4% in Biyela to 81.8% in Kinshasa, with a mean number of 1.9 
ITNs per household (1.1).  
The most common reasons for not owning an ITN, as given by households in both the 2009 
and 2011 surveys, included not having obtained the ITN during the mass distribution 
campaign (38.7% and 23.8%), either because they were absent (26.6%, 2009) during the 
campaign or because the stock had been sold out (3.8% and 18.8%). A high proportion of 
respondents reported having discarded or destroyed their ITN because of rumours (7.4% and 
23.8%). Other reasons given were heat (2.4% and 10.6%) and the absence of mosquitoes at 
home (9.4% in 2009).  
The proportion of respondents who reported that their child slept under an ITN the night 
before the survey decreased from 65.8% (63.5–66.0) in 2009 to 45.0% (43.6–46.8) in 2011. 
Figures 3.6 and 3.7 show the geographical distribution of ITN usage among children under 
five, geo-referenced and mapped at the level of the HA for both surveys. Use rate decreases 
progressively towards the periphery in both surveys, with markedly lower use rates (<30%) in 
the south-eastern and western health zones of Biyela (30.8%, 2009; 17.3%, 2011), Selembao 
(53.3% 2009; 28.4% 2011), Kikimi (27.2% 2009) and Kimbanseke (20.1% 2011).  
A higher proportion of pregnant women, 83.1% (77.5–87.7), reported using an ITN in 2009, 
than in 2011, were reported use decreased to 43.1% (37.5–48.9). Again, the HZs on the 
outskirts of the city showed the lowest use rates. 
 
A malaria risk map in Kinshasa 
45 
 
Table 3-4: Malaria control indicators, by health zone. 
 
 
 
 
Health zone Children < 5 years having slept under an 
ITN the night before the survey [95% 
CI] 
Households that possess at least one ITN  
[95% CI] 
Survey 2009 Survey 2011 Survey 2009 Survey 2011 
% N % N % N % N 
Bandalungwa   36.2 149   61.0 100 
Barumbu   55.9 143   70.7 99 
Binza Météo 63.4 331 34.4 131 79.0 200 47.0 100 
Binza Ozone   50.0 158   58.0 100 
Biyela 30.8 422 17.3 150 51.7 259 34.4 90 
Bumbu 81.2 393   91.2 260   
Gombe   57.9 159   68.0 100 
Kalamu I   53.4 73   60.0 50 
Kalamu II   64.3 221   72.7 150 
Kasa Vubu 78.5 302   82.8 263   
Kikimi   27.2 151   37.0 100 
Kimbanseke   20.1 154   31.0 100 
Kingabwa 68.7 371   66.7 252   
Kingasani   40.8 174   58.0 112 
Kinshasa   73.2 149   81.8 99 
Kintambo   61.8 165   73.5 102 
Kisenso 50.7 341   72.3 242   
Kokolo 72.2 36   92.0 25   
Lemba 66.1 301 36.0 150 83.4 259 60.0 100 
Limete 69.0 390 51.4 148 71.8 262 51.0 100 
Lingwala   53.2 154   70.0 100 
Makala   44.5 155   52.0 100 
Maluku II 84.1 292   92.7 260   
Masina I   47.9 163   57.0 100 
Masina II 60.7 425 37.3 161 82.1 257 46.0 100 
Matete 66.1 387   80.4 260   
Mont Ngafula I   48.1 154   55.0 100 
Mont Ngafula II   37.3 158   56.0 100 
Ndjili 59.8 381   79.5 258   
Ngaba   67.1 152   74.0 100 
Ngiri Ngiri 82.1 418 48.6 140 91.1 259 67.9 106 
Police   33.5 164   50.0 102 
Selembao 53.3 379 28.4 159 68.1 257 51.0 102 
TOTAL 
65.0  
[63.7-66.3] 
5169 
45.0  
[43.6-46.8] 
3835 
78.7  
[77.4-80.0] 
3896 
57.7  
[56.0-59.9] 
2512 
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Figure 3-6: Percentage of children <5 years having slept under an ITN the night before the survey in 2009, by health area. 
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Figure 3-7: Percentage of children <5 years having slept under an ITN the night before the survey in 2011, by health area. 
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3.5 Discussion 
Kinshasa falls within the perennial transmission in the classification of the Mapping Malaria 
Risk in Africa (MARA) project. This study created the first malaria risk map at the scale of a 
health area, the lowest level of the health system in DRC. Although the mean endemicity 
level seems to have declined over the last 30 years in Kinshasa, the results from the 2009 and 
2011 cross-sectional surveys show that malaria was still a public health concern (Kazadi et 
al., 2004; Mulumba et al., 1990; Ngimbi et al., 1982). The geographic pattern of endemicity 
is comparable to that identified in earlier studies done in Kinshasa (Ngimbi et al., 1982; 
Mulumba et al., 1990; Kazadi et al., 2004). Prevalence is clearly highest in the more densely 
populated and less urbanised districts in the periphery, although marked variations in rates are 
apparent, even over a few kilometres. These findings are consistent with a recent meta-
analysis that used data on the prevalence of malaria parasitaemia to document an analogous 
situation in other cities in Sub-Saharan Africa (Pond, 2013). A similar reduction in the annual 
P. falciparum entomological inoculation rates (APfEIR) has been observed in the more 
urbanised central areas, with a tendency to increase gradually towards the peri-urban areas 
(Keiser et al., 2004; Hay et al., 2000; Robert et al., 2003). The relative reduction in the 
APfEIR in urban areas was also reported in Kinshasa and in Brazzaville (Coene et al., 1993; 
Karch et al., 1992; Trape et al., 1987). Trape JF et al. suggested a relationship between levels 
in transmission in certain districts of Brazzaville and prevalence of malaria reported (Trape et 
al., 1987). The existence of a linear correlation between APfEIR and prevalence was also 
confirmed by Hay SI et al. (Hay et al., 2005).  
 
In this study, the overall standardised malaria prevalence was 11.9% in children 6–59 
months, ranging from 0.5% in the downtown health zones of Kinshasa and Lingwala, to 
31.7% in Biyela, a semi-rural peripheral district extending south east. Results also show that 
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spatial heterogeneity is high in the central and northern urbanised HZs, whereas in the 
western and south-eastern HZs, more homogeneous levels of high risk can be found (Figure 
2). It is likely that the proximity to productive breeding sites could account for the uneven 
distribution of malaria risk, together with socio-economic stratification and level of control 
measures (Machault et al., 2009; Clark et al., 2008; WHO, 2007). Kazadi et al. observed that 
initial urbanisation might increase levels of malaria transmission through increased human 
density and the creation of breeding sites favourable to Anopheles gambiae, the main local 
vector (Kazadi et al., 2004; Coene et al., 1993). In a second phase, the densification of human 
habitations reduces potential mosquito breeding sites and hence transmission levels. In 
Kinshasa, the increase in the density of dwellings in older urban districts has progressively 
eliminated the last remaining open spaces, contributing to the scarcity of Anopheles breeding 
sites through elimination and pollution. However, exceptions exist, especially where urban 
agriculture and gardens persist. In particular, the districts extending towards the south-east 
and west maintain a semi-rural character. Various studies have documented the presence of 
higher prevalence or transmission rates in areas close to agriculture fields (Klinkenberg et al., 
2008; Yadouleton et al., 2010; Stoler et al., 2009; Matthys et al., 2006; Afrane et al., 2004; 
Clark et al., 2008). Kinshasa is crossed by rivers from north to south, creating large flood 
zones where much of the gardening is practised. This characteristic is particularly evident in 
the large semi-rural areas south west of the boulevard Lumumba, encompassing the health 
zones of Kingasani, Biyela, Kimbanseke and Kikimi. The areas favour Anopheles sp. 
breeding sites and are consistent with the more homogeneous transmission pattern observed 
in the areas on the outskirts of the city, compared to the more urbanised zones.  
 
Additional factors, such as the use of personal protection against mosquitoes or socio-
economic status, should also be considered as important determinants explaining the 
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distribution of disease prevalence. A spatial regression analysis linking malaria prevalence to 
risk factors for malaria in Kinshasa will be published separately (Ferrari et al., 2016). 
 
Not surprisingly, the age groups with the highest prevalence, independent from the level of 
endemicity in both urban and semi-rural areas (Ngiri Ngiri and Selembao), were those aged 
5–9 and 15–19. Hence, in Kinshasa, malaria infections seem to occur more frequently late in 
childhood. This could be in part explained by the age specific ITN usage across age groups, 
with highest use in younger children in the low endemicity setting (percent of usage in Ngiri 
Ngiri 49% compared to 28% in Selembao) as compared to lower and similar utilization rates 
among age groups in the high transmission setting (Ferrari et al., 2016). Higher malaria 
prevalence rates in older children were also found in school surveys carried out in the 1980s 
in Kinshasa and in Brazzaville. At that time, the finding was attributed to the increased use of 
antimalarials in early childhood (Trape, 1987; Sexton et al. 1984).  
 
A concerted effort to scale-up ITN coverage through a free distribution in Kinshasa led to an 
ITN ownership rate of 78.7% of households in 2009. This represented a 395% increase in 
household possession of  ≥1 ITN over the 2007 estimate of only 15.9% (DHS-DRC, 2007). 
However, 24 months after the distribution campaign, ITN ownership had decreased to 57.7% 
of households. Clearly, this points to the need for stronger programmes for routine ITN 
distribution as it occurs in most endemic settings, in addition to the campaigns, (Grabowsky 
et al., 2007).  
 
The prevalence of anaemia was high in 2009 (65.1% in children 6 to 59 months) and in 2011 
(64.2%). This is consistent with the 69.2% prevalence reported by the DHS 2007 (DHS-
DRC, 2007) Furthermore, the distribution of anaemia across Kinshasa was highly 
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heterogeneous as shown in Figure 4, and the absence of a spatial trend seems in favour of the 
role of additional factors other than malaria in the aetiopathogenesis of this condition. 
Multiple factors account for anaemia and their contributions can vary according to the setting 
(Hall et al., 1982). In Kinshasa, 23% and 9% of children suffer from chronic and severe 
forms of malnutrition (DHS-DRC, 2007) and sickle cell anaemia is widespread (Tshilolo et 
al., 2009).  
 
The maps we present for different variables reflect survey results from two distinct time 
periods and seasons. Since malaria transmission is neither constant throughout the year nor 
between years, this has likely introduced some mistakes. To account for these differences, we 
tried standardising prevalence rates, but that is an imperfect means of accounting for such 
differences. Moreover, surveys were based on detection of cases of uncomplicated malaria 
and, therefore, it is not possible to draw strong conclusions about the prevalence of anaemia, 
which is more often related to severe malaria.  
 
3.6 Conclusions 
This study provides the first comprehensive risk map of malaria at the level of the health 
areas in Kinshasa, a mega-city in a highly endemic malarious zone. Overall malaria 
prevalence has undoubtedly decreased over the last 30 years, but it is impossible to quantify 
the effect given the lack of representative historical data. As expected, prevalence rates were 
lower in the central urban districts compared to the more peripheral and more rural districts 
(Kazadi, 2004 et al.). The penetration of malaria control measures, especially ITNs, remains 
insufficient and is less successful in less developed and less accessible HZs on the outskirts 
of the city. Hopefully, this gap can be closed in the years to come with renewed efforts by the 
National Malaria Control Programme and its partners. Despite the methodological 
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limitations, the risk map provides a good baseline assessment against which to assess the 
effect of future control efforts.  
 
Malaria and anaemia risk factors in Kinshasa 
53 
 
4 Identifying risk factors for Plasmodium infection and anaemia in 
Kinshasa, Democratic Republic of Congo 
 
Giovanfrancesco Ferrari
1,2
, Henry M Ntuku
3
, Amanda Ross
1,2
, Sandro Schmidlin
1,2
, Didier M 
Kalemwa
1,2
, Antoinette T Kitoto
3
, Christian Lengeler
1,2
 
 
1 
Swiss Tropical and Public Health Institute, P.O. Box, 4002, Basel, Switzerland 
2 
University of Basel, Basel, Switzerland 
3 
Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo  
 
 
 
 
 
 
 
 
 
This paper has been published in the Malaria Journal 2016, 15:362. 
 
 
 
 
 
 
Malaria and anaemia risk factors in Kinshasa 
54 
 
4.1 Abstract 
Background 
There is little data on the risk factors for malaria infection in large cities in central Africa and in all 
age groups. There may be different associations with the risk factors for areas with different malaria 
transmission intensities such as the effect of fever or age. This study aimed at identifying risk 
factors associated with Plasmodium infection and anaemia among children 6-59 months and 
individuals aged older than five years in Kinshasa, a large city with heterogeneity in malaria 
prevalence.  
 
Methods 
This study analysed data from 3342 children aged 6-59 months from 25 non-rural health zones 
(HZs) and for 816 individuals aged older than five years from two HZs in Kinshasa (non-rural), 
collected during a cross sectional malaria survey in 2011. Logistic regression with random effects 
was used to investigate predictors for malaria and anaemia. Differences in risk factors in areas with 
a prevalence of less than 10% and 10% or greater were investigated.  
 
Results 
There was evidence of a different age-pattern in the two transmission settings. For children under 
five years, the highest prevalence of malaria was observed in the 48-59 months group in both 
transmission settings but it increased more gently for the lower transmission HZs (p=0.009). In a 
separate analysis in children over five years in two selected HZs, the peak prevalence was in 5-9 
years old in the higher transmission setting and in 15-19 years old in the lower transmission setting. 
Reported fever was associated with malaria in both transmission strata, with no evidence of a 
difference in these associations (p=0.71); however in children older than five years there was a 
significant interaction with a stronger association in the low transmission HZ. Insecticide-treated 
net (ITN) use was associated with a lower risk of malaria infection in children 6-59 months in the 
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high transmission HZs. Similar estimates were found in children over five years and the lower 
transmission HZ but the associations there were not significant. There was no evidence of a 
difference in these associations by strata. The risk of anaemia decreased with increasing age in all 
strata, whereas it increased with malaria infection and reported fever. ITN use did not show 
evidence of protection against anaemia. Low socio-economic status was associated with malaria in 
high transmission setting in children 6-59 months and anaemia in low transmission setting.   
 
Conclusions 
This study shows that in areas of low transmission in Kinshasa, the peak prevalence occurs in older 
age groups however ITN use was highest in children under five years. Targeted distribution of ITN 
to all age groups should be continued. For most risk factors, there was no evidence of an interaction 
with transmission intensity however the associations with age and with fever in the last two weeks 
did vary significantly.  
 
 
 
 
Keywords: Malaria, Malaria risk, Anaemia, Fever, ITN use, ITN ownership,  Democratic Republic 
of Congo, Kinshasa 
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4.2 Background 
Urbanization, widespread use of malaria control measures and effective treatment in recent 
years have had a significant impact in reducing the prevalence of malaria in many African 
cities, as well as contributing to the more heterogeneous risk in malaria observed in many 
urban areas (Keiser et al., 2004; Matthys et al., 2006; Staedke et al., 2003; Wang et al., 2005; 
Keiser et al., 2004; Caldas de Castro et al., 2004). In Kinshasa, the capital of the DRC malaria 
has considerably decreased during the past thirty years. A survey conducted in 2011, showed 
a prevalence of 17% among children 6-59 months of age, and the existence of a gradient of 
prevalence from the centre (lower risk) to the periphery (higher risk) (Ferrari et al., 2016; 
Kazadi et al., 2004; Mulumba et al., 1990; Ngimbi et al., 1982). Moreover, traditionally 
attention has focused on high risk groups, and little attention has been put on older children 
and adults. Understanding the complex heterogeneity of risk factors that can contribute to 
increased risk of malaria in urban settings across different age groups will enable a more 
effective use of control measures.  
In addition, many studies have shown that control of malaria can reduce the prevalence of 
childhood anaemia (Korenromp et al., 2004; Lengeler et al., 2004; Premji et al., 1995; Premji 
et al., 1995; Mathanga et al., 2010). Anaemia, in particular due to iron deficiency, is a major 
public health challenge in paediatric populations in sub-Saharan Africa, and in DRC it is 
among the top five leading causes of years lived with disability (YLDs) (GBD 2010). In 
Kinshasa the current rate of anaemia (Hb<11 g/dl) among pre-school aged children was 65% 
in 2011 (Ferrari et al., 2016).  
The present study investigated individual and household risk factors for Plasmodium 
falciparum infection and anaemia in Kinshasa in children aged 6-59 months in 25 non-rural 
HZs, as well as in individuals aged five years and older in a separate analysis in two HZs.  
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4.3 Method 
Study area and recruitment of study participants 
This study used cross-sectional data from a survey conducted in 2011 in Kinshasa, the capital 
city of the DRC, which is described in detail in Ferrari et al. 2016 (Ferrari et al., 2016). In 
summary, data collection took place from April to June 2011, before the end of the rainy 
season and included 2512 households selected through a multi stage sampling procedure to 
obtain a sample of 3342 children aged 6 to 59 months from 25 health zones (HZs) and 816 
individuals aged five years or older from two HZs selected out of the 25 (Ngiri Ngiri and 
Selembao). The HZ represents the primary operational unit of the health system in DRC, and 
covers about 150.000 inhabitants. It includes a general referral hospital, health centres and 
lower-level health facilities. Each HZ is further divided in health areas. In Kinshasa malaria 
transmission is ensured by Anopheles gambiae s.l., and usually peaks during the long rainy 
season from September to May (Coene et al., 1993). From each participant a finger-prick 
blood sample was collected to test for malaria by rapid diagnostic test (RDT) (SD Bioline 
Malaria Antigen P.f/Pan), providing an immediate on-site diagnosis. The level of 
haemoglobin (Hb) was measured with a HemoCue 201 plus+ photometer (Ångelholm, 
Sweden). Axillary temperature was measured using a digital thermometer and the individual’s 
history of fever in the preceding two weeks was also recorded. A standardized electronic 
survey questionnaire was administered to all heads of eligible household using an HTC 
smartphone running with Android OS. The survey questionnaire was an adaptation of the 
standard Malaria Indicator Survey Questionnaire from the Roll Back Malaria Partnership 
(www.RBM.org) created with the Build component of the Open Data Kit (ODK) software 
(University of Washington & Google Foundation). Respondents were asked about 
demographic information of the residents, educational level, assets owned (such as television 
and bicycle), presence of insecticide treated bed net (ITN) and use of ITN the night prior to 
the survey.  
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Assessing risk factors of Plasmodium infection and anaemia  
The analysis was stratified according to malaria transmission intensity, based on the 
prevalence of malaria infection measured in 2011 among children 6-59 months (Ferrari et al., 
2016). The prevalence ranged from 0.7 % to 46% in children aged 6 to 59 months. Two strata 
were defined at the HZ level: a prevalence of infection below 10% or a prevalence above 
10%. The 10% prevalence cut-off was an arbitrary selection to allow enough observations in 
each strata. Plasmodium infection and anaemia were assessed for their association with a 
number of variables. For individuals aged older than five years, data collection took place in 
only two HZs with different transmission intensities (Ngiri Ngiri, 0.8% and Selembao, 26.8% 
in children younger than 5 years); these data were analysed separately.  
The primary outcomes of the study were the presence or absence of Plasmodium malaria as 
measured by rapid diagnostic test (RDT) and the anaemia test results. A child aged 6 to 59 
months was defined as anaemic if his/her Hb was below 11.0 g/dl. Therefore, the outcomes 
variables were dichotomous. Recorded explanatory variables were: age, gender, educational 
level of the respondent, occupation of the respondent, insecticide mosquito-net use and 
reported fever during the last two weeks and wealth index. A wealth index, calculated 
according to the method of Filmer et al. (2001), was constructed for each household based on 
ownership of household assets (having a television, a radio, etc.) and house characteristics 
(having electricity, drinking water, toilet type, roof and ground material) (Filmer et al., 2001). 
Three categories were generated to classify households ranging from the poorest to the least 
poor in the community.  
 
Statistical methods 
The proportions with malaria infection and with anaemia were analysed using a logistic 
regression model with random effects to take account clustering by health zone and health 
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area. All analysis were performed separately for children (6 to 59 months) and individuals 
older than five years since they were sampled from different HZs. The analysis was carried 
out using STATA version 13 (Stata Corporation College Station, TX, USA). 
 
Ethics approval and consent to participate 
Ethical approval of the study was obtained from the ethics committee of the Kinshasa School 
of Public Health University of Kinshasa, in DRC, as well as the ethical committee in Basel 
(Ethikkommission beider Basel, Basel-Stadt). Individual written informed consent was 
obtained by parents or guardian on behalf of their children (until the age of 10) or by the 
adults study participants themselves. In addition, assent was obtained from children over 10 
years of age. Every precaution to minimize the risk of infection during blood sampling was 
taken. All patients who tested positive for malaria by RDT were treated for free by the 
nationally recommended therapy combination with artemisinin, artesunate plus amodiaquine 
(ASAQ), previously placed at the health centre of reference of the corresponding health area.  
 
4.4 Results  
Data collection took place in 2512 households, in the 25 HZs that were visited. A total of 
3342 children aged 6-59 months were included in the analysis, 1118 and 2224 in the low and 
high transmission setting respectively. A similar number of males (50%) and females were 
included; the median age was 30 months (90% central range 9–55). Table 4-1 shows the 
number of children examined, by HZ and by transmission strata. For individuals above 5 
years, data collection took place in two HZs only and included 816 individuals, of which 34% 
were males and the median age was 22 years (90% central range 6–62).  
 
Malaria and anaemia risk factors in Kinshasa 
60 
 
Table 4-1: Number of children 6 to 59 months examined and the prevalence of Plasmodium 
spp in Kinshasa, by health zone and strata, 2011. 
 
Health zone Malaria prevalence in children aged 6-59 months  
[95% CI] 
<10% >10% 
%  N %  N 
Bandalungwa 1.5 [0.2-5.3] 134    
Barumbu 2.4 [0.5-6.9] 125    
Binza Météo    24.8 [17.0-34.0] 109 
Binza Ozone    19.1 [12.9-26.7] 136 
Biyela    46.0 [37.1-55.1] 126 
Gombe    11.5 [6.7-18.0] 139 
Kalamu I    16.2 [8.4-27.1] 68 
Kalamu II 2.5 [0.8-5.7] 200    
Kikimi    32.8 [24.9-41.6] 131 
Kimbanseke    36.1 [27.9-44.9] 133 
Kingasani    25.0 [18.3-32.7] 152 
Kinshasa 0.7 [0.0-4.0] 136    
Kintambo    11.7 [7.0-18.1] 145 
Lemba 7.7 [3.8-13.7] 130    
Limete    17.3 [11.3-24.8] 133 
Lingwala 0.7 [0.0-4.1] 135    
Makala    17.9 [11.8-25.5] 134 
Masina I    12.3 [7.3-19.0] 138 
Masina II    24.8 [17.7-33.0] 133 
Mont Ngafula I    33.6 [25.7-42.2] 134 
Mont Ngafula II    35.3 [27.3-44.1] 133 
Ngaba 7.5 [3.6-13.3] 134    
Ngiri Ngiri 0.8 [0.0-4.2] 124    
Police    17.0 [11.1-24.5] 135 
Selembao    26.8 [19.9-34.7] 145 
TOTAL N   1118   2224 
 
Risk factors for Plasmodium infection in children aged 6-59 months (25 HZs) 
The risk factors for Plasmodium infections in children 6-59 months are shown in Table 4-2. 
There was an increase in the proportion with malaria infection with age in both transmission 
strata. The greatest risk was in children 48-59 months: an odds ratio (OR) of 5.86 (95% 
confidence interval (CI) 1.62-21.17) for the 36-47 months group and an OR of 15.53 (95% CI 
4.26-56.64) for the 48-59 months group, compared to the youngest age group. The effect was 
also seen in higher transmission strata, although the OR was lower: an OR of 1.73 (95% CI 
1.36-2.20) for the 36-47 months group and an OR of 2.54 (95% CI 1.93-3.35) for the 48-59 
Malaria and anaemia risk factors in Kinshasa 
61 
 
months group compared to the youngest age group. The interaction between age and 
transmission intensity was significant (p=0.009).  
Treated net use was found to significantly lower malaria infection risk in the higher 
transmission strata with 38% protection (OR=0.62, 95% CI 0.50 – 0.77), however the effect 
was not significant in the lower transmission strata. Children who reported fever in the last 
two weeks had a significantly elevated risk of malaria infection in both strata. 
Higher education levels showed a trend towards being protective in both transmission settings 
(Table 2). However there was no evidence of an association with the occupation of the 
respondent. Finally, children living in the wealthiest tertile were significantly less likely to 
have a malaria infection compared to the children from the poorest tertile in strata of high 
transmission (OR=0.27, 95% CI 0.20-0.38, p<0.001). No evidence was found in the HZs with 
less than 10% prevalence (OR=0.82, 95% CI 0.31-2.13, p=0.83), however the interaction 
between socioeconomic status and transmission was not significant (p=0.14).  
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Table 4-2: Univariate and multivariable analysis of risk factors associated with malaria in children between 6 and 59 months of age in Kinshasa, 
stratified by malaria transmission zone, 2011.  
   < 10% prevalence   > 10% prevalence  
   
Univariate analysis Multivariate analysis 
  
Univariate analysis Multivariate analysis 
Interaction by 
transmission zone 
Variable n (%) OR 95% CI P-value OR 95% CI P-value n (%) OR 95% CI P-value OR 95% CI P-value P-value 
Sex 
                 
Male 521 3.1 1 
  
1 
  
1141 23.6 1 
  
1 
   
Female 527 2.7 0.86 0.42-1.8 0.687 0.87 0.41-1.88 0.731 1162 23.3 1.01 0.84-1.23 0.886 0.98 0.80-1.21 0.857 0.670 
Age 
                 
6-35 months 446 0.7 1 
  
1 
  
958 17.8 1 
  
1 
   
36-47 months 416 3.1 4.76 1.35-16-84 
 
5.86 1.62-21.17 
 
872 25.5 1.57 1.26-1.97 
 
1.73 1.36-2.20 
  
48-59 months 186 7.5 12.02 3.41-42.34 < 0.001 15.53 4.26-56.64 < 0.001 473 31.1 2.08 1.61-2.68 < 0.001 2.54 1.93-3.35 < 0.001 0.009 
Reported treated bed net use 
                 
No  446 3.6 1 
  
1 
  
1342 27.6 1 
  
1 
   
Yes 596 2.3 0.65 0.31-1.34 0.240 0.82 0.38-1.76 0.606 961 17.6 0.56 0.46-0.69 < 0.001 0.62 0.50-0.77 < 0.001 0.705 
Fever in the last two weeks  
                 
No 798 1.6 1 
  
1 
  
1744 18.3 1 
  
1 
   
Yes 245 6.9 4.50 2.15-9.41 < 0.001 5.53 2.52-12.11 < 0.001 559 39.4 2.89 2.34-3.56 < 0.001 2.94 2.36-3.68 < 0.001 0.254 
Education of the respondent 
                 
No education 24 8.3 1 
  
1 
  
220 32.3 1 
  
1 
   
Primary 390 3.6 0.41 0.09-1.92 
 
0.35 0.07-1.82 
 
1135 26.5 0.76 0.55-1.03 
 
0.90 0.65-1.26 
  
Secondary 471 2.8 0.31 0.07-1.47 
 
0.28 0.05-1.50 
 
740 19.7 0.52 0.37-0.72 
 
0.78 0.54-1.14 
  
Superior and above 163 0.6 0.07 0.01-0.78 0.080 0.05 0.00-0.68 0.084 208 10.6 0.25 0.15-0.42 < 0.001 0.47 0.26-0.86 0.056 0.754 
Occupation of the respondent 
                 
Without occupation 720 2.8 1 
  
1 
  
1523 23.2 1 
  
1 
   
Manual labour 86 2.3 0.83 0.19-3.63 
 
0.98 0.21-4.47 
 
212 27.8 1.27 0.92-1.76 
 
1.29 0.91-1.84 
  
Self employed 104 3.8 1.40 0.47-4.18 
 
1.58 0.49-5.11 
 
275 24.7 1.08 0.80-1.46 
 
1.01 0.74-1.38 0.236 
 
Employed 138 2.9 1.04 0.35-3.11 0.931 1.79 0.51-6.31 0.742 293 20.1 0.83 0.61-1.13 0.229 1.35 0.95-1.94 
 
0.860 
Wealth tertile 
                 
Poorest 196 4.1 1 
  
1 
  
1175 31.6 1 
      
Middle 298 3.0 0.73 0.28-1.93 
 
0.72 0.26-2.04 
 
575 19.5 0.52 0.41-0.67 
 
0.54 0.42-0.70 
  
Wealthiest 546 2.4 0.57 0.23-1.40 0.488 0.82 0.31-2.13 0.828 540 9.44 0.23 0.17-0.31 < 0.001 0.27 0.20-0.38 < 0.001 0.142 
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Risk factors for Plasmodium infection in individuals older than 5 years (2 HZs) 
The risk factors for Plasmodium infection in individuals aged older than five years are shown 
in Table 4-3. The association between age and malaria infection was strong. The highest 
prevalence was observed in the 15-19 years age group in the low transmission HZ of Ngiri 
Ngiri with an OR of 7.11 (95% CI 1.17-43.05) compared to the 5-9 years-old. In the higher 
transmission HZ of Selembao however, ORs were lower and more homogeneously distributed 
across all age groups, compared to the 5-9 years-old group which showed the highest 
prevalence. The interaction between age and transmission intensity however was not 
significant (p=0.11).  
ITN use was not found to significantly lower the prevalence of malaria infection, although the 
estimates were in the direction of being protective. Individuals aged five years and older who 
reported fever in the last two weeks had an elevated risk of having malaria infection in both 
sites, and the association was stronger for the lower transmission: OR = 38.71 (95% CI 11.08-
135.23), and OR = 2.05 (95% CI 1.07-3.95) in Selembao, with a highly significant interaction 
term (p<0.0001). There was no evidence of an effect of higher education levels, occupation of 
the respondent or socio-economic status.  
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Table 4-3: Univariate and multivariable analysis of risk factors associated with malaria in individuals aged > 5 years in Kinshasa, stratified by 
malaria transmission zone, 2011. 
a
 Combined due to low number of observations 
   Ngiri Ngiri: 0.8% prevalence   Selembao: 26.8% prevalence  
   Univariate analysis Multivariate analysis   Univariate analysis Multivariate analysis 
Interaction by 
transmission zone 
   
  
Variable n (%) OR 95% CI P-value OR 95% CI P-value n (%) OR 95% CI P-value OR 95% CI P-value P-value 
Sex 
                 
Male 142 5.6 1.0 
  
1.0 
  
143 28.7 1.0 
  
1.0 
   
Female 257 4.3 0.75 0.29-1.91 0.548 0.74 0.23-2.37 0.616 274 20.1 0.62 0.39-1.00 0.050 0.66 0.40-1.08 0.102 0.733 
Age 
                 
5-9 years 62 4.8 1.0 
  
1.0 
  
76 34.2 1.0 
  
1.0  
  
10-14 years 68 1.5 0.29 0.03-2.90 
 
0.22 0.01-3.39 
 
68 25.0 0.64 0.31-1.32 
 
0.79 0.37-1.72 
  
15-19 years 48 14.6 3.36 0.82-13.75  7.11 1.17-43.05  46 28.3 0.76 0.34-1.68 
 
0.85 0.37-1.96  
 
> 20  221 3.6 0.74 0.19-2.87 0.022 1.09 0.21-5.72 0.009 227 17.6 0.41 0.23-0.74 0.021 0.45 0.24-0.83 0.042 0.105 
Reported treated bed net use 
                 
No 244 6.1 1.0 
  
1.0 
  
315 25.7 1.0 
  
1.0 
   
Yes 155 2.6 0.40 0.13-1.24 0.089 0.33 0.09-1.21 0.075 102 14.7 0.50 0.27-0.91 0.017 0.57 0.30-1.09 0.078 0.746 
Fever in the last two weeks  
                 
No 366 2.2 1.0 
  
1.0 
  
361 21.6 1.0 
  
1.0 
   
Yes 33 33.3 22.38 8.17-61.27 < 0.001 38.71 11.08-135.23 < 0.001 54 33.3 1.81 0.98-3.37 0.066 2.05 1.07-3.95 0.036 < 0.001 
Education of the respondent 
                 
No education 8 12.5 1.0 
  
1.0 
  
35 34.3 1.0 
  
1.0 
   
Primary 120 5.0 0.37 0.04-3.50 
 
0.18 0.01-2.49 
 
186 26.9 0.70 0.33-1.52 
 
0.82 0.36-1.87 
  
Secondary 189 4.8 0.35 0.04-3.16 
 
0.27 0.02-3.48 
 
145 18.6 0.44 0.19-0.99 
 
0.49 0.20-1.19 
  
Superior and above 82 3.7 0.27 0.02-2.91 0.802 0.17 0.01-2.87 0.647 51 13.7 0.30 0.11-0.88 0.041 0.32 0.09-1.13 0.115 0.865 
Occupation of the respondent 
                 
Without occupation 244 5.7 1.0 
  
1.0 
  
200 26.0 1.0 
  
1.0 
   
Manual labourer  37 2.7 0.46 0.06-3.58 
 
0.82 0.09-7.91 
 
64 23.4 0.87 0.45-1.68 
 
1.17 0.58-2.37 
  
Self employed 27 3.7 0.63 0.08-5.00 
 
1.33 0.13-13.64 
 
56 16.1 0.55 0.25-1.19 0.398 0.56 0.24-1.28 0.425 
 
Employed  91 3.3 0.56 0.16-2.00 0.696 0.59 0.11-3.20 0.913 97 20.6 0.74 0.41-1.33 
 
1.12 0.56-2.23 
 
0.911 
Wealth tertile 
                 
Poorest & middle 
a
 162 4.9 1.0 
  
1.0 
  
201 25.4 1.0 
  
1.0 
   
Wealthiest 237 4.6 0.94 0.37-2.38 0.891 1.31 0.18-9.64 0.618 99 19.2 0.74 0.42-1.30 0.293 0.91 0.48-1.73 0.779 0.676 
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Risk factors for anaemia in children aged 6-59 months (25 HZs) 
The risk of having anaemia was found to decline progressively with increasing age (Table 4-
4) in both low and high transmission strata (p<0.001). Although there was no evidence that 
malaria infection increased the risk of having anaemia in the low transmission strata 
(OR=2.01, 95% CI 0.89-4.51), this effect was significant in the higher transmission strata 
(OR=3.40, 95% CI = 2.60–4.44). There was no evidence that reported ITN use was protective 
for the anaemia status in either strata. There was also no evidence of an association with 
fever, nor with education or occupation. Belonging to the wealthiest tertile was borderline 
significantly associated with the risk of having anaemia in both low transmission (OR=0.68, 
95% CI=0.47-0.99) and high transmission strata. 
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Table 4-4: Univariate and multivariable analysis of risk factors associated with anaemia in children between 6 and 59 months of age Kinshasa, 
stratified by malaria transmission zone, 2011 
   < 10%    > 10%   
   Univariate analysis Multivariate analysis   Univariate analysis Multivariate analysis 
Interaction by 
transmission zone 
     
Variable n (%) OR 95% CI P-value OR 95% CI P-value n (%) OR 95% CI P-value OR 95% CI P-value P-value 
Sex 
                 
Male 521 55.5 1.0 
  
1.0 
  
1161 69.0 1.0 
  
1.0 
   
Female 526 59.7 1.19 0.93-1.52 0.167 1.21 0.93-1.58 0.160 1142 66.5 0.89 0.75-1.07 0.210 0.93 0.77-1.12 0.355 0.064 
Age 
                 
6-35 months 445 73.0 1.0   1.0   957 80.6 1.0   1.0    
36-47 months 416 50.5 0.38 0.28-0.50  0.38 0.28-0.51  873 61.6 0.39 0.31-0.48  0.35 0.28-0.43   
48-59 months 186 36.6 0.21 0.15-0.31 < 0.001 0.19 0.13-0.28 < 0.001 473 53.3 0.28 0.22-0.35 < 0.001 0.23 0.18-0.29 < 0.001 0.473 
Education of the respondent 
                 
No education 24 70.8 1.0 
  
1.0 
  
220 75.0 1.0 
  
1.0 
   
Primary 390 62.1 0.67 0.27-1.66 
 
0.64 0.24-1.70 
 
1135 69.4 0.76 0.54-1.05 
 
0.83 0.58-1.20 
  
Secondary 471 57.7 0.56 0.23-1.38 
 
0.57 0.21-1.50 
 
740 64.9 0.62 0.44-0.86 
 
0.78 0.53-1.15 
  
Superior and above 162 44.4 0.33 0.13-0.84 < 0.001 0.35 0.13-0.99 0.037 208 61.5 0.53 0.35-0.81 0.004 0.80 0.49-1.31 0.629 0.412 
Occupation of the respondent 
                 
Without occupation 720 60.7 1.0 
  
1.0 
  
1523 68.8 1.0 
  
1.0 
   
Manual labourer 86 39.5 0.42 0.27-0.67 
 
0.41 0.25-0.68 
 
212 69.3 1.03 0.75-1.40 
 
0.97 0.69-1.36 
  
Self-employed 104 60.6 1.00 0.65-1.52  1.03 0.65-1.63 
 
275 65.1 0.85 0.64-1.11  0.77 0.58-1.03  0.010 
Employed 137 50.4 0.66 0.46-0.95 < 0.001 0.94 0.61-1.44 0.005 293 63.8 0.80 0.62-1.04 0.268 0.92 0.68-1.24 0.313 
 
Net use 
                 
No 446 57.2 1.0 
  
1.0 
  
1341 68.3 1.0 
  
1.0 
   
Yes 595 57.5 1.01 0.79-1.30 0.922 0.91 0.70-1.20 0.515 962 67.0 0.94 0.79-1.13 0.524 1.09 0.90-1.32 0.512 0.653 
Malaria infection 
                 
No 1017 57.3 1.0 
  
1.0 
  
1762 63.1 1.0 
  
1.0 
   
Yes 30 66.7 1.49 0.69-3.21 0.302 2.01 0.89-4.51 0.078 540 83.1 2.89 2.26-3.69 < 0.001 3.40 2.60-4.44 < 0.001 0.119 
Fever in the last two weeks  
                 
No 798 54.6 1.0 
  
1.0 
  
1744 65.0 1.0 
  
1.0 
   
Yes 244 66.4 1.64 1.22-2.21 < 0.001 1.30 0.93-1.80 0.197 559 76.4 1.74 1.40-2.17 < 0.001 1.32 1.04-1.67 0.039 0.755 
Wealth tertile 
                 
Poorest 196 62.2 1.0 
  
1.0 
  
1176 72.9 1.0 
  
1.0 
   
Middle 298 65.8 1.17 0.80-1.70 0.423 1.14 0.76-1.71 
 
574 64.1 0.66 0.54-0.82 0.000 0.78 0.62-0.99 
  
Wealthiest 545 51.9 0.66 0.47-0.92 0.013 0.68 0.47-0.99 0.003 540 60.7 0.58 0.46-0.71 0.000 0.77 0.60-0.99 0.073 0.022 
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ITN use 
There were some age-specific differences in ITN usage (Figure 4-1), with highest use in 
younger children (p-value=0.006) in the low transmission strata. In areas of high 
transmission, ITN usage although lower appeared more homogeneously distributed across age 
groups (Figure1). No significant differences in the utilization were found among individuals 
age more than five years, in both low and high transmission strata (Figure 1).  
 
Figure 4-1: Left panel: ITN usage among children 6 to 59 months by transmission intensity. 
Right panel: ITN usage among individuals older than five years in Ngiri Ngiri (0.8%) and 
Selembao (26.8%) in Kinshasa, 2011. Light grey bars represent proportions of reported ITN 
usage in high transmission strata, and dark grey bars in low transmission strata. Error bars 
indicate 95% CI.  
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4.5 Discussion 
The identification of risk factors for malaria infection and anaemia, provides information on 
the local malaria epidemiology and has the potential to lead to a more effective and targeted 
use of malaria control measures. This study presents the results of an analysis of the 
association of a number of variables that alone or in combination could affect the risk of 
acquiring Plasmodium infection and anaemia, in a city with diverse malaria transmission 
patterns. The key results from this analysis are the association between malaria infection and 
age, with older age groups being exposed to higher risk of malaria in low transmission 
settings and a lower and more homogeneous risk across all age groups in high transmission 
settings. Shift in the age of peak prevalence towards the older groups has been described for 
malaria and other infectious diseases and is consistent with exposure-related acquired 
immunity (Woolhouse et al., 1998; Snow et al., 2002). In zones of low transmission, children 
are less exposed to infective malaria, hence delaying the age of the first infection and the 
acquisition of immunity (Winskill et al., 2011). Clearly, in Kinshasa the risk of Plasmodium 
infection seems to occur later in childhood, which is consistent with areas of rather low levels 
of transmission. The prevalence rates by HZ shown in Table 1 (range: 0.7-46.0), with most 
HZs below 30% confirm that Kinshasa overall has a moderate endemicity level. Recent 
school surveys done in Kimbanseke, a relatively high prevalence HZ southeast of Kinshasa, 
found similar results, showing children aged 10-13 at higher risk of malaria and a high 
prevalence of asymptomatic infections (Matangila et al., 2014).  
 
The relationship of ITN use by the different age groups could also influence the age pattern of 
risk that was observed: children in the youngest age group, 6-35 months, were significantly 
more likely to sleep under an ITN in the low transmission setting, whereas utilization was 
similar among age groups in high transmission setting. A similar shift in age of peak of 
prevalence towards the older children has been observed elsewhere with an increase in net 
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coverage (Wang et al., 2006). Only 44% of children 6-59 months used an ITN the night 
preceding the survey, which is still far from universal coverage. In individuals > 5 years, 
overall ITN use was even lower, with only 38% and 23.3% using an ITN in Ngiri Ngiri and 
Selembao, respectively. In addition, less than 58% of HHs owned enough ITNs to cover all 
household members in 2011. These low values are of concern.  
Higher malaria prevalence in older children has also been attributed to increased use of 
antimalarials in early childhood (Trape et al., 1987). In case of fever in Kinshasa, it is 
common practice by the caregivers to initially treat their child at home (54% of the cases) 
although only 4.3% of the children treated for fever receive a recommended combination 
therapy containing artemisinin (unpublished data). 
 
Results indicated that sleeping under an ITN the previous night reduced the risk of 
Plasmodium infection by 38% (OR=0.62, 95% CI 0.50 – 0.77) among children 6-59 months 
of age in areas of high transmission, consistent with the vast body of evidence supporting the 
efficacy and effectiveness of ITN in protecting against malaria (Lengeler et al., 2004). In low 
transmission areas, however, there was no evidence of such an association, presumably 
because the overall risk of infection was lower.  
Reported history of fever was associated with malaria infection overall. There was evidence 
of a difference in this association with transmission level among individuals aged older than 
five years (p<0.001). The weaker association of reported fever with malaria in areas of high 
transmission could be explained by differences in the levels of acquired immunity. 
 
The data confirm that anaemia is frequent in urban Kinshasa, with 65% prevalence among 
children 6-59 months, 30% moderate (7.0-9.9 g/dl) and 1.9% severe (< 7.0 g/dl). ITN use in 
Kinshasa did not appear to be associated with benefits in lower anaemia risk, contrary to what 
has been documented in other settings (Premji et al., 1995; Lengeler et al., 2004; Korenromp 
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et al., 2004; Mathanga et al., 2010). These findings are consistent with a Kenyan study that 
found only a small difference in prevalence of anaemia between villages with and without 
ITNs (Mathanga et al., 2010). Anaemia has many causes in addition to malaria (nutrition 
(UNICEF, 2010), soil transmitted infections (STH) and schistosomes), and in Kinshasa these 
are likely to also be contributors to this morbidity. A recent study revealed a high prevalence 
of STH infections among primary school children in Kinshasa (32.8%) (Matangila et al., 
2014). Nevertheless, the estimated odds of anaemia in zones of high transmission were 3.5 
times (95% CI 2.70-4.62) higher in malaria infected children.  
 
In this study, the risk of anaemia was shown to decrease with increasing age in both low and 
high transmission strata. These results are consistent with studies conducted in West Africa, 
showing a significant reduction in the mean haemoglobin level in children aged 2-5 years 
compared to children aged 1-2 (Soares Magalhaes et al., 2011).  
 
This study also showed differences in the effect in malaria risk or anaemia risk by 
socioeconomic status, consistent with previous studies carried out in sub-Saharan Africa (De 
Beaudrap et al., 2011; Gahutu et al., 2011; Winskill et al., 2011; Ayele et al., 2012), and as 
documented in a multi country analysis of DHS data (Balarajan et al., 2011).  
 
This study however has some limitations. Foremost, the analysis draws on cross-sectional 
data; hence the causal nature of associations should be viewed with a certain caution. A 
second most important limitation of the study relates to the smaller sample size for individuals 
over five years compared to that of children 6-59 months, limiting our ability to potentially 
detect important differences and interactions between risk factors and transmission. 
Furthermore, the low proportion of males for this survey (34%) may have triggered a gender-
response bias, with consequences on the prevalence and associations found. The direction and 
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magnitude of a possible bias remain unknown. Lastly, RDTs are limited in sensitivity to 
detect low density parasitaemia and their use may have led to an underestimation of the true 
proportion of people infected with Plasmodium falciparum. The underestimation may have 
differed with acquired immunity affecting the age pattern (Harris et al., 2010; Alves et al., 
2002; Nicastri et al., 2009; Wu et al., 2015). 
 
4.6 Conclusions 
For the most part, there was no evidence of an interaction between malaria infections and the 
risk factors with transmission intensity; however the associations with age and with fever in 
the last two weeks did vary significantly. The results also show that school-aged children are 
the least protected with ITN, across the different transmission settings, hence representing an 
important reservoir for infection. The observation of a shift in the peak age of risk for malaria 
to older groups is consistent with areas of low transmission and highlights the need for a more 
equal distribution of ITN in Kinshasa to target all age groups and not only the traditional 
high-risk group of young children.  
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5.1 Abstract 
Background 
The Democratic Republic of the Congo (DRC) has the highest number of severe malaria cases 
in the world. In early 2012, the National Malaria Control Programme (NMCP) changed the 
policy for treating severe malaria in children and adults from injectable quinine to injectable 
artesunate. To inform the scaling up of injectable artesunate nationwide, operational research 
is needed to identify constraints and challenges in the DRC’s specific setting.  
 
Methods 
The implementation of injectable quinine treatment in 350 patients aged two months or older 
in eight health facilities from October 2012 to January 2013 and injectable artesunate in 399 
patients in the same facilities from April to June 2013 was compared. Since this was an 
implementation study, concurrent randomised controls were not possible. Four key 
components were evaluated during each phase: 1) clinical assessment, 2) time and motion, 3) 
feasibility and acceptability, and 4) financial cost.  
 
Results 
The time to discharge was lower in the artesunate (median = 2, 90% central range 1 – 9) 
compared to the quinine group (3 (1 – 9) days; p <0.001). Similarly, the interval between 
admission and the start of intravenous (IV) treatment (2 (0 – 15) compared to 3 (0 – 20) 
hours; p <0.001) and parasite clearance time (23 (11 – 49) compared to 24 (10 – 82) hours; p 
<0.001) were lower in the artesunate group. The overall staff pre-administration time (13 (6 – 
38) compared to 20 (7 – 50) minutes; p <0.001) and the personnel time spent on patient 
management (9 (1 – 24) compared to 12 (3 – 52) minutes; p <0.001) were lower in the 
artesunate group. In hospitals and health centres, the mean (standard deviation, SD) total cost 
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per patient treated for severe malaria with injectable artesunate was USD 51.94 (16.20) and 
19.51 (9.58); and USD 60.35 (17.73) and 20.36 (6.80) with injectable quinine.  
 
Conclusions 
This study demonstrates that injectable artesunate in the DRC is easier to use and that it costs 
less than injectable quinine. These findings provide the basis for practical recommendations 
for rapid national deployment of injectable artesunate in the DRC.  
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5.2 Background 
The Democratic Republic of the Congo (DRC) has the highest severe malaria burden in the 
world (WHO, . Geneva: World Health Organization. 2011). The combination of artesunate 
plus amodiaquine (AS-AQ) was adopted as a first-line treatment for uncomplicated malaria in 
2005, with a second ACT, artemether plus lumefantrine (AL), added in 2010. Meanwhile, 
injectable quinine remained the recommended first-line drug for cases of treatment failure 
and for severe malaria.  
 
In 2010, the AQUAMAT trial demonstrated that treating severe malaria with artesunate 
reduced the case fatality rate in African children (<15 years) by 22.5% compared to treatment 
with injectable quinine (Dondorp et al., 2010). Previously, the benefit of artesunate compared 
to quinine had been demonstrated in adults in the SEAQUAMAT trial carried out in 
Southeast Asia (Dondorp et al., 2005). These results led to the recommendation of injectable 
artesunate as the treatment of first choice for severe malaria in children and adults in the 
WHO guidelines in 2011 (WHO, 2011a).Nevertheless, cases of delayed haemolytic anaemia 
secondary to injectable artesunate administration were reported and the causative role of 
artesunate is still controversial. Its long-term safety profile is under evaluation. In addition to 
its efficacy, injectable artesunate offers a number of programmatic advantages over quinine, 
such as eliminating the need for rate-controlled infusions or cardiac monitoring, and the risk 
of induced hypoglycaemia (WHO, 2011a).  
 
In 2012, the National Malaria Control Programme (NMCP) of the DRC, with support from 
the relevant ministry departments, decided to adopt the revised WHO severe malaria 
treatment guidelines, which strongly recommended injectable artesunate in preference to 
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quinine or artemether as first-line treatment for severe malaria. An implementation period of 
three years to scale up injectable artesunate was included in the national strategic plan.  
 
This transition will require many operational and clinical adaptations. To support this 
process, there is a need for locally derived operational experience addressing constraints and 
challenges, something that all implementing countries will have to consider. These data are 
essential for three reasons: 1) better planning of the implementation of the new treatment 
based on quantified operational parameters; 2) identifying constraints and pitfalls to guide the 
training of health care providers; and, 3) providing strong and locally relevant arguments in 
situations where the health staff are reluctant to accept the change of treatment.  
 
The present MATIAS study (‘MAlaria Treatment with Injectable ArteSunate’) aims to 
support the national introduction of injectable artesunate as the first-line treatment of severe 
malaria in the DRC by assessing four key components: 1) clinical safety, 2) time and motion, 
3) feasibility and acceptability, and 4) cost.  
 
 
5.3 Methods 
Study design  
The MATIAS study was an observational implementation study of patients aged two months 
and older with severe malaria and included two successive phases. In the first phase, between 
October 2012 and January 2013, severe malaria patients were treated with intravenous (IV) 
quinine. Then, between April and June 2013, severe malaria patients were treated with IV 
artesunate.  
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Four components were evaluated in each phase: 1) clinical safety, assessed on the basis of 
limited routine patient information; 2) time and motion parameters; 3) feasibility and 
acceptability; and 4) financial costs. The results of the feasibility and acceptability 
component required additional in-depth studies and are reported elsewhere (Ntuku et al., 
personal communication). 
 
Participants (population, inclusion, exclusion criteria) 
The study population consisted of patients admitted with severe malaria to one of the study 
sites between October 2012 and June 2013. Patients were included in the study if they were 
older than two months, fulfilled the WHO criteria of severe Plasmodium falciparum malaria 
(WHO, 2013b), had either a positive rapid diagnostic test (RDT) for P. falciparum (SD 
Bioline Malaria Antigen P.f/Pan Standard Diagnostics Inc, Yongin, South Korea) and/or a 
positive Giemsa-stained thick blood smear on admission, and they or their relative or 
guardian gave informed written consent. Patients were excluded if they had a known serious 
adverse reaction to quinine and/or artemisinin derivatives, or if there was a history of 
adequate anti-malarial treatment for more than 24 hours before admission. Women with 
known or suspected pregnancy in all trimesters during the second (artesunate) phase were not 
included and were treated with quinine according to the national guidelines (PNLP, 2012). 
Pregnancy status was determined by details from the patient’s history and/or by a positive 
pregnancy test.  
 
Signed informed consent for participation was obtained in French or in the local language 
from all participants or from their relatives or guardians. Because of the life-threatening 
nature of the disease, an initial consent was obtained from the accompanying relative or 
guardian on behalf of the patient, if necessary, and final consent was solicited as soon as the 
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patient was able to decide and respond. Since this was an observational study, investigators 
did not intervene in patient management, which was left to the discretion of the attending 
physicians. Ethical clearance for the study was obtained from the Ethics Committee of both 
Cantons of Basel, Switzerland (EKBB, Ref No 201/12) and from the Ethics Committee of the 
Kinshasa School of Public Health (KSPH Ethics Commission, Ref No 057/12), University of 
Kinshasa, DRC. The study was registered in ClinicalTrials.gov (Identifier: NCT01828333).  
 
Study settings 
The study sites consisted of three hospitals and five health centres in one urban and three 
rural health zones (HZs) in the DRC, representative of typical health facilities in the country 
(Figure 1). The sample included a large public health hospital (Institut Médical Evangélique, 
Kimpese, Bas Congo); one medium-sized, non-profit, missionary hospital (St Luc Kisantu); 
and a medium-sized, government hospital (Centre Hospitalier Roi Baudouin). In addition, 
five rural health centres were selected within the same HZ (Health Centre Bita, Health Centre 
Menkao, Health Centre Ngeba, Health Centre CECO, Health centre La Famille) (Figure 5-1 
and see additional file 1). 
 
Figure 5-1: Map showing the location of the study sites and the selected health zones 
 
 
 
 
 
 
 
Dem Rep Congo 
 
HZ of Kisantu 
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Interventions 
During the first phase, patients receiving IV quinine were treated according to the national 
treatment guidelines. An initial loading dose of 20 mg of quinine salt/kg in 5 – 10 ml isotonic 
glucose solution (5%) per kg body weight was infused over four hours. Following a rest 
period of eight hours and 12 hours after administration of the loading dose began, a 
maintenance dose of 10 mg of quinine salt/kg was given. The maintenance dose was repeated 
every 12 hours until the patient was able to swallow the oral treatment (PNLP 2012; WHO, 
2013b). Patients receiving artesunate (Guilin Pharmaceuticals, Shanghai, China) received 
doses intravenously at 2.4 mg/kg on admission, at 12 and 24 hours, and then once daily until 
oral treatment could be swallowed (WHO, 2013b). The content of each 60 mg vial of 
artesunate powder was dissolved in 1 ml of sodium bicarbonate and then diluted with normal 
saline solution or dextrose 5% before IV injection (WHOPARs) . At least three doses of 
artesunate had to be given before switching to a full course of oral treatment. The drugs used 
for the study were provided for free by the manufacturer (Artesunate, Guilin Pharmaceutical 
Co. Ltd, Shanghai, China) and by the funding agency, Medicines for Malaria Venture 
(MMV) (quinine).  
 
Study outcomes 
Outcome measures were defined for each of the four study components. For the clinical 
assessment component, the outcomes were: 1) duration of hospitalisation, defined as the time 
from hospital registration to discharge, (this was the primary study endpoint); 2) time from 
hospital admission to start of parenteral treatment; 3) time from initiation of parenteral 
treatment to initiation of oral treatment; 4) parasite clearance time (PCT), defined as the time 
from the initiation of a patient’s parenteral treatment until the patient’s first negative blood 
film; and 5) clinical status at discharge. For the time and motion component, the main 
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outcome measure was the cumulative staff time required for all steps of drug preparation, 
administration and patient management. For the feasibility and acceptability component, the 
main outcomes were health-provider perceived feasibility of patient management, perceived 
ease of applying drug treatment, and perceived quality of case management by 
patient/caretaker. These results are reported separately (Ntuku et al. in prep). For the financial 
cost component, the main outcome was the total financial cost of patient management, 
including treatment.  
 
Sample size calculation 
The study sample size was calculated based on seven centres, a mean hospitalisation of 2.23 
days (standard deviation of 1.64) (Dondorp et al., 2005), 80% power and an assumed 20% 
shorter hospital stay with injectable artesunate. This calculation yielded 25 patients per centre 
and study period. Under the assumption of an effect variation by centre with a standard 
deviation of 0.05, the required number per centre was corrected to 27. This effect was 
presumed to be moderate, as each centre acted as its own control in the study. The two-phase 
study design was selected to fit the implementation strategy in this area. To ensure a safety 
margin and to aid disaggregation of the data by centre, the number of patients to be recruited 
was finally set to 50 patients of all ages from each centre and per study phase. One of the 
sites initially selected was removed due to difficulties in initiating the study. However, due to 
recruitment numbers slightly below expectations during the quinine phase, two additional 
study centres were added. This amendment increased the number of treatment centres to 
eight. 
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Statistical methods 
Continuous outcomes were described using their mean and standard deviation, or median and 
90% central range if the distribution was skewed. Dichotomous outcomes were summarised 
as proportions. Clinical characteristics are presented by age groups <five years and ≥five 
years. Skewed data, such as the time to event outcomes, were compared using the non-
parametric Wilcoxon rank sum test. The paper-based questionnaires were double-entered and 
validated in EpiData version 3.1 software (The EpiData Association, Odense, Denmark) and 
analysed in Stata version 12.1 (Stata Corp, College Station, TX, USA).  
 
Key procedures  
Prior to the first study phase, all investigators and staff involved in the study in each 
hospital/health centre participated in a three-day training on study procedures. Laboratory 
technicians received a refresher course on thick blood smear preparation/reading and, before 
the second phase, a refresher course on haemoglobin (Hb) measurement with the HemoCue 
201 plus system (Angelholm, Sweden). Simulated interviews were conducted to practice 
obtaining informed consent. Local principal investigators took part in practical sessions on 
filling in the case report forms (CRF). Nurses and doctors attended a separate training on 
reporting serious adverse events (SAE). Nurses also participated in piloting the time and 
motion study tool, which included observing and timing the activities related to drug 
preparation/administration prior to the first data collection. Upon completion of the first 
phase, hospital and health centre personnel involved in the study convened in Kinshasa for a 
two-day training on preparing and administering injectable artesunate. Job aids and training 
tools developed by MMV were used for this training. In addition, each site received ten doses 
of injectable artesunate for training purposes, allowing health care providers to become 
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familiar with the new drug prior to patient recruitment. Weekly supervision visits to each site 
throughout the duration of the study ensured regular monitoring of the study team.  
Patient assessment 
Demographic information and limited routine clinical history data were collected for each 
patient and local study physicians (hospitals) or nurses (health centres) performed basic 
routine clinical assessments. A Giemsa-stained thick blood smear was performed and 
examined every 12 hours during the first 24 hours and then every 24 hours until negative or 
until patient discharge. For PCT calculations, thick blood smears were later reread for quality 
control by experienced microscopists at the KSPH, blinded to the results of the first reading 
and to the RDT results. Hb levels were systematically assessed with a HemoCue 201 plus+ 
photometer (Angelholm, Sweden) during the second study phase, at hospital admission, at 
discharge and at follow-up visits on days 7, 14, 21, and 28. The HemoCue testing resulted in 
a change in study protocol because of reports of haemolytic anaemia following artesunate 
treatment (CDC, 2013). The results of that extension are presented elsewhere (Burri et al., 
2014). To ensure the proper functioning of the photometer, high and low Hb liquid controls 
(HemoCue Eurotrol HemoTrol) were run weekly at each site. Given the observational nature 
of the study, laboratory tests were not systematically performed and were left to the 
discretion of the physician or treating nurse, except for parasitological tests required for 
inclusion in the study and the Hb assessment during the second phase. Time of admission, 
time of start and end of parenteral treatment, and time to discharge were also recorded for 
every patient during both phases. 
 
Parenteral treatment was completed by administering a full course of the recommended first-
line, oral, combination therapy AS-AQ or AL in the artesunate phase, or with quinine tablets 
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or the standard treatment practiced by the centre in the quinine phase. The first dose of the 
oral treatment was administered at the health facility in the presence of the nurse responsible. 
Subsequent doses were administered at home, according to the instructions given to parents 
and guardians. Patients were discharged at the discretion of the attending physician/nurse, 
after a final clinical assessment. During the first study phase, patients were asked to return to 
the hospital/health centre for follow-up seven days after discharge to assess their clinical 
status and their adherence to oral therapy. In the second study phase, patients were asked to 
return on days 7, 14, 21, and 28 after discharge to assess the clinical status and adherence to 
oral therapy and to determine their Hb levels at these time points.  
 
Time and motion  
The time and motion methodology consisted of 1) dividing a process into key tasks, and 2) 
observing each task to assess the average time required to perform it. The sum of the average 
times spent on each task was used to compute the total average time to complete the process. 
In each of the three participating hospitals, an external study nurse supervised the time and 
motion component and was present throughout the study. In the five health centres, the health 
centre personnel were responsible for the measurements. Therefore, the number of patients 
followed up was limited as a second nurse was not always available. Observed activities 
included: 1) pre-administration tasks (preparation of all materials and injectable solution, 
searching for the vein, setting the infusion in case of quinine), 2) drug administration, and 3) 
all other activities related to patient management. Observations were made by the nurses 
using digital stopwatches and a checklist to record the time taken for each task. Inter-observer 
agreement was not formally assessed. Materials required for all tasks were also recorded on 
the same observer checklist and this information was used later to calculate financial costs.  
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Cost of treatment component  
A financial cost analysis was carried out from the provider’s perspective, accounting only for 
costs incurred by the hospitals and the health centres. Complete unit cost data on resources 
used were recorded for 386 patients under quinine and for 333 patients under artesunate. To 
estimate the mean unit cost, the 2014 average exchange rate (USD 0.00107 to the Congolese 
Franc) was adopted (OANDA). Health care costs were divided into four main categories: 1) 
drug costs (parenteral quinine and artesunate, oral therapy), 2) diagnostic costs (blood smear), 
3) administration equipment costs (infusion set, IV solution, syringes), and 4) in-patient costs 
(consultation cost, bed occupancy, blood transfusion, and nursing care). Administration 
equipment, blood smear and parenteral quinine unit costs were estimated from the 
hospital/health centre price lists, as well as in-patient costs. The full dose costs for both 
parenteral quinine and artesunate were applied, since the recommendation given in the study 
was to avoid re-using the drug once it was opened, and hence partially used ampoules had to 
be discarded. Artesunate was used in the 60-mg vial, the WHO pre-qualified formulation at 
the time. Costs of oral treatment with AS-AQ/AL were included in the analysis despite being 
subsidised by the Global Fund to Fight AIDS, TB and Malaria (GFATM) in the selected 
health facilities. Costs of artesunate and of AS-AQ/AL were obtained from the Management 
Sciences for Health (MSH) International Drug Price Indicator Guide (MSH, 2014).  
 
Additional treatments and diagnostic costs, other than the parenteral drug and the thick blood 
smear, were not included in the analysis. Specific costs associated with co-morbidities, with 
the exception of blood transfusions (severe anaemia), were not considered in the analysis 
because they would have required a level of clinical monitoring that was not possible in this 
study. In two sites (referral hospital Saint Luc and Health Centre Ngeba), a lump sum health 
care payment system was in place, thus unit costs were unavailable. The decision was made 
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to reflect as closely as possible the local practice and to generate nationally relevant data 
rather than internationally, fully costed estimates. Hence, the lump sum estimates were taken 
for this analysis. However, the two sites were analysed separately to take these differences 
into account, since lump sums are likely to underestimate the full cost of treatment, especially 
if there is a central subsidy by an external donor, as in the case of these two facilities.  
 
5.4 Results 
Clinical assessment 
A total of 749 patients were recruited from eight sites, 399 in the quinine group from October 
2012 to January 2013 (study phase one), and 350 in the artesunate group from April to July 
2013 (study phase two). The quinine group consisted of 248 (62%) children between two and 
59 months, and 151 (38%) individuals aged five years and above. The artesunate group 
consisted of 215 (61%) children between two and 59 months and 135 (39%) individuals aged 
five years and above. The demographic and baseline characteristics were similar for the two 
study groups (Table 5.1). All patients tested positive for malaria, either by thick blood smear 
or RDT on the day of inclusion. Overall mortality was 2.8% (21/749), with 3.8% for patients 
treated with quinine (15/399) and 1.7% for patients treated with artesunate (6/350) (p=0.110). 
The majority of deaths (13 of 21, 62%) occurred within the first 24 hours after admission, of 
which nine of 15 were in the quinine group (with two dying before receiving the treatment) 
and four of six were in the artesunate group (zero before receiving the treatment). Of the 
eight deaths that occurred after 24 hours, six occurred in the quinine group and two in the 
artesunate group. Prostration was the most frequent manifestation of severe malaria at 
admission in children between two to 59 months in the quinine (204/248, 82%) and 
artesunate groups (171/215, 80%), as well as in individuals five years and above (122/151, 
81% and 120/135, 90%). Respiratory distress and convulsions were also frequent symptoms 
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at admission in both groups. The total number of patients who received a blood transfusion 
was 214 (29%), with 128 (32%) and 88 (25%) in the quinine and artesunate groups, 
respectively. Five per cent of the patients under the quinine regimen had persistent symptoms 
at discharge, compared to 3% under the artesunate regimen (Table 5.2). A decrease in Hb 
levels at one of the follow-up visits was a frequent SAE reported during the artesunate 
regimen (Burri et al., 2014). A seven-day oral quinine course was the most frequently 
prescribed oral medication to complete treatment after the initial injectable quinine regimen 
(92%), whereas AS-AQ was the most prescribed oral medication (97%) after injectable 
artesunate for all ages. Patient adherence was assessed by the duration of oral treatment and 
the reported number of tablets taken. Following injectable quinine and injectable artesunate, 
236 (85%) and 308 (99%) patients fully adhered to the treatment, respectively.  
 
The time to discharge was slightly lower in the artesunate group compared to the quinine 
group, with a median of two (90% central range 1 – 9) versus three (1 – 9) days, respectively 
(p <0.001). Given that mortality was slightly higher in the quinine group, this would have led 
to a shorter hospital stay but the effect would be minimal because of the low case fatality rate. 
The interval between admission and start of parenteral treatment was significantly shorter in 
the artesunate group compared to the quinine group, two (0 – 15) versus three (0 – 20) hours 
(p <0.001). The interval from beginning parenteral treatment initiating oral treatment was 
slightly longer in the artesunate group (45 (32 – 56) versus 39 (12 – 67) hours in the quinine 
group, p <0.001). Parasite clearance time was 23 (11 – 49) hours for artesunate versus 24 (10 
– 82) hours for quinine (p <0.001) (Table 5.3).  
 
 
 
An operational comparative study of quinine and artesunate 
 
87 
 
Table 5-1: Characteristics and clinical presentation of patients at recruitment 
 
 
Quinine  
(N = 399) 
Artesunate  
(N = 350) 
 
2-59 months 
(N = 248) 
>5 years 
(N = 151) 
2-59 months  
(N = 215) 
>5 years 
(N = 135) 
Sex      
   Female 122 (49%) 72 (48%) 115 (53%) 71 (53%) 
Age 24 (7-53) 10 (5-48) 24 (7-48) 8 (5-48) 
Medical history (past 30 days)     
  Other malaria episode  18 (7%) 7 (5%) 16 (7%) 16 (12%) 
 Fever (N=398) 90 (37%) 78 (52%) 59 (27%) 76 (56%) 
 Pre-treatment with anti-malarial 31 (12%) 20 (13%) 20 (9%) 20 (15%) 
 Other treatment(s) received 113 (46%) 75 (50%) 98 (46 %) 83 (61%) 
 Other major health problem(s) 6 (2%) 3 (2%) 0 (0%) 4 (3%) 
 Episode of convulsion (N=394) 34 (14%) 10 (7%) 13 (6%) 11 (8%) 
 Known hypersensitivity to other  
drugs 
0 (0%) 5 (3%) 2 (1%) 5 (7%) 
Signs and symptoms on 
admission 
    
 Fever 220 (89%) 129 (85%) 197 (92%) 121 (90%) 
 Fever before enrolment (days 
and range) 
3 (2-4) 3 (2-5) 3 (1-7) 3 (1-7) 
 Vomiting 100 (40%) 78 (52%) 113 (53%) 78 (58%) 
 Coma 23 (9%) 12 (8%) 5 (2%) 11 (8%) 
 Reported convulsions 72 (29%) 19 (13%) 59 (27%) 14 (10%) 
 Blantyre coma score (8-24 
months) 
3 (2-5) - 4 (3-8) - 
 Glasgow coma score (>2 years) 10.5 (5-13) 10 (8-15) 7.5 (4-5) NA 
 Pallor NA NA 77 (36%) 20 (15%) 
 Jaundice 3 (1%) 4 (3%) 7 (3%) 2 (1%) 
 Shock 10 (4%) 2 (1%) 2 (1%) 2 (1%) 
 Respiratory distress 128 (52%) 58 (38%) 96 (45%) 64 (47%) 
 Severe anaemia (<5 g/dl) 
     (N=326 Q; 334 A)  
8.1 (3%)
a
 9.1 (2%)
a
 15 (7%)
b
 1 (1%)
b
 
 Parasite count (per μl); 
 geometric mean (95 % CI) 
17068 
(12119-24038)
c
 
12022 
(7040-20527)
c
 
22289 
(15498-32057)
c
 
12346  
(7812-19511)
c
 
 Prostration 204 (82%) 122 (81%) 171 (79%) 120 (89%) 
 Urine colouration (N=391) 2 (1%) 2 (1%) 10 (5%) 8 (6%) 
Clinical examination on 
admission 
    
 Weight (kg and SD) 11.1 (3.0) 33.2 (17) 11.2 (4) 27.6 (15) 
 Temperature (°C and SD) 
(N=398) 
38.1 (1) 38.3 (1) 38.1 (1) 38.4 (1) 
 Pulse 125 (70-180) 102 (64-148) 119 (60-171) 94 (60-140) 
 Respiratory rate per minute 42.5 (28-72) 39.0 (24-60) 40 (24-72) 40 (20-58) 
Co-morbidity 82 (34%) 51 (34%) 80 (37%) 58 (43%) 
Data are summarised as numbers (%), median (90% central range) or mean (SD); NA = Not available; 
a
 Clinical assessment only; 
b 
HemoCue; 
c
 The initial parasitaemia was calculated only for those patients for 
whom the biological confirmation was done by thick blood smear 
An operational comparative study of quinine and artesunate 
 
88 
 
Table 5-2: Clinical examination at discharge 
 
 Quinine Artesunate 
 
2-59 months  
(N = 226) 
>5 years  
(N = 144) 
2-59 months  
(N = 208) 
>5 years 
(N = 131) 
Weight (kg)  11.1 (3.0) 32.8 (16.7) 11.2 (4.3) 27.2 (14.9) 
Temperature (°C)  36.7 (0.5) 36.6 (0.5) 36.7 (0.4) 36.5 (0.4) 
Pulse 100 (70-128) 90 (41-120) 90 (64 - 124) 85.4 (18.8) 
Respiratory rate per minute  35 (22-40) 28 (16-48) 31.8 (6.6) 29.2 (8.0) 
Persistence of signs at 
discharge 
12 (5.4%) 6 (4.3%) 7 (3.4%) 4 (3.0%) 
Data are summarised as numbers (%), median (90% central range) or mean (SD). 
 
Table 5-3: Key time intervals 
 Quinine Artesunate p-value 
Time to discharge (days) 3 (1-9) 2 (1-9) p <0.001 
Interval between admission and beginning of 
parenteral treatment (hours) 
3 (0-20) 2 (0-15) p <0.001 
Interval between beginning of parenteral 
treatment and oral treatment (hours) 
39 (12-67) 45 (32-56) p <0.001 
Parasite clearance time (hours) 24 (10-82) 23 (11-49) p <0.001 
Median and 90% central range 
 
Time and motion study 
Administration times by task are shown in Tables 5.4 and 5.5. There was a reduction in the 
staff time required for all tasks during the artesunate phase. The total median personnel time 
for pre-administration and patient management tasks was 33 (10 – 60) for artesunate and 36 
(13 – 92) minutes for quinine. The median cumulative staff time for observed drug pre-
administration tasks per patient per drug session was 13 (6 – 38) for artesunate and 20 (7 – 
50) minutes for quinine. Cumulative median personnel time spent for patient management 
was 9 (1 – 24) for artesunate and 12 (3 – 52) minutes for quinine.  
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Table 5-4: Personnel time (in minutes) required to complete pre-administration tasks, by 
drug type 
Quinine (N = 832)  Artesunate (N = 795)  
Material preparation 6 (2-18) Material preparation 4 (1-10) 
Drug preparation 4 (1-14) Reconstitution 3 (1- 8) 
Search for the vein 5 (1-14) Dilution 2 (1-10) 
Perfusion regulation 4 (1-10) Dose verification 2 (1-6) 
-   Search for the vein 3 (1-10) 
Median and 90% central range 
Table 5-5: Overall cumulative personnel time (in minutes) 
  Quinine Artesunate p-value 
Overall personnel pre-administration time 20 (7-50) 13 (6-38) p <0.001 
Overall personnel patient management time 12 (3-52) 9 (1-24) p <0.001 
Overall personnel time 36 (13- 92) 33 (10-60) p <0.001 
Median and 90% central range 
 
Cost analysis 
In hospitals and health centres, the mean (SD) total costs per patient treated for severe 
malaria with injectable artesunate were USD 51.94 (16.20) and 19.51 (9.58); and USD 60.35 
(17.73) and 20.36 (6.80) with injectable quinine. Costing details for individual study sites are 
given in Table 5.6. 
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Table 5-6: Mean cost (with SD) for treating one episode of severe malaria in patients admitted to hospitals and health centres in the Democratic 
Republic of Congo 
Hospital/ Health 
centre 
Mean length 
of stay, days 
(SD) 
Blood smear 
unit cost 
Mean 
injectable 
drug cost 
Mean oral 
drug cost
a
 
Mean 
administratio
n cost 
Mean 
inpatient cost 
Mean total 
cost per 
patient 
 QNN ART QNN ART QNN ART QNN ART QNN ART QNN ART QNN ART 
Kimpese referral 
hospital  
7.12 
(4.43) 
6.26 
(5.01) 
2.94 2.94 
0.45 
(0.22) 
7.72 
(3.28) 
0.66 
(0.38) 
0.48 
(0.06) 
1.89 
(0.83) 
1.39 
(0.48) 
49.56  
(18.0
4) 
47.25 
(19.8
2) 
61.58 
(18.7
2) 
59.57 
(20.9
7) 
Centre 
Hospitalier Roi 
Baudouin 
4.09 
(3.41) 
3.72 
(2.17) 
3.21 3.21 
0.78 
(0.17) 
3.24 
(1.51) 
0.97 
(0.30) 
0.56 
(0.21) 
6.59 
(1.56) 
0.90 
(0.83) 
38.60  
(12.9
9) 
38.76 
(8.32) 
53.29 
(7.86) 
46.58 
(8.55) 
Hôpital St Luc 
Kisantu 
3.13 
(1.06) 
6.68 
(4.00) 
NA NA NA 
3.87(
1.72) 
0.70 
(0.23) 
0.50 
(0.18) 
NA NA NA NA 
50.34  
(9.98) 
b
 
55.44 
(11.8
1)
 b
 
Health Centre 
CECO 
3.96 
(2.35) 
4.28 
(3.36) 
1.07 1.07 
0.57 
(0.14) 
7.19 
(2.51) 
1.00 
(0.49) 
0.48 
(0.13) 
2.10 
(0.34) 
1.62 
(0.45) 
40.28 
(10.3
2) 
41.62 
(14.4
7) 
32.53 
(14.2
5)
 c
 
28.21 
(9.41)
 
c
 
Health Centre La 
Famille 
3.80 
(1.54) 
2.58 
(1.50) 
1.07 1.07 
0.94 
(0.43) 
7.26 
(3.95) 
1.58 
(0.59) 
0.66 
(0.30) 
3.89 
(1.59) 
1.22 
(0.45) 
10.48 
(3.63) 
8.19 
(3.21) 
19.35 
(4.46) 
18.21 
(5.02) 
Health Centre 
Bita 
2.18 
(0.68) 
1.99 
(0.11) 
1.07 1.07 
1.49 
(0.33) 
7.30 
(2.68) 
1.99 
(0.78) 
0.49 
(0.17) 
6.48 
(1.23) 
1.51 
(0.23) 
6.71 
(2.07) 
6.39 
(0.30) 
21.97 
(2.73) 
16.56 
(2.87) 
Health Centre 
Menkao 
1.78 
(0.97) 
1.27 
(1.34) 
1.07 1.07 
1.81 
(0.72) 
9.12(
5.09) 
1.05 
(0.45) 
0.63 
(0.24) 
5.10 
(1.19) 
2.60 
(0.73) 
3.15 
(1.29) 
2.49 
(1.76) 
13.92 
(2.59) 
15.66 
(5.84) 
Health Centre 
Ngeba 
4.6 
(2.59) 
2.7 
(0.98) 
NA NA NA 
5.87 
(1.95) 
0.97 
(0.30) 
0.43 
(0.04) 
NA NA NA NA 
6.86 
(0.84) 
b
 
4.47 
(0.10) 
b
 
In 2014 USD; NA = Not available  
a Mean cost for oral quinine and AS-AQ 
b Unit costs not available. Lump sum payment system. All exams and drugs other than anti-malarial are included. Patients pay a part of the total costs; the rest is supported by a partner. 
c Among health centres, blood transfusion was only performed in CECO. To allow cost comparison with the other health centres, costs of blood transfusion were not  included in the 
total costs. Total costs for CECO under ART and QNN are USD47.47 (9.41) and USD51.79 (14.25) respectively if blood transfusion is included.  
An operational comparative study of quinine and artesunate 
 
91 
 
5.5 Discussion 
This study is the first to quantify key operational parameters in the management of patients 
with severe malaria treated with injectable artesunate. Injectable artesunate was superior to 
quinine for almost all of the parameters assessed. Furthermore, from the provider’s 
perspective, overall costs were lower for injectable artesunate in hospitals and similar in 
health centres. The aim of the study was to assess operational aspects rather than safety and 
efficacy. However, there was no indication for any of the outcomes obtained from available 
clinical charts that patients fared worse with injectable artesunate compared to parenteral 
quinine, concurring with available data on the efficacy and safety of the use of injectable 
artesunate in the DRC (Dondorp et al., 2010).  
 
A major reason for conducting the study in two phases was the need for comparative 
operational data between the new regimen and the old regimen. Because many aspects in 
health services are setting-specific, it was thought that the best controls would be the facilities 
themselves. The strongest study design would include a randomised concurrent control trial 
with enough health facilities to account for inter-facility variability, however, time and 
logistical reasons precluded such an approach for the current study. The design outlined here 
was the best suited to the Ministry of Health’s current plan for scaling up artesunate. The 
operational parameters of treating severe malaria are unlikely to be sensitive to seasonal 
effects, and also unlikely to change much in a given facility over time periods equal to that of 
the study. Hence, although not randomised, this design allowed a reasonable comparison of 
the two regimens in real-world implementation settings. Although injectable quinine has been 
the mainstay for treating severe malaria for many years, there are virtually no existing data in 
the literature quantifying the operational parameters of interest. 
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In this study, patients admitted with severe malaria experienced a median delay of three hours 
before receiving their initial quinine dose compared to two hours with artesunate (Table 3). 
This time delay depended on several factors that should be further investigated. In particular, 
it could reflect the difficulties of promptly and safely administering quinine via IV. Although 
comparable in its preparation, quinine is a difficult drug to administer because of its 
unfavourable safety profile; it requires correct dose calculation, taking into account previous 
quinine treatment to avoid overdosing and serious consequences for the patient.  
 
In the AQUAMAT trial (Dondorp et al., 2010), the risk of children dying while waiting to 
receive quinine was almost four times higher than the risk in children treated with artesunate. 
This delay adds to the time needed for referral, during which the condition of the patient can 
deteriorate (WHO, 2010). In this study, two patients died before receiving quinine compared 
to none in the artesunate group. Although this delay is still critical for both regimens, it can be 
expected to decrease further for injectable artesunate as skills and confidence are acquired 
through repeated administration and preparation by health personnel.  
 
The well-known difficulties in administering quinine may also explain the difference 
observed in the time interval between the beginning of the parenteral treatment and the 
initiation of oral treatment. Lack of confidence or uncertainty in reconstructing the history of 
previous treatments with quinine could potentially limit the number of doses a patient 
receives. According to the national DRC directives on the treatment of severe malaria (PNLP, 
2012), the number of doses of quinine administered should be minimised until the patient can 
tolerate an oral medication. Under the artesunate regimen in this study, the WHO’s 
recommendations of a minimum of three injections during the first 24 hours, irrespective of 
the patient’s ability to tolerate oral medication were strictly followed. This is one possible 
explanation for the prolonged time interval to the initiation of oral therapy.  
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The artesunate regimen achieved parasite clearance faster than the quinine regimen, which 
likely accounts for the shorter hospital stay. The reduction in median hospital stay by a day 
reduces costs of malaria treatment and minimises socio-economic impacts on patients and 
their families. This is especially important for poorer and more vulnerable segments of the 
population.  
 
The estimated costs of treating a patient with severe malaria in this study are similar to those 
calculated in previous studies (Lubell et al., 2011; Lubell et al., 2009), although lower than 
those reported by Kyaw et al., which used a more detailed cost analysis approach (Kyaw et 
al., 2014). The costs were highly variable, depending on the level and type of facility (public, 
private or missionary). The mean pooled estimate total cost was found to be similar for 
artesunate compared to quinine in health centres, USD 19.51 (9.58) and 20.36 (6.80), while 
lower in hospitals, USD 51.94 (16.20) to USD 60.35 (17.73). Inpatient costs were the major 
driver costs for the difference observed between hospitals and health centres. Less 
standardized inpatient costs are established by each hospital and health centre and take into 
account a number of parameters, which include cost of labour, and the organisation of the 
health service. Since it was not possible to analyse all patient costs, particularly the cost 
related to supportive measures and the presence of co-morbidities, the total treatment costs are 
clearly underestimated. For the purpose of this study, a new vial of quinine was used for every 
dose, but this is not necessarily the case in the real world. As a result, drug costs were likely 
overestimated. However, not all sessions of drug preparation and administration were 
included due to understaffed health centres and the inability to reliably observe the most 
severe cases in need of prompt treatment.  
 
The results show that the overall time spent on pre-administration tasks and on direct post-
treatment patient care was slightly lower in the artesunate compared to the quinine group. 
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Although statistically significant, this time difference is smaller than expected considering 
that artesunate is easier to use. This could be explained by the fact that health personnel had a 
limited time to get used to preparing and administering artesunate before starting patient 
enrolment in the second phase. Therefore, it could be that the overall difference in the pre-
administration times will increase over time, in favour of artesunate. The overall personnel 
time spent on patient care was lower with artesunate administration compared to quinine. This 
is likely to have resulted in more time to care for other patients, leading to a positive effect on 
the overall quality of care. This was consistent with health care providers’ higher satisfaction 
when using artesunate, as described elsewhere (Ntuku et al, in prep).  
 
5.6 Conclusions 
This study provides for the first time descriptive evidence of the effectiveness and 
practicability of using injectable artesunate for treating severe malaria in hospitals and health 
centres in the DRC. For most operational and cost parameters, injectable artesunate was found 
to be superior to injectable quinine. Combined with its higher efficacy, these findings support 
the rapid switchover in the country. These findings also provide some useful operational and 
cost data for national authorities and for local health care managers involved in planning the 
transition.  
 
Training health personnel is obviously a key factor for a successful transition, including a 
change in the attitudes and behaviours of providers.  
 
The MATIAS study has contributed further evidence that injectable artesunate is a better 
treatment option than injectable quinine for patients with severe malaria. The findings suggest 
that transition to the new drug should be accelerated as quickly as possible. The Ministry of 
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Health of the DRC is currently scaling up the use of injectable artesunate in the public sector, 
with the support of the GFATM and the other partners, which will enable 100% coverage of 
in-patient cases within a three-year period.  
 
Delayed anaemia after treatment with injectable artesunate in DRC 
96 
 
6 Delayed anaemia after treatment with injectable artesunate in 
the Democratic Republic of Congo: a manageable issue 
 
Christian Burri
1,2
, Giovanfrancesco Ferrari
1,2
, Henry Maggi Ntuku
3
, Antoinette Tshefu 
Kitoto
3
, Stephan Duparc
4
, Pierre Hugo
4
, Didier Kalemwa Mitembo
1,2
, and Christian 
Lengeler
1,2 
 
1 
Swiss Tropical and Public Health Institute, P.O. Box, 4002, Basel, Switzerland 
2 
University of Basel, Basel, Switzerland 
3 
Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo  
4 
Medicines for Malaria Venture, Geneva, Switzerland 
 
 
 
 
 
This paper has been published in the American Journal of Tropical Medicine 2014, 91:821-
823 
 
 
 
 
Delayed anaemia after treatment with injectable artesunate in DRC 
97 
 
6.1 Abstract 
Cases of delayed haemolytic anaemia have been described after treatment with injectable 
artesunate, the current World Health Organization (WHO)–recommended first-line drug for 
the treatment of severe malaria. A total of 350 patients (215 [61.4%] < 5 years of age and 135 
[38.6%] ≥ 5 years of age) were followed-up after treatment with injectable artesunate for 
severe malaria in hospitals and health centres of the Democratic Republic of the Congo. 
Complete series of hemoglobin (Hb) measurements were available for 201 patients. A 
decrease in Hb levels between 2 and 5 g/dL was detected in 23 (11.4%) patients during the 
follow-up period. For five patients, Hb levels decreased below 5 g/dL during at least one 
follow-up visit. All cases of delayed anaemia were clinically manageable and resolved within 
one month. 
Acute Plasmodium falciparum malaria and improperly treated uncomplicated malaria can 
progress rapidly, especially in young children and almost invariably results in death (WHO, 
2006). The second edition of the WHO guidelines for the treatment of malaria updated in 
April 2011 recommends injectable artesunate for the management of severe malaria in all age 
groups and epidemiologic settings (WHO, 2011a, 2012b)
  
In early 2012, the National Malaria Control Program of the Democratic Republic of the 
Congo adopted the new guidelines. To assess the feasibility and acceptability of use of the 
new drug in the Democratic Republic of the Congo, we conducted a longitudinal operational 
study (Malaria Treatment with Injectable Artesunate [MATIAS]). 
In mid-January 2013, during the recruitment phase of MATIAS, the Centres for Disease 
Control and Prevention (CDC) reported 19 cases of delayed haemolytic anaemia in 
hyperparasitaemic travellers in the second and third weeks after treatment with parenteral 
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artesunate (CDC, 2013). The haemolysis resolved and Hb levels improved in all patients 
within 4–8 weeks after artesunate therapy. 
In view of the large scale deployment of parenteral artesunate at national level, these results 
warranted further investigations. On the basis of this report, the MATIAS protocol was 
amended to extend the follow-up of patients from 7 to 28 days after parenteral treatment with 
artesunate and to include weekly measurements of Hb levels. We present the results of a sub-
study conducted within the MATIAS study in eight sites in the Democratic Republic of the 
Congo. 
A total of 350 patients who fulfilled the WHO criteria for severe P. falciparum malaria were 
treated with intravenous artesunate (Guilin Pharmaceuticals, Shanghai, China). Details of 
history and clinical assessment obtained by local physicians and nurses were collected for all 
patients. A thick blood smear was prepared and a rapid diagnostic test was conducted at 
admission for each patient. Thereafter, a thick blood film was prepared every 12 hours during 
the first 24 hours and then every 24 hours until results were negative or patient discharge. The 
patients were treated with injectable artesunate at a dose of 2.4 mg/kg given at admission, at 
12 hours, at 24 hours, and then once a day until the patient was able to tolerate oral 
medication, in accordance with WHO recommendations. Parenteral treatment was completed 
by giving a full course of the recommended first-line oral combination therapy: artesunate 
plus amodiaquine or artemether plus lumefantrine. 
Hb levels were assessed by using a HemoCue (Ängelholm, Sweden) Hb201 plus photometer 
at hospital admission, at discharge, and at follow-up visits on days 7, 14, 21, and 28. To 
ensure proper functioning of the photometer, high and low liquid controls were tested weekly 
at each site. No additional biologic or serum markers were investigated. 
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Of 350 patients treated with intravenous artesunate, 61.4% were children 2–59 months of age. 
Four (1.1%) patients were referred to another health facility and six (1.7%) died during the 
treatment period. A total of 270 (77.1%) patients made all four scheduled follow-up visits and 
successfully completed the full clinical assessment. A total of 41 (11.7%) patients made only 
one follow-up visit, either at day 21 or at day 28, and 29 (8.3%) did not make any visit. 
Of the 270 patients seen at all planned follow-up visits, complete series of Hb measurements 
(admission, discharge, and four follow-up visits) were available for 201 (57.4%) patients. The 
proportion of severe anaemia cases at admission was 5.5% (11 patients). Among 201 patients 
with full follow-up, a delayed decrease in the Hb level (2–5 g/dL) was observed in 23 patients 
(11.4%) between day 7 and day 21 (95% confidence interval = 3.1–36.2%) treated with 
injectable artesunate. The wide confidence interval highlights the uncertainty of this estimate. 
Of these 23 patients, 5 showed a decrease in Hb levels below 5 g/dL on least one of the 
follow-up visits (Table 6.1). This decrease was observed eight days after the first dose of 
artesunate for 1 patient, 15 days after the first dose for 2 patients, and 16 days after the first 
dose for 1 patient. All four patients received a blood transfusion. A decrease was observed 23 
days after the first dose for 1 patient. All five patients had received three doses of artesunate 
except for one of the patients with anaemia on day 15, who had received 5 doses. All patients 
had completed the parenteral treatment with a full course of artesunate plus amodiaquine. For 
those patients, Hb levels increased by the day 28 clinical assessment. 
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Table 6-1: Summary data of patients presenting with life-threatening anaemia during follow-
up visits, Democratic Republic of Congo 
NA=not available
 
1
Peak parasitaemia (parasites/ µl) 
2
Parasite Clearance Time (hours) 
*The patients received a blood transfusion 
**The patient had an abscess at injection site and the Hb dropped after the incision 
 
We observed in our patients a pattern similar to that reported
4
 with respect to the time of 
occurrence of anaemia (median minimum Hb level at approximately 15 days) (Figure 6.1). 
The Hb pattern of patient 904 resembled the natural Hb course associated with malaria; the 
Hb level decreased during the first week post-treatment (early onset). Four patients showed a 
delayed decrease in the Hb level during the second or third week post-treatment with 
artesunate. Three patients showed a tendency to normalization of the Hb level by day 28. For 
patient 913, the Hb level normalized after day 28. Two of the three patients for whom 
parasitaemia results at admission were available were hyperparasitaemic, a condition reported 
to be a potential prognostic factor in a high proportion of patients with delayed haemolytic 
anaemia (CDC, 2013). No deaths were observed, and all patients fully recovered at the end of 
the follow-up period. 
 
 
Case 
no 
Age PP
1
 PCT
2
 Hb 
admissio
n (g/dl) 
Hb nadir 
(g/dl) 
Day of 
lowest 
Hb 
drop  
Hb  
at day 
28 
603 3 years 435’815 NA 9.8 4.2 23 13.0 
659 30 months 199’299 NA 10 4.2*, ** 16 9.0 
904 26 months NA 24 7.5 5.0* 8 10.5 
909 6 months 53’293 23.6 5.0* 4.0* 15 9.7 
913 8 months NA 24 9.9 4.6* 15 6.3 
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Figure 6-1: Hb time course of persons with severe anaemia at follow-up visits, Democratic 
Republic of the Congo 
 
 
 
A limitation of this study was that we had no follow-up information for 29 patients because 
the follow-up was only expanded from 7 to 28 days after the start of the study and no 
resources were available for home visits. We could therefore not ascertain whether there were 
severe haemolytic events or deaths in this group. Half of these patients came from one site 
near the border with Angola, and some of these patients might have crossed the border. 
However, the site with the largest number of patients enrolled (n = 80) had a follow-up rate of 
100%, and no cases of severe delayed anaemia or deaths were reported. In addition, three 
other sites that had 104 patients enrolled had follow-up rates of 95% and no deaths. 
Another limitation of the study was that no control group was available and no markers of 
haemolysis were investigated beyond the Hb level. Thus, it is not possible to associate the 
delayed decrease in the Hb level observed during the follow-up period with artesunate 
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treatment or disease-specific pathologic processes. In addition, the lack of a control group did 
not enable measuring the contribution of potential confounders, such as soil-transmitted 
helminth infections, or reinfections with P. falciparum within the 28-day follow-up period. 
In a recent study conducted in Gabon and Ghana, delayed haemolysis occurred in 7% of 
children treated with injectable artesunate (Rolling et al., 2014), which is consistent with our 
findings. Given that artemisinin derivatives could increase the cumulative total dose of 
artemisinins, thus contributing to an increment in the risk of delayed haemolysis, the risk 
versus benefit of using alternative antimalarial drugs should be considered. Unfortunately, 
data for hematologic follow-up of patients after antimalarial treatment are still scarce, 
including for quinine treatment. A study of imported malaria cases in the United Kingdom 
reported a decrease in Hb levels in 61% of cases 5–21 days after treatment with quinine 
(Ladhani et al., 2005). 
The proportion of patients with severe anaemia in our study groups was below 1% for the 
whole duration of the follow-up period. In all cases, delayed anaemia was clinically 
manageable with appropriate and prompt care. The outcomes of this study supports recent 
WHO recommendations (WHO, 2013a) for continued use of injectable artesunate as a life-
saving treatment and that healthcare professionals should be made aware of the potential for 
delayed haemolytic anaemia for up to one month post-treatment and encouraged to actively 
monitor patients during this period. Our data support the need for strengthening 
pharmacovigilance systems as recommended by a meeting convened by Medicines for 
Malaria Venture that involved malaria experts working in the field of severe malaria 
(Medicines for Malaria Venture (MMV)).  
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7.1 Abstract 
Background  
The Democratic Republic of the Congo (DRC) changed its national policy for the treatment of 
severe malaria in both children and adults in 2012 from intravenous quinine to injectable 
artesunate. The country is now planning to deploy nationwide injectable artesunate as the 
preferred treatment for the management of severe malaria. To support this process, we 
assessed the feasibility and acceptability of the use of injectable artesunate in the context of 
the DRC, from the perspective of both health care providers and patients/caretakers. 
Methods  
Questionnaires and observations were used to collect information from health care providers 
and patients/guardians in 8 health facilities in the Province of Kinshasa and in the Province of 
Bas-Congo  
Results  
A total of 31 health care providers and 134 patients/care takers were interviewed. Seventy five 
percent (75%) of health care providers found it less difficult to prepare injectable artesunate 
compared to quinine. None of them encountered problems during preparation and 
administration of injectable artesunate. The large majority of care providers (93%) and 
patients/care takers (93%) answered that injectable artesunate took less time than quinine to 
cure the symptoms of the patients. Twenty six (84%) health care providers reported that the 
personnel workload had diminished with the use of injectable artesunate. Seven (22.6%) 
health workers reported adverse drug reactions, of which a decrease in the hemoglobin rate 
was the most common (56%). All care providers and the majority of patients/guardians (96%, 
N=128) were either satisfied or very satisfied with injectable artesunate. 
Conclusions 
Our findings show that the use of injectable artesunate for the treatment of severe malaria is 
feasible and acceptable in the context of DRC, with appropriate training of care providers. 
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Both care providers and patients/guardians perceived injectable artesunate to be effective and 
safe, thus promoting acceptability. 
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7.2 Background 
In the Democratic Republic of the Congo (DRC), malaria is one of the leading causes of death 
in children under 5 years of age, with an estimated 9,000,000 cases and 22,000 deaths 
reported in 2012 (PNLP, 2013a). As a result, the DRC is the second country in the world in 
terms of burden of malaria (PNLP, 2013b; WHO, 2011c). For severe malaria, the case fatality 
is reaching 10% (Likwela et al., 2012).   
Severe malaria is obviously a medical emergency, and reducing its burden is currently the 
highest priority of malaria control, as evidenced by the Roll Back malaria (RBM) target of  
near-zero deaths by 2015 (Roll Back Malaria Partnership, 2011).  
 
For the management of severe malaria cases, comparative clinical trials between quinine and 
injectable artesunate have demonstrated that the treatment with artesunate was associated with 
a substantial reduction of case fatality in both children and adults (A. Dondorp et al., 2005; A. 
M. Dondorp et al., 2010; Sinclair et al., 2012). In addition, intravenous artesunate offers a 
number of programmatic advantages over quinine in terms of not requiring rate-controlled 
infusion or cardiac monitoring (WHO, 2013b). These results led to a change in the WHO 
guidelines for the treatment of severe malaria in 2011, recommending intravenous artesunate 
as the preferred treatment for severe malaria in children and adults (WHO, 2011a). As a result 
of this change, an additional 195,000 deaths could be averted every year in Africa (MMV, 
2012). 
Following the new WHO guidelines, the Programme National de Lutte contre le Paludisme 
(PNLP) of the DRC changed the national policy for the treatment of severe malaria in both 
children and adults from intravenous quinine to injectable artesunate in 2012 (PNLP, 2012). 
However, this policy change requires a number of clinical and operational adaptations, as 
quinine has been the treatment of choice for many decades. 
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One important element for a successful transition, besides logistical aspects, is that there is 
good acceptability of the new treatment by the health care providers, as well as by the 
patients.  Finally, there is also a need to determine the perceived effectiveness and safety of 
the new treatment. These factors are a prerequisite for achieving a successful rollout and 
therefore high public health impact. Here we investigate the feasibility and acceptability of 
the use of injectable artesunate in the context of the DRC, in order to identify arising issues 
and propose solutions before the start of the national roll-out.  
 
Although a number of studies have investigated the efficacy of Injectable artesunate for the 
treatment of severe malaria as well as some issues related to its use (Burri et al., 2014; 
Rolling, Agbenyega, et al., 2013; Rolling, Wichmann, et al., 2013), to our knowledge, none 
has focused so far on the feasibility of the implementation of the new IV/IM antimalarial drug 
from the perspective of care providers, as well as its acceptability from the perspective of the 
patient/caretaker.  
 
7.3 Methods 
Study sites and population 
This study was conducted between January and July 2013 as part of the MATIAS study 
(Treatment of severe malaria – An operational comparative study for the treatment of severe 
malaria between quinine and artesunate in Hospitals and Health Centres of Kinshasa and Bas 
Congo province). The MATIAS study was a non-controlled longitudinal observational 
comparative descriptive implementation study conducted in children and adults admitted with 
severe malaria to hospital and health centres. 
The study was implemented in 8 health facilities, of which 3 hospitals and 5 health centres in 
Greater Kinshasa, the capital of the DRC (Referral Hospital Roi Baudoin, Health Centre Bita, 
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Health Centre Menkao) and in the Province of Bas Congo (Referral Hospital Saint Luc 
Kisantu, Health Centre Ngeba, Referral hospital of Kimpese, Health centre Ceco, Health 
centre La Famille). Figure1 shows the location of the study sites.  
Kinshasa sites were visited by urban and semi-rural populations, whereas the Bas-Congo sites 
served largely a rural population. All sites are hyper to holoendemic for malaria and 
transmission is perennial with seasonal variation (Malaria Atlas Project, 2010; S. M. Taylor et 
al., 2011). At the time the study started, injectable artesunate had not been deployed to public 
health facilities and was not available in the private sector. 
The study was conducted in two consecutive phases; in the first phase, in the 8 selected study 
sites, a target number of 350 patients was recruited over three months, from October 2012 to 
January 2013, with intravenous quinine as the treatment drug. In the second phase, following 
the introduction of injectable artesunate the same target number of patients was recruited over 
the following three months period, from April to July 2013. Between the two phases a three 
months interval was kept in order to train the hospital and health centres healthcare providers 
in the preparation and administration of the new drug.  
The MATIAS study included four key components: (1) clinical assessment of patients, (2) a 
time and motion study, (3) financial costs, (4) feasibility and acceptability assessments 
through provider and patient/caretaker questionnaires 
The results of the first three components are reported elsewhere (Ferrari et al., 2015), while 
the results of the fourth component are reported here. 
All interviews for the feasibility and acceptability assessment were conducted during the 
second phase (Artesunate phase), since the aim was chiefly to have comparative quinine 
versus artesunate assessments. Participants belonged to two groups with separate 
questionnaires: (1) Health care providers who prescribed or administered the drug (2) Patients 
or guardians of patients who were treated with injectable artesunate in one of the study sites.  
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Training and implementation of injectable artesunate 
In preparation for the first part of the study (quinine treatment), a three-day training on study 
procedures was given to all investigators and staff involved in patient’s clinical management 
in each hospital and health centre. The training included an update of knowledge on malaria 
diagnosis and management. 
Before starting the second phase, a two-day training on the preparation and administration of 
injectable artesunate was given to all staff involved in clinical management in the study sites. 
During these sessions we used a new training tool kit provided by the Medicines for Malaria 
Venture (MMV) product development partnership (MMV). This kit consisted of a very 
detailed user guide, an explicit and straightforward job aid and a practical training video. Prior 
to patient recruitment, health care providers were allowed some time to become familiar with 
handling of the new drug under supervision.  
Injectable artesunate (Guilin Pharmaceutical Co, Ltd, Shanghai, China) was packed in boxes 
containing each 1 vial of 60 mg of artesunate powder for injection, 1 ampoule of sodium 
bicarbonate and 1 ampoule of sodium chloride. The following steps were necessary prior to 
drug injection: (1) calculation of number of vials required based on patient weight, (2) 
reconstitution of artesunate solution with sodium bicarbonate solution, (3) dilution of the 
solution with sodium chloride. 
Artesunate was given intravenously at a dose of 2.4mg/kg bodyweight at 0, 12 and 24 hours, 
and then once a day. In line with the WHO recommendations (WHO, 2013b), parenteral 
treatment was given for a minimum of 24h irrespective of the patient’s ability to tolerate oral 
medication. After completion of the injectable treatment, the patient was given a full course of 
a recommended oral artemisinin-based combination therapy. Parenteral artesunate was given 
for a maximum of 7 days, until oral treatment could be taken reliably.  
Patients were followed up at day 7, day 14, day 21 and day 28 after discharge. Artesunate was 
provided free of charge by the manufacturer (Guilin Pharmaceuticals, Shanghai, PDR China) 
Feasibility and acceptability of injectable artesunate in DRC 
110 
 
while the costs of quinine were covered by the study. Hence the treatment was free for all 
patients. In each site the study recruited local clinicians to manage patients, while the research 
team carried out a weekly supervision at each study site throughout the duration of the study. 
The National Malaria Control Program provided political support. All authorizations for drug 
importation were obtained from the Ministry of Health through the National Drug Authority. 
All relevant authorities were actively involved in the planning of the study and preliminary 
results of the study were shared and discussed during stakeholders meetings. Unpublished 
preliminary results of the study were used by the National Malaria Control Program to 
develop training manuals for healthcare providers and communication tools in prevision of 
deployment of injectable artesunate.   
 
Data collection 
Two questionnaires were used to collect data. Interviews were conducted by nine trained 
interviewers recruited from the local community. Two of them were physicians, 4 were nurses 
and 3 were social workers. These interviewers were supervised by study field scientists. A 
three-day training was given to all interviewers prior to data collection. The training included 
familiarization with the study tools and practicing interviews. Basic techniques of probing and 
recording responses were also discussed during the training. Interview guides were developed 
and pre-tested prior to use.  
Interviews with care providers focused on ease of application and drug handling, perceived 
safety of the treatment, quality of the patient management, perception of old versus new 
treatment on staff work load, and level of satisfaction with the new treatment. The core 
questions of the interviews compared injectable artesunate and quinine. While obviously there 
could have been a recall bias due to the fact that the interviews were done during the 
artesunate phase of the study, about 3-6 months after the quinine phase, this should not have 
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been too much of an issue since quinine has been used for decades in the DRC, and all health 
care providers were very familiar with it.  
 
Interviews with patients / caregivers focused on the perception of the effectiveness and safety 
of injectable artesunate, especially with regard to adverse events. Here recall bias could have 
been more of an issue since patients were less familiar with quinine. In order to minimize this 
problem, one inclusion criterion for the interviews of patients/caretakers was a past 
experience with quinine treatment, either for themselves or for one member of the family.   
Interviews were conducted in French, the official language in DR Congo or in Lingala and 
Kikongo, the national languages spoken in Kinshasa and Bas–Congo, respectively. Interviews 
typically lasted from a minimum of twenty to a maximum of thirty minutes. Multiple choice 
closed-ended questions were followed by open-ended questions to collect narratives 
responses.  All answers were written down in French by the interviewers. 
 
Ethics 
The MATIAS study protocol was reviewed and approved by the ethics committee of the 
Kinshasa School of Public Health (University of Kinshasa) and by the ethics commission of 
both cantons of Basel, EKBB (Ethikkommission beider Basel) in Switzerland. Informed 
consent was obtained from health care providers, patients and care givers who participated in 
the study.  
 
Data processing 
Data were entered electronically using Epi data 3.1 (Epidata Association; Odense, Denmark). 
After standard quality control checks, data were transferred to Stata version 12 (Stata 
Corporation; College Station, Texas) for analysis. Qualitative data were summarized in 
emerging themes and presented as proportions of different variables. Some answers are 
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reported as narratives. Categorical variables were compared using pearson’s Chi square test or 
fisher’s exact test in case the expected value of any of the cells of the table was less than 5.   
A p-value ≤0.05 was considered as statistically significant. 
 
7.4 Results 
Health care providers 
Key results of interviews with health care providers are summarized in Table 7.1. A total of 
31 health care providers were interviewed, whereby medical doctors and nurses accounted for 
22.6% (7/31) and 77.4% (24/31) of the interviewed personnel, respectively. The median 
number of providers interviewed per health facility was four, ranging from three to five per 
facility. The majority of the personnel interviewed (28/31, 90.3%) had more than three years 
of working experience, whilst three individuals (9.7%) had one to three years experience. 
None of the health care providers interviewed had used injectable artesunate before the 
beginning of the study. 
Table 7-1: Summary of interviews with health care providers 
Question / Parameter 
 
Frequency 
 
Percentage 
 
Did you find more or less difficult to prepare artesunate 
compared to quinine (N=24)?   
 More difficult 3 12.5 
 Same difficulty 3 12.5 
 Less difficult 18 75 
Have you noticed any adverse effect that you think could be 
related to artesunate (N=31)?   
 Yes 7 22.6 
 No 24 77.4 
Do you think that the workload has reduced with artesunate 
compare to quinine (N=31)?   
 The workload has diminished  26 83.9 
 The workload is the same 4 12.9 
 The workload has increased 1 3.2 
What is your level of satisfaction with injectable artesunate 
(N=31)?    
 Satisfied 12 38.7 
 Very satisfied 19 61.3 
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# No answer was given for the category “dissatisfied”. 
 
Ease of use 
Questions related to the handling of the drug were only asked to the 24 nurses who were 
responsible for the drug preparation and administration. 
Compared to quinine, eighteen (75%) of all interviewed nurses reported to have spent less 
time to prepare and administer injectable artesunate, three (12.5%) spent more time and three 
(12.5%) said to have spent the same time. Eighteen (75%) found less difficult to prepare 
injectable artesunate compared to quinine, three (12.5%) found more difficult and three 
reported to have experienced the same difficulty. All those who found it more difficult to 
prepare injectable artesunate compared to quinine specified that too many steps were needed 
in artesunate preparation. For patients above 50 kg body weight, a minimum of 3 vials are 
needed for a single dose and obviously this increased the time spent in drug preparation since 
each vial must be opened and reconstituted separately. 
All interviewed nurses involved in the administration of the treatment found it less difficult to 
administer artesunate compared to quinine. The most important reasons cited by the 
respondents were the rapid way of administration (48.4%), no accidents related to infusion 
(35.5%) and the reduced patient monitoring time (16.1%). None of the nurses interviewed 
encountered problems during drug preparation and drug administration. 
All patients’ files reviewed during supervision visits showed that health care providers 
handled and administered the drug according to recommendations in terms of dosing and time 
of administration. 
 
Perceived effectiveness and safety 
Regarding the time to observe the effects of injectable artesunate on their patients, twenty 
eight (93.3%) health workers reported that it took less time compared to quinine, one (3.3%) 
estimated it took the same time and one (3.3%) estimated it took more time. Thirty (96.7%) 
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health care providers reported to be very satisfied with the capacity of injectable artesunate to 
cure the symptoms of their patients compared to quinine, one (3.2%) experienced the same 
satisfaction level, and none found AS less satisfactory. 
Seven (22.6%) health workers reported to have noticed adverse drug reactions: The most 
common ones mentioned were a decrease of hemoglobin rate (55.6%), shivering following 
the drug injection (33.3%) and loss of weight (11.1%). However, all the seven health care 
providers who reported adverse drug reactions answered that they were less frequent than 
those observed with quinine (data not shown). 
 
Patient management 
The majority (96.8%) of health care providers reported to have dedicated less time for patient 
monitoring after administration of artesunate compared to quinine. This proportion was not 
significantly different according to the type of health facility (hospitals vs. health centres; 
p=0.388 Fisher’s exact test). Of all health care providers interviewed, twenty six (83.9%) 
reported that the personnel workload had diminished with the use of injectable artesunate, 
four (12.9%) reported the workload to be the same, while one (3.2%) reported that the 
workload had increased (Table 7.1). The most important reasons for reported workload 
reductions were reduced patient monitoring time (47.9%), gain of time by health personnel 
(43.8%) and shorter treatment duration (8.3%). A reason reported by one health care provider 
from Ngeba Health Centre for workload increase was increased patient monitoring time. 
 
Care providers general satisfaction 
When health care providers were asked about their level of satisfaction with injectable 
artesunate they were either satisfied (38.7%, 12/31) or very satisfied (61.3%, 19/31) with the 
new treatment, with nobody giving a negative feedback (Table 7.1). Reasons for being 
satisfied/very satisfied were lack of side effects (22.4%), rapid action of the drug (19.7%), the 
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easy way to prepare and administer the drug (11,8%) and injectable artesunate being more 
effective (11.8%) compared to quinine. The level of satisfaction towards injectable artesunate 
was not significantly different among type of health facility (hospitals vs. health centres; 
p=0.452 Fisher’s exact test) and health care providers (medical doctors vs. nurses; p=0.384 
Fisher’s exact test).  
 
A nurse said about Injectable artesunate: “… I am very satisfied, it makes work easier, we 
have good time management, patient monitoring has been improved, there are no side effects, 
it has reduced mortality rate among children treated, the drug has attracted many patients to 
come to our health facility”. 
 
A medical doctor stated: “very satisfied ... it responds well, no side effects, but there’s a risk 
of a high cost because it is so precise and easier to use that such a product can only be more 
expensive than quinine. .. Good outcome after treatment” 
 
Patients or caretakers 
Results of interviews with patients/caretakers are summarized in Table 7.2. A total of 134 
patients/care takers were interviewed (124 care takers and 10 patients aged 12 years or older). 
There were more female (73.3%, 96/134) than male (26.7%, 35/134) respondents (p-
value<0.05). Of the 124 care takers interviewed, seventy six (61.3%) were mothers of 
patients, thirty three (26.6%) were fathers, fourteen (11.3%) were other members of the 
family and the remaining one (0.8%) was another member of the neighbourhood who 
accompanied a 2 years old female patient at Ceco Health Centre. 
 
Effectiveness and safety 
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With regards to the time needed for injectable artesunate to cure the symptoms of the patients, 
the large majority of respondents (93.3%, N=125) felt that it took less time compared to 
quinine, while eight (5.9%) respondents said it took the same time and one (0.7%) more time. 
Forty six (34.6%) respondents reported to have noticed adverse events; asthenia (42.6%) and 
loss of appetite (10.3%) were the most common ones, while eighty seven (65.4%) did not 
report any complication. The proportion of care takers/patients reporting adverse events was 
not significantly different from that of care providers (p-value=0.2). Statistical analysis 
showed no significant difference in the occurrence of adverse events between patients under 
and above five years of age (p-value=0.687). Of those who reported to have noticed adverse 
events, twenty seven (65.9%) considered that they were less than those observed with quinine, 
while seven (17.1%) and one (2.4%) said respectively they are the same and more than those 
observed with quinine.  Six (14.6%) did not know. Given the point made above on recall bias, 
these results should be interpreted with some caution. 
 
Satisfaction 
Regarding general satisfaction towards the ability of injectable artesunate to cure the 
symptoms that motivated the patients’ consultation, the vast majority of patients/care takers 
(95.5%, N=128) reported to have been either satisfied or very satisfied. Six (4.5%) reported 
being less satisfied than with quinine, of whom three reported persistent fever as a main 
reason for their dissatisfaction, while two (33.3%) reported asthenia and dizziness. One 
respondent said he did not know what could be the long term side effects of this new drug. 
Patients/care takers level of satisfaction was not significantly different among type of health 
facility they consulted. (P-value=0.46, Fisher’s exact test) and patient’s age (p-value=0.77 
Fisher’s exact test). When asked if they would choose or recommend again injectable 
artesunate over quinine next time for themselves or a family member, the majority of 
respondents (97.7%) said they would choose injectable artesunate. The most important 
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reasons for choosing artesunate were rapid action (35.3%), no or less adverse events(33.4%), 
shorter treatment course and shorter hospital stay (19.9%). 
 
A mother said: “This is a short duration treatment, the symptoms disappear quickly. There is 
less manipulation compared to quinine, where you have to be in bed for 4 hours of infusion 
but with this treatment, just a few minutes of injection. This drug takes less time compared to 
quinine and there are no side effects. I think it is better suited to malaria treatment for 
children” 
A young mother said: “Very satisfied - After the first injection, my child was doing fine 
already. The fever had dropped quickly. The treatment duration is very short. We stayed for a 
short time at the hospital”. 
 
Table 7-2: Summary of interviews with patients/caretakers 
Question / Parameter Frequency Percentage 
Have you noticed any side effect that you think could be 
related to artesunate? 
      Yes 46 34.3 
    No 88 65.7 
If you had to make the choice in the future between quinine 
and artesunate, which one would you choose? (N=121) 
  
    Quinine 4 3.3 
    Artesunate 117 96.7 
Most important reasons for choosing injectable artesunate 
instead of injectable quinine (N=117) 
  
    Rapid action  55 35.3 
    No side effects 38 24.4 
    Short treatment course 24 15.4 
    Less side effects 14 9.0 
    Rapid way of administration  13 8.3 
    Short hospital stay 7 4.5 
    More efficacious 5 3.2 
What is your level of satisfaction towards injectable 
artesunate? 
      Dissatisfied 6 4.5 
    Satisfied 66 49.2 
    Very satisfied 62 46.3 
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7.5 Discussion 
This study was designed to assess the feasibility and acceptability of the implementation of 
IV/IM artesunate from the perspective of care providers, as well as its acceptability versus 
quinine treatment from the perspective of the patients / caretakers.  
Results clearly show that utilization of injectable artesunate for the treatment of severe 
malaria in the context of the DRC is feasible and very well accepted. Patients/caretakers were 
very receptive to the new drug as it is perceived as being highly efficacious. Despite a few 
number of health providers reporting that several steps were needed in the preparation of 
artesunate, the handling of the drug was perceived to be easy. The vast majority of providers 
reported to have spent less time in this task. This is consistent with the results of quantitative 
measures of time and motion reported by Ferrari et al., which showed that the overall 
cumulative staff time dedicated to drug pre-administration tasks was 20 minutes for quinine 
compared to 13 minutes for artesunate. This difference is expected to improve in favour of the 
latter with health personnel gaining more experience (Ferrari et al., 2015). 
Drug formulation had a significant impact on the duration of the preparation and 
administration. The drug used in the study was packaged in vials of 60 mg which, when 
reconstituted, was equivalent to 6 ml of solution for intravenous route. For an average 60 kg 
body weight adult, this equates to prepare 3 vials and repeating three times all steps of 
preparation, resulting in a longer preparation time. On the other hand, this drug formulation 
may cause significant drug wastage especially in small children who need small quantities. As 
the reconstituted solution is stable for only one hour, and that an opened vial cannot be 
reused, it is possible to lose up to more than half of the vial. In the context of limited 
resources, it is important that drug manufacturers develop adapted and easy-to-use forms of 
injectable artesunate. 
The observations that health providers reported the use of artesunate to be easy and less time 
is required for patient management compared to quinine are in related to the characteristics of 
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the two drugs. Contrary to artesunate, the administration of quinine requires special 
precautions because of its potential toxicity, and close monitoring of the patient as the risk of 
incorrect dosage and side effects are common (AlKadi, 2007; W. R. Taylor & White, 2004; 
WHO, 2013b; Wolf et al., 1992). 
 
The superior efficacy of injectable artesunate compared to intravenous quinine in the 
management of severe malaria has been demonstrated in clinical trials (A. Dondorp et al., 
2005; Dondorp et al., 2010; Sinclair et al., 2012). Because of its small scale nature based on 
purposive sampling, this study cannot draw a conclusion on the effectiveness of injectable 
artesunate. However, both health care providers and patients/guardians perceive artesunate to 
be highly efficacious. 
 
Findings of this study are consistent with what is known so far about the better short term 
safety of artesunate compared to quinine (Sam-Wobo et al., 2012; Sinclair et al., 2012), the 
most common adverse events reported by health workers was a decrease in haemoglobin, a 
fact supporting recent findings on the occurrence of delayed anaemia after parenteral 
artesunate for severe malaria (Ferrari et al., 2015; Rolling et al., 2014; Rolling et al., 2013). 
However, the training received by health workers before the implementation of artesunate had 
an emphasis on the monitoring of adverse events and especially a drop in hemoglobin, and 
this may have influenced the frequency of reporting.  
The majority of interview questions were comparative between quinine and artesunate and 
since artesunate was implemented second, this could have led to a recall bias, especially for 
interviews with patients/care takers. The inclusion criterion of past experience with quinine 
treatment, either for themselves or for one member of the family was made to minimize this 
issue.  
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The design with a lack of concurrent controls and the relatively small scale nature of the study 
constitute a limitation to the generalizability of findings. Thus, the results of this study cannot 
be used to draw conclusion on the safety of intravenous artesunate, but rather only as 
supportive evidence to the acceptability of the new treatment.  
 
One of the major challenges in switching from quinine to injectable artesunate is adherence of 
practitioners. Health workers may be reluctant to switch to a new treatment (MSF, 2011). In 
our study, the majority of health care providers were not aware of the latest evidence on safety 
and efficacy. It is important to promote the benefits of injectable artesunate among health 
workers and train them well in the use of the new treatment. The new treatment guidelines 
should be included in training curricula in medical and nursing schools and public awareness 
of the new drug should be raised through effective communication canals.  
 
Our findings showed that the use of injectable artesunate for the treatment of severe malaria is 
feasible and acceptable in the context of the DRC and has the potential of improving the 
quality of patient management, and thus improving outcome of this life threatening condition. 
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8 General discussion and conclusions 
The main purpose of the first part of this thesis was to update data on the prevalence of 
malaria among children aged six to 59 months in Kinshasa, the capital city of the Democratic 
Republic of the Congo (DRC), as well as to compile a comprehensive report on ongoing 
malaria control activities. Because Kinshasa has been expanding very rapidly over the past 
twenty years and the last epidemiological study dates back to 2000 (Kazadi et al., 2004), the 
updating of these data is urgently required. The first comprehensive map of malaria risk at the 
scale of the health area in greater Kinshasa is now available.  
Generally, our findings, as described in Chapter 3, emphasise that the prevalence of malaria 
has decreased in Kinshasa over the last thirty years, and that the risk is higher in the peri-
urban areas of recent occupation. At the same time, malaria control activities in Kinshasa 
have made significant progress in key malaria indicators compared to the DHS 2007 results 
(DHS-DRC, 2007). Nevertheless, ITN coverage is still too low in the less accessible areas on 
the periphery. Based on these results a number of suggestions for future research and 
interventions in urban malaria control were made. 
In Chapter 4, a logistic regression analysis describes the contribution of various risk factors 
for Plasmodium infection in both children aged six to 59 months and individuals older than 
five years, and how these vary with varying prevalence in Kinshasa. In particular we observed 
that the effect of age and reported history of fever varied according to transmission setting. 
We observed a shift in the peak prevalence of malaria towards the older age groups, 
especially in the low transmission setting. For children under five years of age, the highest 
prevalence was observed in the 48 to 59 months group in both transmission settings but it 
increased more gradually for the lower transmission HZs (p = 0.009). In a separate analysis in 
children over five years in two selected HZs, the peak prevalence was in five to nine year-olds 
in the higher transmission setting and in 15 to 19 year-olds in the lower transmission setting. 
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Reported fever in the last two weeks increased the risk of having malaria in all age groups in 
all transmission settings. In addition, ITN usage was associated with a lower risk of malaria 
infection in children six to 59 months. Similar estimates were found in children over five 
years and the lower transmission HZ but the associations there were not significant. There 
was no evidence of a difference in these associations by strata. Finally, the risk of having 
anaemia decreased with increasing age, but was found to increase with malaria and reported 
fever. Socioeconomic status was also associated with the risk of having malaria and anaemia.  
This thesis also aimed at proving the feasibility of using injectable artesunate for the treatment 
of severe malaria among health facilities in the DRC (Chapter 5), and to provide a cost 
estimate from the provider perspective at different levels of the health system. The DRC is 
one of the countries with the highest burden of severe cases of malaria and the rapid 
nationwide deployment of the new treatment is urgently required. We also assessed the 
perceived feasibility and acceptability of the new drug from both the health care and patient 
perspective. The results showed that injectable artesunate can be successfully offered by 
health care providers in hospitals and health centres in the DRC, with a reduced cost 
compared to quinine and with high acceptability by both patients and health-care providers. 
Although limited in design, the sub-study conducted in the frame of the MATIAS study 
described in Chapter 6, indicates a decrease in the hb levels during the seven to 21 days post-
artesunate treatment. 
 
8.1 Prospects for future research on risk map data  
Continued routine malaria prevalence surveys are recommended to update the city malaria 
risk map in order to monitor progress in malaria control. Additional cross-sectional surveys 
carried out during the wet and dry seasons and covering Greater Kinshasa, done in a 
standardised way, could highlight differences in seasonal prevalence patterns. In the dry 
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season, malaria prevalence, although generally not very seasonal in areas of high transmission 
(Smith et al. 1993), can be much lower in areas of low transmission than in the wet season. 
Many surveys are carried out during the peak transmission season, potentially introducing a 
bias and this needs to be accounted for (Gemperli et al., 2006). Our risk map covers cross-
sectional data from two different time periods and seasons and we have standardised malaria 
prevalence to allow a comparison and to reduce potential differences resulting from different 
seasons or years. We documented an increase in prevalence from the dry season in the year 
2009 to the rainy season in the year 2011 in the HZ of Selembao (from 14.1 to 26.8%). 
However, we could not ascertain whether this reflected a true seasonal increase in the 
frequency of the disease or a between-year natural evolution of malaria transmission.  
By using the Inverse Distance Weighting (IDW) spatial interpolation technique in ArcGIS 
10.3 (Esri, Redlands CA), the distribution pattern of malaria prevalence was smoothed in the 
Kinshasa area. The IDW technique uses prevalence values in locations that are nearby to 
predict prevalence in unsampled locations, based on the assumption that, on average, 
neighbouring points have similar values (Messina et al., 2011). However, given the 
complexity of malaria transmission, additional environmental covariates could improve the 
accuracy of predicted risk maps. Hence, a possible extension for our analysis would be to 
develop a risk map including such environmental variables.  
 
8.2 Prospects for malaria control in Kinshasa 
The prevalence of malaria is highly dependent on the EIR (Beier et al., 1999), as well as other 
factors such as socioeconomic status, use of personal protective measures, the availability of 
effective treatment, urbanisation and age (Geissbuhler et al., 2007). Frequency, longevity of 
infection and disease outcomes are also interrelated (Smith et al., 2005). These factors could 
be important for explaining the heterogeneous infection patterns observed in the more central 
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urbanised areas of Kinshasa, based on experience obtained from other urban settings in Africa 
(Caldas de Castro et al., 2004; Keiser et al., 2004; Matthys et al., 2006; Staedke et al., 2003; 
Wang et al., 2005). Future malaria control measures will require adopting policies based on 
the specific context and the ecology of transmission to best target populations at higher risk.  
In the DRC, existing distribution programmes are scaling up ITN with the support of many 
partners. The high coverage of ITNs (78.7%) seen in the 2009 survey has almost certainly 
contributed to a decrease in malaria transmission. In certain peripheral districts of Kinshasa, 
however, access to ITNs is still limited (Kikimi 37.0%; Byiela 34.4%; Kimbanseke 31.0%). 
The overall reduction of 27% in ITN ownership between the two surveys stresses the well-
known issue of net coverage decay and calls for stronger programmes for routine ITN 
distribution in order to maintain coverage between campaigns. Our estimate is slightly above 
the expected 20% loss of nets in the second year post campaign, as assumed by the RBM 
Harmonisation Group. Currently, the NMCP recommends replacing nets every three years 
(PNLP, 2013a). In addition, complementary distribution measures (keep-up strategies) should 
be considered, in particular targeting the less accessible health areas (Grabowsky et al., 2007; 
Lengeler et al., 2007). It is evident that net attrition begins a few months after distribution 
campaigns, either because nets deteriorate or are given away, or because of population growth 
(Ochomo et al., 2013; Zhou et al., 2014). In addition, strengthening ITN distribution through 
antenatal care would likely increase the still too low utilisation rate among pregnant women.  
Our findings indicate that history of fever has a low positive predictive value in identifying 
children with malaria in urban settings, consistent with results from other large cities in sub-
Saharan Africa (Pond, 2013; Wang et al., 2006; Wang et al., 2005). This leads to 
overtreatment and a waste of resources and exposes patients to unnecessary side effects or to 
the risk of not being treated correctly for an alternative cause of fever (D'Acremont et al., 
2010; Wang et al., 2006). In case of fever in Kinshasa, it is common practice by caregivers to 
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initially treat their child at home (54% of the cases) and private drug outlets represent the 
principal source of drugs (96.3% of all obtained drugs).  
The high proportion of asymptomatic infections, particularly in older children and adults in 
high-transmission areas, plays a fundamental role in ensuring transmission in these areas 
(Greenwood et al., 1987). In order to reduce further the risk of transmission and hence 
parasitaemia, additional control measures including environmental management and 
larviciding could be beneficial. Very little research has been done on larval ecology and 
control in Kinshasa, and the last entomological studies on vectors date back to the end of the 
1980s (Coene, 1993). Larval control should be considered an integral part of vector control 
programmes to prevent remaining transmission, including outdoor biting, together with a 
good vector monitoring system (Sharp et al., 2007). Larviciding could be feasible particularly 
in those central urban areas where prevalence is low and breeding sites are easily detectable. 
Larviciding has proven to be cost-effective for urban malaria control (Maheu-Giroux & 
Castro, 2014) but it remains to be established whether this approach would be feasible in 
Kinshasa. Finally, there are studies reporting exophagic behaviour in Anopheles species in 
urban Africa (Geissbuhler et al., 2007; Oyewole & Awolola, 2006) and this has clear 
implications for personal protection through ITN use. 
The current malaria information system in DRC is based on passive detection of clinical 
malaria cases; hence asymptomatic individuals are not detected and dealt with. More 
measures targeting parasites in asymptomatic populations could be effective in addition to 
early diagnosis and treatment. The identification of clusters of asymptomatic carriers could be 
particularly useful in areas of the city where transmission has decreased to the point where no 
further progress can be expected using existing measures (Bautista et al., 2006; Ernst et al., 
2006; Gaudart et al., 2006). In such areas a small fraction of human hosts is likely to maintain 
transmission during the low transmission season (Clark et al., 2008; Mwangi et al., 2008; 
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Smith et al., 2005; Trape et al., 2002). Possible approaches to targeting parasite reservoirs 
include school surveys to identify possible hotspots in the community (Bousema et al., 2012). 
Furthermore, sensitive serological markers have been shown to be promising in defining 
small-scale variations in malaria exposure and in guiding targeted malaria control efforts 
(Bousema et al., 2010).  
 
8.3 Prospects for the implementation of injectable artesunate in the DRC 
There have been concerns that malaria control could lead to an increase in the number of 
cases of severe malaria in older age groups following a decline in transmission and the later 
acquisition of immunity (Carneiro et al., 2010; Ceesay et al., 2008; Griffin et al., 2015; Robert 
et al., 2003; Schellenberg et al., 2004). The observation of increased risk of malaria in older 
age groups in Kinshasa seems to point in this direction, and highlights the need for a more 
equal distribution of ITNs.  
Our findings also point to increased attention being paid to severe malaria in older individuals 
and the fact that injectable artesunate has been clearly shown to be highly efficacious, 
acceptable and cost-effective in the treatment of this condition is a positive development. 
Operational research has helped to define the way in which an intervention of proven efficacy 
(Dondorp et al., 2010) can be implemented in settings of routine care (Bedelu et al., 2007; 
Culbert et al., 2007; Van Griensven et al., 2008; Zachariah et al., 2009).  
 
8.4 Challenges to the introduction of injectable artesunate in the DRC setting 
There may nevertheless be obstacles that could hinder the nationwide implementation of 
injectable artesunate. Firstly, the correct management of cases of severe malaria can be 
challenging in resource-limited settings (Achan et al., 2011; Losimba Likwela et al., 2012). In 
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DRC the percentage of children with severe malaria who are correctly managed is still very 
low (PNLP, 2013a). In Nigeria, the first country in Africa to officially adopt injectable 
artesunate in April 2011, low knowledge about severe malaria among health workers was a 
key challenge (unpublished information, Medicines for Malaria Venture [MMV]). 
Distinguishing severe malaria from other febrile infection can be difficult in the absence of 
laboratory confirmation, leading to under- or over-reporting of number of cases of severe 
malaria (Makani et al., 2003; Mudenda et al., 2011; Snow et al., 1992). Hence, the provision 
of an effective treatment will only have an impact on clinical outcome if it is accompanied by 
improvements in the management of severe malaria (Achan et al., 2011). This will be 
particularly relevant at the peripheral health care level, where nurses are mainly responsible of 
the provision of care. In addition, a large proportion of severe malaria illnesses and death 
occur in people’s home, without coming to the attention of a formal health service 
(Greenwood et al., 1987; Mudenda et al., 2011; WHO, 2014). Re-training and updating the 
knowledge of clinical health workers on severe malaria diagnosis and case management will 
be critical to successful implementation, as will be the better engagement of caretakers of 
children and the community at large.  
Improving laboratory capacity to either properly prepare thick blood smears or introduce 
reliable RDTs will increase the reliability of the results, which is likely to be low in the DRC 
setting (Mukadi et al., 2011). Children with delayed haemolysis seem to have in common 
higher parasitaemia. Hence, correctly measuring the level of parasitaemia could be helpful in 
dealing with the risk of delayed haemolysis following artesunate therapy (Jaureguiberry et al., 
2014; Rolling, Agbenyega, et al., 2013; Rolling et al., 2012; Zoller et al., 2011).  
Secondly, in endemic countries, post-discharge complications may remain undetected due to 
deficiencies in health care (Cramer et al., 2011; Rolling et al., 2014). This could explain why 
no cases of late onset anaemia/haemolysis have been reported from pharmacovigilance 
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systems in endemic areas so far (to the WHO centre in Uppsala, Sweden). A study done in 
Gabon and Ghana showed that delayed haemolysis occurred with a frequency of 7% among 
children treated with injectable artesunate, with clinically relevant consequences for one 
patient who required multiple blood transfusions (Rolling et al., 2014). MMV has proposed 
that haematological parameters and serological markers of haemolysis should be assessed 
weekly on days 0, 3, 7, 14, 21 and 28 to ascertain potential changes in hb levels (MMV 
Expert Meeting, Vienna). However, at present it is unclear how realistic this recommendation 
is, given the deficiencies in the laboratory systems at peripheral level. Our findings show that 
it can be feasible provided that patients receive transportation vouchers and other incentives 
to encourage them to make follow-up visits. Clearly, pharmacovigilance systems should be 
strengthened at country level with a strong involvement of the WHO Programme for 
International Drug Monitoring, to improve the detection of adverse events following the use 
of artesunate. In addition, further research is needed to understand the pathophysiological 
mechanism of delayed haemolysis and to define the frequency and magnitude of this event, 
and possibly be able to prevent it in the future.  
Thirdly, in our study, injectable artesunate vials were donated by Guillin Pharmaceuticals and 
were consistently available; hence we could not investigate issues of drug stock out, which 
represent a major constraint in managing malaria and other diseases in the DRC. 
Strengthening the supply chain will therefore be critical to a successful implementation. 
Fourthly, adherence of the health personnel to the new policy can also be challenging. For 
example, many factors are linked to the persistently low use of ACTs, despite a policy of 
general ACT use since 2005, with the consequence that chloroquine and oral quinine are still 
widely used (ACT Watch report). Reluctance to change among health staff was observed on 
the ground during preliminary visits to selected health centres for this study. Qualitative 
findings from Chapter 5 indicate a high level of acceptance of the new drug by health care 
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providers, following a carefully planned introduction of the new drug and consistent 
availability. Similarly, patients showed a high level of acceptance, and those who could recall 
previous treatment with injectable quinine perceived the new drug as a more effective 
treatment compared to quinine. Hence, promoting the benefits of injectable artesunate to 
clinicians and patients by providing additional arguments in situations where the health staff 
are reluctant to accept the change of treatment will be a key step in the dissemination of the 
new policy.  
Fifthly, financial costs are a highly sensitive aspect for governments and international buyers. 
Findings from Chapter 3 provide a cost estimate for treating a case of severe malaria in real 
situations, and the fact that injectable artesunate is not more expensive when considering all 
costs should be useful and assist in the calculation of the national financial requirements 
required for its introduction. Training, communication supervision and monitoring should be 
included in the procurement costs (unpublished Stakeholders’ Meeting Report).  
Owing to the urgency to fit the results of the MATIAS study into the implementation plan of 
the Ministry of Health, the study was small in terms of the number of facilities surveyed. 
Consequently, the generalisability of the findings may be compromised as a result of the 
heterogeneity within of the facilities and whether these facilities are representative within and 
outside the DRC. 
Despite these shortcomings, however, our results clearly support the need for the rapid 
adoption of injectable artesunate as a life-saving treatment by malaria endemic countries as 
recommended by the WHO. Currently, a large initiative supported by UNAID is supporting 
the procurement and introduction of injectable artesunate in the DRC, and hence the prospects 
are good for the improved treatment of severely ill children in the country. 
References 
130 
 
9 References 
Achan, J., Tibenderana, J., Kyabayinze, D., Mawejje, H., Mugizi, R., Mpeka, B., Talisuna, A., 
& D'Alessandro, U. (2011). Case management of severe malaria--a forgotten practice: 
experiences from health facilities in Uganda. PLoS One, 6(3), e17053.  
Afrane, Y. A., Klinkenberg, E., Drechsel, P., Owusu-Daaku, K., Garms, R., & Kruppa, T. 
(2004). Does irrigated urban agriculture influence the transmission of malaria in the 
city of Kumasi, Ghana? Acta Trop, 89(2), 125-134.  
Alirol, E., Getaz, L., Stoll, B., Chappuis, F., & Loutan, L. (2011). Urbanisation and infectious 
diseases in a globalised world. Lancet Infectious Diseases, 11(2), 131-141.  
AlKadi, H. O. (2007). Antimalarial drug toxicity: a review. Chemotherapy, 53(6), 385-391.  
Alves, F. P., Durlacher, R. R., Menezes, M. J., Krieger, H., Silva, L. H., Camargo, E. P 
(2002). High prevalence of asymptomatic Plasmodium vivax and Plasmodium 
falciparum infections in native Amazonian populations. Am J Trop Med Hyg, 66: 641–
648. 
Awolola, T. S., Oduola, A. O., Obansa, J. B., Chukwurar, N. J., & Unyimadu, J. P. (2007). 
Anopheles gambiae s.s. breeding in polluted water bodies in urban Lagos, 
southwestern Nigeria. J Vector Borne Dis, 44(4), 241-244.  
Ayele, D. G., Zewotir, T. T., & Mwambi, H. G. (2012). Prevalence and risk factors of malaria 
in Ethiopia. Malar J, 11, 195.  
Baird, J. K., Bangs, M. J., Maguire, J. D., & Barcus, M. J. (2002). Epidemiological measures 
of risk of malaria. Methods Mol Med, 72, 13-22.  
Balarajan, Y., Ramakrishnan, U., Ozaltin, E., Shankar, A. H., & Subramanian, S. V. (2011). 
Anaemia in low-income and middle-income countries. Lancet, 378(9809), 2123-2135.  
Barbazan, P., Baldet, T., Darriet, F., Escaffre, H., Djoda, D. H., & Hougard, J. M. (1998). 
Impact of treatments with Bacillus sphaericus on Anopheles populations and the 
transmission of malaria in Maroua, a large city in a savannah region of Cameroon. J 
Am Mosq Control Assoc, 14(1), 33-39.  
Batra, C. P., Adak, T., Sharma, V. P., & Mittal, P. K. (2001). Impact of urbanization on 
bionomics of An. culicifacies and An. stephensi in Delhi. Indian J Malariol, 38(3-4), 
61-75.  
References 
131 
 
Bautista, C. T., Chan, A. S., Ryan, J. R., Calampa, C., Roper, M. H., Hightower, A. W., & 
Magill, A. J. (2006). Epidemiology and spatial analysis of malaria in the Northern 
Peruvian Amazon. Am J Trop Med Hyg, 75(6), 1216-1222.  
Bedelu, M., Ford, N., Hilderbrand, K., & Reuter, H. (2007). Implementing antiretroviral 
therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. J 
Infect Dis, 196 Suppl 3, S464-468.  
Beier, J. C., Killeen, G. F., & Githure, J. I. (1999). Short report: entomologic inoculation rates 
and Plasmodium falciparum malaria prevalence in Africa. Am J Trop Med Hyg, 61(1), 
109-113.  
Biemba, G., Dolmans, D., Thuma, P. E., Weiss, G., & Gordeuk, V. R. (2000). Severe anaemia 
in Zambian children with Plasmodium falciparum malaria. Trop Med Int Health, 5(1), 
9-16.  
Bousema, T., Drakeley, C., Gesase, S., Hashim, R., Magesa, S., Mosha, F., Otieno, S., 
Carneiro, I., Cox, J., Msuya, E., Kleinschmidt, I., Maxwell, C., Greenwood, B., Riley, 
E., Sauerwein, R., Chandramohan, D., & Gosling, R. (2010). Identification of hot 
spots of malaria transmission for targeted malaria control. J Infect Dis, 201(11), 1764-
1774.  
Bousema, T., Griffin, J. T., Sauerwein, R. W., Smith, D. L., Churcher, T. S., Takken, W., 
Ghani, A., Drakeley, C., & Gosling, R. (2012). Hitting hotspots: spatial targeting of 
malaria for control and elimination. PLoS Med, 9(1), e1001165.  
Brabin, B. J., Premji, Z., & Verhoeff, F. (2001). An analysis of anaemia and child mortality. J 
Nutr, 131(2S-2), 636S-645S; discussion 646S-648S.  
Brooker, S., Akhwale, W., Pullan, R., Estambale, B., Clarke, S. E., Snow, R. W., & Hotez, P. 
J. (2007). Epidemiology of plasmodium-helminth co-infection in Africa: populations 
at risk, potential impact on anaemia, and prospects for combining control. Am J Trop 
Med Hyg, 77(6 Suppl), 88-98.  
Burri, C., Ferrari, G., Ntuku, H. M., Kitoto, A. T., Duparc, S., Hugo, P., Mitembo, D. K., & 
Lengeler, C. (2014). Delayed anaemia after treatment with injectable artesunate in the 
democratic republic of the congo: a manageable issue. Am J Trop Med Hyg, 91(4), 
821-823.  
Byrne, N. (2007). Urban malaria risk in sub-Saharan Africa: where is the evidence? Travel 
Med Infect Dis, 5(2), 135-137.  
References 
132 
 
Caldas de Castro, M., Yamagata, Y., Mtasiwa, D., Tanner, M., Utzinger, J., Keiser, J., & 
Singer, B. H. (2004). Integrated urban malaria control: a case study in dar es salaam, 
Tanzania. Am J Trop Med Hyg, 71(2 Suppl), 103-117.  
Carneiro, I., Roca-Feltrer, A., Griffin, J. T., Smith, L., Tanner, M., Schellenberg, J. A., 
Greenwood, B., & Schellenberg, D. (2010). Age-patterns of malaria vary with 
severity, transmission intensity and seasonality in sub-Saharan Africa: a systematic 
review and pooled analysis. PLoS One, 5(2), e8988.  
CDC. (2013). Published reports of delayed hemolytic anaemia after treatment with artesunate 
for severe malaria--worldwide, 2010-2012. MMWR Morbidity Mortality Weekly 
Report, 62(1), 5-8.  
Ceesay, S. J., Casals-Pascual, C., Erskine, J., Anya, S. E., Duah, N. O., Fulford, A. J., Sesay, 
S. S., Abubakar, I., Dunyo, S., Sey, O., Palmer, A., Fofana, M., Corrah, T., Bojang, K. 
A., Whittle, H. C., Greenwood, B. M., & Conway, D. J. (2008). Changes in malaria 
indices between 1999 and 2007 in The Gambia: a retrospective analysis. Lancet, 
372(9649), 1545-1554.  
Clark, T. D., Greenhouse, B., Njama-Meya, D., Nzarubara, B., Maiteki-Sebuguzi, C., 
Staedke, S. G., Seto, E., Kamya, M. R., Rosenthal, P. J., & Dorsey, G. (2008). Factors 
determining the heterogeneity of malaria incidence in children in Kampala, Uganda. J 
Infect Dis, 198(3), 393-400.  
Coene, J. (1993). Malaria in urban and rural Kinshasa: the entomological input. Med Vet 
Entomol, 7(2), 127-137.  
Cramer, J. P., Lopez-Velez, R., Burchard, G. D., Grobusch, M. P., & de Vries, P. J. (2011). 
Treatment of imported severe malaria with artesunate instead of quinine--more 
evidence needed? Malar J, 10, 256.  
Culbert, H., Tu, D., O'Brien, D. P., Ellman, T., Mills, C., Ford, N., Amisi, T., Chan, K., & 
Venis, S. (2007). HIV treatment in a conflict setting: outcomes and experiences from 
Bukavu, Democratic Republic of the Congo. PLoS Med, 4(5), e129.  
D'Acremont, V., Lengeler, C., & Genton, B. (2010). Reduction in the proportion of fevers 
associated with Plasmodium falciparum parasitaemia in Africa: a systematic review. 
Malar J, 9, 240.  
D’Ascenzo, F. (2010). La territorialità urbana a Kinshasa. Università degli Studi di Padova.  
De Beaudrap, P., Nabasumba, C., Grandesso, F., Turyakira, E., Schramm, B., Boum, Y., 2nd, 
& Etard, J. F. (2011). Heterogeneous decrease in malaria prevalence in children over a 
six-year period in south-western Uganda. Malar J, 10, 132.  
References 
133 
 
de Benoist, B., Fontaine, O., Lynch, S., & Allen, L. (2007). Report of the world health 
organization technical consultation on prevention and control of iron deficiency in 
infants and young children in malaria-endemic areas - Foreword. Food and Nutrition 
Bulletin, 28(4), S489-S490.  
de Maximy, R., 1975, Site général, in: J. Flouriot, R. de Maximy, M. Pain, Atlas de Kinshasa, 
Kinshasa, Institut Géographique du Zarïe (IGZ), Bureau d’Études d’Aménagement du 
territoire. (1975).  
Demographia (2014). World Urban Areas. 10th Ed. May 2014 Revision.  
Dempster TE (1848). Notes on the application of the test of organic disease of the spleen, as 
an easy and certain method of detecting malarious localities in hot climates, Agra. 
(reprint in Rec Malar Surv India; 1930; 1: 69).  
Desai, M. R., Terlouw, D. J., Kwena, A. M., Phillips-Howard, P. A., Kariuki, S. K., 
Wannemuehler, K. A., Odhacha, A., Hawley, W. A., Shi, Y. P., Nahlen, B. L., & Ter 
Kuile, F. O. (2005). Factors associated with hemoglobin concentrations in pre-school 
children in Western Kenya: cross-sectional studies. Am J Trop Med Hyg, 72(1), 47-59.  
DHS-DRC (2007). Demographic and Health Survey Ministère du plan, Measure DHS.  
DHS-DRC (2013). Demographic and Health Survey. Ministère du plan, Measure DHS.  
Dondorp, A., Nosten, F., Stepniewska, K., Day, N., & White, N. (2005). Artesunate versus 
quinine for treatment of severe falciparum malaria: a randomised trial. Lancet, 
366(9487), 717-725.  
Dondorp, A. M., Fanello, C. I., Hendriksen, I. C., Gomes, E., Seni, A., Chhaganlal, K. D., 
Bojang, K., Olaosebikan, R., Anunobi, N., Maitland, K., Kivaya, E., Agbenyega, T., 
Nguah, S. B., Evans, J., Gesase, S., Kahabuka, C., Mtove, G., Nadjm, B., Deen, J., 
Mwanga-Amumpaire, J., Nansumba, M., Karema, C., Umulisa, N., Uwimana, A., 
Mokuolu, O. A., Adedoyin, O. T., Johnson, W. B., Tshefu, A. K., Onyamboko, M. A., 
Sakulthaew, T., Ngum, W. P., Silamut, K., Stepniewska, K., Woodrow, C. J., Bethell, 
D., Wills, B., Oneko, M., Peto, T. E., von Seidlein, L., Day, N. P., & White, N. J. 
(2010). Artesunate versus quinine in the treatment of severe falciparum malaria in 
African children (AQUAMAT): an open-label, randomised trial. Lancet, 376(9753), 
1647-1657.  
Ekvall, H. (2003). Malaria and anaemia. Curr Opin Hematol, 10(2), 108-114.  
Ernst, K. C., Adoka, S. O., Kowuor, D. O., Wilson, M. L., & John, C. C. (2006). Malaria 
hotspot areas in a highland Kenya site are consistent in epidemic and non-epidemic 
years and are associated with ecological factors. Malar J, 5, 78.  
References 
134 
 
Ferrari, G., Ntuku, H. M., Burri, C., Tshefu, A. K., Duparc, S., Hugo, P., Mitembo, D. K., 
Ross, A., Ngwala, P. L., Luwawu, J. N., Musafiri, P. N., Ngoie, S. E., & Lengeler, C. 
(2015). An operational comparative study of quinine and artesunate for the treatment 
of severe malaria in hospitals and health centres in the Democratic Republic of Congo: 
the MATIAS study. Malar J, 14(1), 226.  
Filmer, D., & Pritchett, L. H. (2001). Estimating wealth effects without expenditure data--or 
tears: an application to educational enrollments in states of India. Demography, 38(1), 
115-132.  
Gahutu, J. B., Steininger, C., Shyirambere, C., Zeile, I., Cwinya-Ay, N., Danquah, I., Larsen, 
C. H., Eggelte, T. A., Uwimana, A., Karema, C., Musemakweri, A., Harms, G., & 
Mockenhaupt, F. P. (2011). Prevalence and risk factors of malaria among children in 
southern highland Rwanda. Malar J, 10, 134.  
Gaudart, J., Poudiougou, B., Dicko, A., Ranque, S., Toure, O., Sagara, I., Diallo, M., 
Diawara, S., Ouattara, A., Diakite, M., & Doumbo, O. K. (2006). Space-time 
clustering of childhood malaria at the household level: a dynamic cohort in a Mali 
village. BMC Public Health, 6, 286.  
Geissbuhler, Y., Chaki, P., Emidi, B., Govella, N. J., Shirima, R., Mayagaya, V., Mtasiwa, D., 
Mshinda, H., Fillinger, U., Lindsay, S. W., Kannady, K., de Castro, M. C., Tanner, M., 
& Killeen, G. F. (2007). Interdependence of domestic malaria prevention measures 
and mosquito-human interactions in urban Dar es Salaam, Tanzania. Malar J, 6, 126. 
Gemperli, A., Sogoba, N., Fondjo, E., Mabaso, M., Bagayoko, M., Briet, O. J., Anderegg, D., 
Liebe, J., Smith, T., & Vounatsou, P. (2006). Mapping malaria transmission in West 
and Central Africa. Trop Med Int Health, 11(7), 1032-1046.  
Gillies MT, & de Meillon B. (1968). The Anophelinae of Africa South of the Sahara. 
Publications of the South African Institute forMedical Research, no. 54, 
Johannesburg, South Africa.  
Grabowsky, M., Nobiya, T., & Selanikio, J. (2007). Sustained high coverage of insecticide-
treated bednets through combined Catch-up and Keep-up strategies. Trop Med Int 
Health, 12(7), 815-822.  
Greenberg, A. E., Ntumbanzondo, M., Ntula, N., Mawa, L., Howell, J., & Davachi, F. (1989). 
Hospital-based surveillance of malaria-related paediatric morbidity and mortality in 
Kinshasa, Zaire. Bull World Health Organ, 67(2), 189-196.  
Greenwood, B. M., Bradley, A. K., Greenwood, A. M., Byass, P., Jammeh, K., Marsh, K., 
Tulloch, S., Oldfield, F. S., & Hayes, R. (1987). Mortality and morbidity from malaria 
References 
135 
 
among children in a rural area of The Gambia, West Africa. Trans R Soc Trop Med 
Hyg, 81(3), 478-486.  
Griffin, J. T., Hollingsworth, T. D., Reyburn, H., Drakeley, C. J., Riley, E. M., & Ghani, A. 
C. (2015). Gradual acquisition of immunity to severe malaria with increasing 
exposure. Proc Biol Sci, 282(1801).  
Guerra, C. A., Gikandi, P. W., Tatem, A. J., Noor, A. M., Smith, D. L., Hay, S. I., & Snow, R. 
W. (2008). The limits and intensity of Plasmodium falciparum transmission: 
implications for malaria control and elimination worldwide. PLoS Med, 5(2), e38.  
Guerra, C. A., Hay, S. I., Lucioparedes, L. S., Gikandi, P. W., Tatem, A. J., Noor, A. M., & 
Snow, R. W. (2007). Assembling a global database of malaria parasite prevalence for 
the Malaria Atlas Project. Malar J, 6, 17.  
Hall, A., Latham, M. C., Crompton, D. W., Stephenson, L. S., & Wolgemuth, J. C. (1982). 
Intestinal parasitic infections of men in four regions of rural Kenya. Trans R Soc Trop 
Med Hyg, 76(6), 728-733.  
Harris I, Sharrock, W. W., Bain, L. M., Gray, K. A., Bobogare, A., Boaz, L., Lilley, K., 
Krause, D., Vallely, A., Johnson, M. L., Gatton, M. L., Shanks, G. D., Cheng, Q. 
(2010). A large proportion of asymptomatic Plasmodium infections with low and sub-
microscopic parasite densities in the low transmission setting of Temotu Province, 
Solomon Islands: challenges for malaria diagnostics in an elimination setting. Malar J, 
9, 254. 
Hay, S. I., Guerra, C. A., Tatem, A. J., Atkinson, P. M., & Snow, R. W. (2005). Urbanization, 
malaria transmission and disease burden in Africa. Nat Rev Microbiol, 3(1), 81-90.  
Hay, S. I., Rogers, D. J., Toomer, J. F., & Snow, R. W. (2000). Annual Plasmodium 
falciparum entomological inoculation rates (EIR) across Africa: literature survey, 
Internet access and review. Trans R Soc Trop Med Hyg, 94(2), 113-127.  
Hotez, P. J., & Molyneux, D. H. (2008). Tropical anaemia: one of Africa's great killers and a 
rationale for linking malaria and neglected tropical disease control to achieve a 
common goal. PLoS Negl Trop Dis, 2(7), e270.  
Idro, R., Aloyo, J., Mayende, L., Bitarakwate, E., John, C. C., & Kivumbi, G. W. (2006). 
Severe malaria in children in areas with low, moderate and high transmission intensity 
in Uganda. Trop Med Int Health, 11(1), 115-124.  
Jaureguiberry, S., Ndour, P. A., Roussel, C., Ader, F., Safeukui, I., Nguyen, M., Biligui, S., 
Ciceron, L., Mouri, O., Kendjo, E., Bricaire, F., Vray, M., Angoulvant, A., Mayaux, 
J., Haldar, K., Mazier, D., Danis, M., Caumes, E., Thellier, M., & Buffet, P. (2014). 
References 
136 
 
Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect 
of artemisinins. Blood, 124(2), 167-175.  
Karch, S., Asidi, N., Manzambi, Z. M., & Salaun, J. J. (1992). [The Anopheles fauna and the 
transmission of human malaria in Kinshasa (Zaire)]. Bull Soc Pathol Exot, 85(4), 304-
309.  
Kazadi, W., Sexton, J. D., Bigonsa, M., W'Okanga, B., & Way, M. (2004). Malaria in primary 
school children and infants in kinshasa, democratic republic of the congo: surveys 
from the 1980s and 2000. Am J Trop Med Hyg, 71(2 Suppl), 97-102.  
Keiser, J., Utzinger, J., Caldas de Castro, M., Smith, T. A., Tanner, M., & Singer, B. H. 
(2004). Urbanization in sub-saharan Africa and implication for malaria control. Am J 
Trop Med Hyg, 71(2 Suppl), 118-127.  
Kinshasa, Ville de Kinshasa 
http://www.kinshasa.cd/index.php?option=com_content&view=article&id=300&Itemi
d=146].  
Klinkenberg, E., McCall, P., Wilson, M. D., Amerasinghe, F. P., & Donnelly, M. J. (2008). 
Impact of urban agriculture on malaria vectors in Accra, Ghana. Malar J, 7, 151. 
Knudsen, A. B., & Slooff, R. (1992). Vector-borne disease problems in rapid urbanization: 
new approaches to vector control. Bull World Health Organ, 70(1), 1-6.  
Korenromp, E. L., Armstrong-Schellenberg, J. R., Williams, B. G., Nahlen, B. L., & Snow, R. 
W. (2004). Impact of malaria control on childhood anaemia in Africa - a quantitative 
review. Trop Med Int Health, 9(10), 1050-1065.  
Kottek, M., Greiser, J., Beck, C., Rudolf, B., Rubel, F. (2006): World Map of the Köppen-
Geiger climate classification updated. Meteorol Z, 15:259-263 
Kyaw, S. S., Drake, T., Ruangveerayuth, R., Chierakul, W., White, N. J., Newton, P. N., & 
Lubell, Y. (2014). Cost of treating inpatient falciparum malaria on the Thai-Myanmar 
border. Malar J, 13, 416.  
Ladhani, S., Patel, V. S., El Bashir, H., & Shingadia, D. (2005). Changes in laboratory 
features of 192 children with imported falciparum malaria treated with quinine. 
Pediatr Infect Dis J, 24(11), 1017-1020.  
Lengeler, C. (2004). Insecticide-treated bed nets and curtains for preventing malaria. 
Cochrane Database Syst Rev(2), CD000363.  
Lengeler, C., Grabowsky, M., McGuire, D., & deSavigny, D. (2007). Quick wins versus 
sustainability: options for the upscaling of insecticide-treated nets. Am J Trop Med 
Hyg, 77(6 Suppl), 222-226.  
References 
137 
 
Lindsay, S. W., & Martens, W. J. (1998). Malaria in the African highlands: past, present and 
future. Bull World Health Organ, 76(1), 33-45.  
Losimba Likwela, J., D'Alessandro, U., Donnen, P., & Wilmet Dramaix, M. (2012). Clinical 
aspects and outcome of suspected severe pediatric malaria. Med Mal Infect, 42(7), 
315-320.  
Lubell, Y., Mills, A. J., Whitty, C. J., & Staedke, S. G. (2010). An economic evaluation of 
home management of malaria in Uganda: an interactive Markov model. PLoS One, 
5(8), e12439.  
Lubell, Y., Riewpaiboon, A., Dondorp, A. M., von Seidlein, L., Mokuolu, O. A., Nansumba, 
M., Gesase, S., Kent, A., Mtove, G., Olaosebikan, R., Ngum, W. P., Fanello, C. I., 
Hendriksen, I., Day, N. P., White, N. J., & Yeung, S. (2011). Cost-effectiveness of 
parenteral artesunate for treating children with severe malaria in sub-Saharan Africa. 
Bull World Health Organ, 89(7), 504-512.  
Lubell, Y., Yeung, S., Dondorp, A. M., Day, N. P., Nosten, F., Tjitra, E., Abul Faiz, M., 
Yunus, E. B., Anstey, N. M., Mishra, S. K., Mohanty, S., White, N. J., & Mills, A. J. 
(2009). Cost-effectiveness of artesunate for the treatment of severe malaria. Trop Med 
Int Health, 14(3), 332-337.  
Macdonald, G. (1957). The epidemiology and control of malaria. London. Oxford University 
Press, 201.  
Machault, V., Gadiaga, L., Vignolles, C., Jarjaval, F., Bouzid, S., Sokhna, C., Lacaux, J. P., 
Trape, J. F., Rogier, C., & Pages, F. (2009). Highly focused anopheline breeding sites 
and malaria transmission in Dakar. Malar J, 8, 138.  
Maheu-Giroux, M., & Castro, M. C. (2014). Cost-effectiveness of larviciding for urban 
malaria control in Tanzania. Malar J, 13, 477.  
Makani, J., Matuja, W., Liyombo, E., Snow, R. W., Marsh, K., & Warrell, D. A. (2003). 
Admission diagnosis of cerebral malaria in adults in an endemic area of Tanzania: 
implications and clinical description. QJM, 96(5), 355-362.  
Malaria Atlas Project. (2010). Democratic Republic of Congo, Malaria risk. 2010.  
MARA/ARMA (1998). Towards an Atlas of Malaria Risk in Africa. First technical report of 
the MARA/ARMA collaboration (www.mara.org.za) South Africa.  
Marsh, K., Forster, D., Waruiru, C., Mwangi, I., Winstanley, M., Marsh, V., Newton, C., 
Winstanley, P., Warn, P., Peshu, N., & et al. (1995). Indicators of life-threatening 
malaria in African children. N Engl J Med, 332(21), 1399-1404.  
References 
138 
 
Martens, P., & Hall, L. (2000). Malaria on the move: human population movement and 
malaria transmission. Emerg Infect Dis, 6(2), 103-109.  
Matangila, J. R., Doua, J. Y., Linsuke, S., Madinga, J., Inocencio da Luz, R., Van 
Geertruyden, J. P., & Lutumba, P. (2014). Malaria, schistosomiasis and soil 
transmitted helminth burden and their correlation with anaemia in children attending 
primary schools in Kinshasa, Democratic Republic of Congo. PLoS One, 9(11), 
e110789.  
Mathanga, D. P., Campbell, C. H., Jr., Vanden Eng, J., Wolkon, A., Bronzan, R. N., Malenga, 
G. J., Ali, D., & Desai, M. (2010). Comparison of anaemia and parasitaemia as 
indicators of malaria control in household and EPI-health facility surveys in Malawi. 
Malar J, 9, 107.  
Matthys, B., Vounatsou, P., Raso, G., Tschannen, A. B., Becket, E. G., Gosoniu, L., Cisse, G., 
Tanner, M., N'Goran E, K., & Utzinger, J. (2006). Urban farming and malaria risk 
factors in a medium-sized town in Cote d'Ivoire. Am J Trop Med Hyg, 75(6), 1223-
1231.  
Messina, J. P., Taylor, S. M., Meshnick, S. R., Linke, A. M., Tshefu, A. K., Atua, B., 
Mwandagalirwa, K., & Emch, M. (2011). Population, behavioural and environmental 
drivers of malaria prevalence in the Democratic Republic of Congo. Malar J, 10, 161.  
Metselaar, D., & Van Thiel, P. (1959). Classification of malaria. Trop Geogr Med, 11, 157–
161.  
MMV (2013) Expert group meeting on the safety profile of injectable artesunate. Medicines 
for Malaria Venture; Vienna; 2013.  
MMV Medicines for Malaria Venture. Available at http://www.mmv.org/access/injectable-
artesunate-tool-kit. Retrieved 04 September 2014 
MMV (2012). Saving more lives with artesunate injectable. Injectable Artesunate 
Stakeholders’ Meeting Report. Geneva. Medicines for Malaria Venture. Available at: 
http://www.mmv.org/sites/default/files/uploads/docs/publications/Injectable%20Artes
unate%20Stakeholders%20Meeting%20Report.pdf [accessed 03.06.15]).  
Modiano, D., Sirima, B. S., Sawadogo, A., Sanou, I., Pare, J., Konate, A., & Pagnoni, F. 
(1998). Severe malaria in Burkina Faso: influence of age and transmission level on 
clinical presentation. Am J Trop Med Hyg, 59(4), 539-542.  
Modiano, D., Sirima, B. S., Sawadogo, A., Sanou, I., Pare, J., Konate, A., & Pagnoni, F. 
(1999). Severe malaria in Burkina Faso: urban and rural environment. Parassitologia, 
41(1-3), 251-254.  
References 
139 
 
MSF (2011). Making the Switch. Ensuring access to improved treatment for severe malaria in 
Africa. Médecins Sans Frontières. Geneva; 2011.  
MSH (2014). International Drug Price Indicator Guide, 2013 Edition. Medford: Mass: 
Management Science for Health; 2014. Updated annually.  
Mudenda, S. S., Kamocha, S., Mswia, R., Conkling, M., Sikanyiti, P., Potter, D., Mayaka, W. 
C., & Marx, M. A. (2011). Feasibility of using a World Health Organization-standard 
methodology for Sample Vital Registration with Verbal Autopsy (SAVVY) to report 
leading causes of death in Zambia: results of a pilot in four provinces, 2010. Popul 
Health Metr, 9, 40.  
Mukadi, P., Gillet, P., Lukuka, A., Atua, B., Kahodi, S., Lokombe, J., Muyembe, J. J., & 
Jacobs, J. (2011). External quality assessment of malaria microscopy in the 
Democratic Republic of the Congo. Malar J, 10, 308.  
Mulumba, M. P., Wery, M., Ngimbi, N. N., Paluku, K., Van der Stuyft, P., & De Muynck, A. 
(1990). [Childhood malaria in Kinshasa (Zaire). Influence of seasons, age, 
environment, and family social conditions]. Med Trop (Mars), 50(1), 53-64.  
Mwangi, T. W., Fegan, G., Williams, T. N., Kinyanjui, S. M., Snow, R. W., & Marsh, K. 
(2008). Evidence for over-dispersion in the distribution of clinical malaria episodes in 
children. PLoS One, 3(5), e2196.  
Nations, U. World Urbanization Prospects, the 2014 revision. Department of Economic and 
Social Affairs, Population Division.  
Ngimbi, N. P., Beckers, A., & Wery, M. (1982). [Survey of the epidemiological status of 
malaria in Kinshasa (Republic of Zaire) in 1980]. Ann Soc Belg Med Trop, 62(2), 121-
137.  
Nguyen-Dinh P, Schwartz IK, Sexton JD, Bomboto E, Botomwito B, Kalisa R, Ngimbi NP, 
& Wery M. (1985). In vivo and in vitro susceptibility to chloroquine of Plasmodium 
falciparum in Kinshasa and Mbuji-Mayi, Zaire. Bull World Health Organ, 63, 325–
330.  
Nicastri, E., Bevilacqua, N., Sane Schepisi, M., Paglia, M. G., Meschi, S., Ame, S. M., 
Mohamed, J. A., Mangi, S., Fumakule, R., Di Caro, A., Capobianchi, M. R., Kitua, A., 
Molteni, F., Racalbuto, V., Ippolito, G. (2009). Accuracy of malaria diagnosis by 
microscopy, rapid diagnostic test, and PCR methods and evidence of antimalarial 
overprescription in nonsevere febrile patients in two Tanzanian hospitals. Am J Trop 
Med Hyg, 80, 712–717. 
OANDA. Currency Converter. http://www.oanda.com [accessed 07 August 2014].  
References 
140 
 
Ochomo, E. O., Bayoh, N. M., Walker, E. D., Abongo, B. O., Ombok, M. O., Ouma, C., 
Githeko, A. K., Vulule, J., Yan, G., & Gimnig, J. E. (2013). The efficacy of long-
lasting nets with declining physical integrity may be compromised in areas with high 
levels of pyrethroid resistance. Malar J, 12, 368.  
Okiro, E. A., Kazembe, L. N., Kabaria, C. W., Ligomeka, J., Noor, A. M., Ali, D., & Snow, 
R. W. (2013). Childhood malaria admission rates to four hospitals in Malawi between 
2000 and 2010. PLoS One, 8(4), e62214.  
Omumbo, J. A., Guerra, C. A., Hay, S. I., & Snow, R. W. (2005). The influence of 
urbanisation on measures of Plasmodium falciparum infection prevalence in East 
Africa. Acta Trop, 93(1), 11-21.  
Ong'echa, J. M., Keller, C. C., Were, T., Ouma, C., Otieno, R. O., Landis-Lewis, Z., Ochiel, 
D., Slingluff, J. L., Mogere, S., Ogonji, G. A., Orago, A. S., Vulule, J. M., Kaplan, S. 
S., Day, R. D., & Perkins, D. J. (2006). Parasiteamia, anaemia, and malarial anaemia 
in infants and young children in a rural holoendemic Plasmodium falciparum 
transmission area. Am J Trop Med Hyg, 74(3), 376-385.  
Owusu-Agyei, S., Fryauff, D. J., Chandramohan, D., Koram, K. A., Binka, F. N., Nkrumah, 
F. K., Utz, G. C., & Hoffman, S. L. (2002). Characteristics of severe anaemia and its 
association with malaria in young children of the Kassena-Nankana District of 
northern Ghana. Am J Trop Med Hyg, 67(4), 371-377.  
Oyewole, I. O., & Awolola, T. S. (2006). Impact of urbanisation on bionomics and 
distribution of malaria vectors in Lagos, southwestern Nigeria. J Vector Borne Dis, 
43(4), 173-178.  
Peel E, & van Hoof L. (1948). Le paludisme a la maternite indigene de Leopoldville. Ann Soc 
Belg Med Trop(18), 413–420.  
PMI (2015). Malaria Operational Plan FY 2015, Democratic Republic of the Congo. 
President's Malaria Initiative.  
PNLP: Guide technique de formation en prevention et prise en charge du paludisme (Hopital 
General de reference), RDC.  
PNLP (2012). Directives nationales de traitement du paludisme en République Démocratique 
du Congo (Draft). Kinshasa, Ministère de la Santé.  
PNLP (2013a). Plan Stratégique National de Lutte contre le Paludisme 2013-2015. Kinshasa; 
2013.  
PNLP (2013b). Rapport annuel d’activités 2012.  
References 
141 
 
Pond, B. S. (2013). Malaria indicator surveys demonstrate a markedly lower prevalence of 
malaria in large cities of sub-Saharan Africa. Malar J, 12, 313.  
Premji, Z., Hamisi, Y., Shiff, C., Minjas, J., Lubega, P., & Makwaya, C. (1995). Anaemia and 
Plasmodium falciparum infections among young children in an holoendemic area, 
Bagamoyo, Tanzania. Acta Trop, 59(1), 55-64.  
Premji, Z., Lubega, P., Hamisi, Y., McHopa, E., Minjas, J., Checkley, W., & Shiff, C. (1995). 
Changes in malaria associated morbidity in children using insecticide treated mosquito 
nets in the Bagamoyo district of coastal Tanzania. Trop Med Parasitol, 46(3), 147-
153.  
Reyburn, H., Mbatia, R., Drakeley, C., Bruce, J., Carneiro, I., Olomi, R., Cox, J., Nkya, W. 
M., Lemnge, M., Greenwood, B. M., & Riley, E. M. (2005). Association of 
transmission intensity and age with clinical manifestations and case fatality of severe 
Plasmodium falciparum malaria. JAMA, 293(12), 1461-1470.  
Reyburn, H., Mbatia, R., Drakeley, C., Carneiro, I., Mwakasungula, E., Mwerinde, O., 
Saganda, K., Shao, J., Kitua, A., Olomi, R., Greenwood, B. M., & Whitty, C. J. 
(2004). Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a 
prospective study. BMJ, 329(7476), 1212.  
Robert, V., Macintyre, K., Keating, J., Trape, J. F., Duchemin, J. B., Warren, M., & Beier, J. 
C. (2003). Malaria transmission in urban sub-Saharan Africa. Am J Trop Med Hyg, 
68(2), 169-176.  
Roll Back Malaria. (2014). Malaria situation and response, Democratic Republic of the 
Congo. 2014(5 Dec).  
Roll Back Malaria Partnership. (2011). Refined / Updated GMAP Objectives , Targets , 
Milestones and Priorities Beyond 2011. Geneva; 2011.  
Rolling, T., Agbenyega, T., Issifou, S., Adegnika, A. A., Sylverken, J., Spahlinger, D., 
Ansong, D., Lohr, S. J., Burchard, G. D., May, J., Mordmuller, B., Krishna, S., 
Kremsner, P. G., & Cramer, J. P. (2013). Delayed hemolysis after treatment with 
parenteral artesunate in African children with severe malaria - a double-center 
prospective study. J Infect Dis.  
Rolling, T., Agbenyega, T., Issifou, S., Adegnika, A. A., Sylverken, J., Spahlinger, D., 
Ansong, D., Lohr, S. J., Burchard, G. D., May, J., Mordmuller, B., Krishna, S., 
Kremsner, P. G., & Cramer, J. P. (2014). Delayed Hemolysis After Treatment With 
Parenteral Artesunate in African Children With Severe Malaria--A Double-center 
Prospective Study. J Infect Dis.  
References 
142 
 
Rolling, T., Schmiedel, S., Wichmann, D., Wittkopf, D., Burchard, G. D., & Cramer, J. P. 
(2012). Post-treatment haemolysis in severe imported malaria after intravenous 
artesunate: case report of three patients with hyperparasitaemia. Malar J, 11, 169.  
Rolling, T., Wichmann, D., Schmiedel, S., Burchard, G. D., Kluge, S., & Cramer, J. P. 
(2013). Artesunate versus quinine in the treatment of severe imported malaria: 
comparative analysis of adverse events focussing on delayed haemolysis. Malar J, 12, 
241.  
Sam-Wobo, S. O., Agbeyangi, O. A., Ekpo, U. F., Akinloye, O. A., Mafiana, C. F., & 
Adeleke, M. A. (2012). Rectal artesunates, their utilization, and parental perception in 
the management of malaria in children from Abeokuta, southwestern Nigeria. Vector 
Borne Zoonotic Dis, 12(2), 151-155.  
Sattler, M. A., Mtasiwa, D., Kiama, M., Premji, Z., Tanner, M., Killeen, G. F., & Lengeler, C. 
(2005). Habitat characterization and spatial distribution of Anopheles sp. mosquito 
larvae in Dar es Salaam (Tanzania) during an extended dry period. Malar J, 4, 4.  
Schellenberg, D., Menendez, C., Aponte, J., Guinovart, C., Mshinda, H., Tanner, M., & 
Alonso, P. (2004). The changing epidemiology of malaria in Ifakara Town, southern 
Tanzania. Trop Med Int Health, 9(1), 68-76.  
Sexton, J. D., Bigonsa, M., Okanga, B., & W. & Waty, M. (Baltimore, December 2-6 1984, 
99). The prevalence of malaria in primariy schoolchildren in Kinshasa, Zaire 
Proceeding of the Joint Meetings of the Royal and American Societies of Tropical 
Medicine and Hygiene.  
Sharp, B. L., Kleinschmidt, I., Streat, E., Maharaj, R., Barnes, K. I., Durrheim, D. N., Ridl, F. 
C., Morris, N., Seocharan, I., Kunene, S., JJ, L. A. G., Mthembu, J. D., Maartens, F., 
Martin, C. L., & Barreto, A. (2007). Seven years of regional malaria control 
collaboration--Mozambique, South Africa, and Swaziland. Am J Trop Med Hyg, 
76(1), 42-47.  
Shaukat, A. M., Breman, J. G., & McKenzie, F. E. (2010). Using the entomological 
inoculation rate to assess the impact of vector control on malaria parasite transmission 
and elimination. Malar J, 9, 122.  
Sinclair, D., Donegan, S., Isba, R., & Lalloo, D. G. (2012). Artesunate versus quinine for 
treating severe malaria. Cochrane Database Syst Rev, 6, CD005967.  
Slutsker, L., Taylor, T. E., Wirima, J. J., & Steketee, R. W. (1994). In-hospital morbidity and 
mortality due to malaria-associated severe anaemia in two areas of Malawi with 
different patterns of malaria infection. Trans R Soc Trop Med Hyg, 88(5), 548-551.  
References 
143 
 
Smith, D. L., Dushoff, J., Snow, R. W., & Hay, S. I. (2005). The entomological inoculation 
rate and Plasmodium falciparum infection in African children. Nature, 438(7067), 
492-495.  
Smith, T., Hii, J. L., Genton, B., Muller, I., Booth, M., Gibson, N., Narara, A., & Alpers, M. 
P. (2001). Associations of peak shifts in age--prevalence for human malarias with 
bednet coverage. Trans R Soc Trop Med Hyg, 95(1), 1-6.  
Snow, R. W., Armstrong, J. R., Forster, D., Winstanley, M. T., Marsh, V. M., Newton, C. R., 
Waruiru, C., Mwangi, I., Winstanley, P. A., & Marsh, K. (1992). Childhood deaths in 
Africa: uses and limitations of verbal autopsies. Lancet, 340(8815), 351-355.  
Snow, R. W., Bastos de Azevedo, I., Lowe, B. S., Kabiru, E. W., Nevill, C. G., Mwankusye, 
S., Kassiga, G., Marsh, K., & Teuscher, T. (1994). Severe childhood malaria in two 
areas of markedly different falciparum transmission in east Africa. Acta Trop, 57(4), 
289-300.  
Snow, R. W., & Marsh, K. (2002). The consequences of reducing transmission of 
Plasmodium falciparum in Africa. Adv Parasitol, 52, 235-264.  
Snow, R. W., Omumbo, J. A., Lowe, B., Molyneux, C. S., Obiero, J. O., Palmer, A., Weber, 
M. W., Pinder, M., Nahlen, B., Obonyo, C., Newbold, C., Gupta, S., & Marsh, K. 
(1997). Relation between severe malaria morbidity in children and level of 
Plasmodium falciparum transmission in Africa. Lancet, 349(9066), 1650-1654.  
Soares Magalhaes, R. J., & Clements, A. C. (2011). Spatial heterogeneity of haemoglobin 
concentration in preschool-age children in sub-Saharan Africa. Bull World Health 
Organ, 89(6), 459-468.  
Staedke, S. G., Nottingham, E. W., Cox, J., Kamya, M. R., Rosenthal, P. J., & Dorsey, G. 
(2003). Short report: proximity to mosquito breeding sites as a risk factor for clinical 
malaria episodes in an urban cohort of Ugandan children. Am J Trop Med Hyg, 69(3), 
244-246.  
Stoler, J., Weeks, J. R., Getis, A., & Hill, A. G. (2009). Distance threshold for the effect of 
urban agriculture on elevated self-reported malaria prevalence in Accra, Ghana. Am J 
Trop Med Hyg, 80(4), 547-554.  
Taylor, S. M., Messina, J. P., Hand, C. C., Juliano, J. J., Muwonga, J., Tshefu, A. K., Atua, 
B., Emch, M., & Meshnick, S. R. (2011). Molecular malaria epidemiology: mapping 
and burden estimates for the Democratic Republic of the Congo, 2007. PLoS One, 
6(1), e16420.  
References 
144 
 
Taylor, T. E., Fu, W. J., Carr, R. A., Whitten, R. O., Mueller, J. S., Fosiko, N. G., Lewallen, 
S., Liomba, N. G., & Molyneux, M. E. (2004). Differentiating the pathologies of 
cerebral malaria by postmortem parasite counts. Nat Med, 10(2), 143-145.  
Taylor, W. R., & White, N. J. (2004). Antimalarial drug toxicity: a review. Drug Saf, 27(1), 
25-61.  
ter Kuile, F. O., Terlouw, D. J., Phillips-Howard, P. A., Hawley, W. A., Friedman, J. F., 
Kolczak, M. S., Kariuki, S. K., Shi, Y. P., Kwena, A. M., Vulule, J. M., & Nahlen, B. 
L. (2003). Impact of permethrin-treated bed nets on malaria and all-cause morbidity in 
young children in an area of intense perennial malaria transmission in western Kenya: 
cross-sectional survey. Am J Trop Med Hyg, 68(4 Suppl), 100-107.  
Trape, J. F. (1987). Malaria and urbanization in central Africa: the example of Brazzaville. 
Part IV. Parasitological and serological surveys in urban and surrounding rural areas. 
Trans R Soc Trop Med Hyg, 81 Suppl 2, 26-33.  
Trape, J. F., Lefebvre-Zante, E., Legros, F., Ndiaye, G., Bouganali, H., Druilhe, P., & Salem, 
G. (1992). Vector density gradients and the epidemiology of urban malaria in Dakar, 
Senegal. Am J Trop Med Hyg, 47(2), 181-189.  
Trape, J. F., Pison, G., Spiegel, A., Enel, C., & Rogier, C. (2002). Combating malaria in 
Africa. Trends Parasitol, 18(5), 224-230.  
Trape, J. F., & Zoulani, A. (1987). Malaria and urbanization in central Africa: the example of 
Brazzaville. Part II: Results of entomological surveys and epidemiological analysis. 
Trans R Soc Trop Med Hyg, 81 Suppl 2, 10-18.  
Tshilolo, L., Aissi, L. M., Lukusa, D., Kinsiama, C., Wembonyama, S., Gulbis, B., & 
Vertongen, F. (2009). Neonatal screening for sickle cell anaemia in the Democratic 
Republic of the Congo: experience from a pioneer project on 31 204 newborns. J Clin 
Pathol, 62(1), 35-38.  
UN-HABITAT. (2003). The Challenge of Slums. Global Report on Human Settlements. 
United Nations Human Settlements Prgramme.  
UN (2014a). The State of African Cities. United Nations Human Settlements Programme. 
UN-Habitat 2014.  
UN (2014c). World Urbanization Prospects. The 2014 Revision. United Nations 2014.  
UNDP (2014). Human Development Report 2014 Sustaining Human Progress: Reducing 
Vulnerabilities and Building Resilience. United Nations Development Programme.  
UNICEF (2010). Multiple Indicator Cluster Survey (MICS), Democratic Republic of Congo, 
Preliminary Findings.  
References 
145 
 
van Griensven, J., De Naeyer, L., Uwera, J., Asiimwe, A., Gazille, C., & Reid, T. (2008). 
Success with antiretroviral treatment for children in Kigali, Rwanda: experience with 
health center/nurse-based care. BMC Pediatr, 8, 39.  
Wang, S. J., Lengeler, C., Smith, T. A., Vounatsou, P., Akogbeto, M., & Tanner, M. (2006). 
Rapid Urban Malaria Appraisal (RUMA) IV: epidemiology of urban malaria in 
Cotonou (Benin). Malar J, 5, 45.  
Wang, S. J., Lengeler, C., Smith, T. A., Vounatsou, P., Cisse, G., Diallo, D. A., Akogbeto, 
M., Mtasiwa, D., Teklehaimanot, A., & Tanner, M. (2005). Rapid urban malaria 
appraisal (RUMA) in sub-Saharan Africa. Malar J, 4, 40.  
Ward RA. (1977). Recent changes in the epidemiology of malaria relating to human ecology. 
Proceedings of the 15th International Congress of Entomology, Washington, DC, 
August 19−22, 1976. New York: Plenum Press, 523−529.  
Watts, T. E., Wray, J. R., Ng'andu, N. H., & Draper, C. C. (1990). Malaria in an urban and a 
rural area of Zambia. Trans R Soc Trop Med Hyg, 84(2), 196-200.  
WHO (2006). Guidelines for the Treatment of Malaria. Geneva: World Health Organization. 
2006. 
WHO (2007). Malaria elimination: a field manual for low and moderate endemic countries. 
Geneva: World Health Organization; 2007.  
WHO (2010). Guidelines for the Treatment of Malaria. 2nd edition. Geneva: World Health 
Organization; 2010.  
WHO (2011a). Guidelines for the Treatment of Malaria. 2nd edition. Geneva: World Health 
Organization; 2011.  
WHO (2011c). World Malaria Report. Geneva: World Health Organization; 2011.  
WHO (2012a). World Health Organization. Disease Surveillance for Malaria Control: an 
operational manual. Geneva 2012. 
http://www.who.int/malaria/surveillance_monitoring/operationalmanuals/en, accessed 
4 June 2015.  
WHO (2012b). World Malaria Report. Geneva: World Health Organization. 2012.  
WHO (2013a). Information Note on Delayed Haemolytic Anaemia following Treatment with 
Artesunate. 
http://www.who.int/malaria/publications/atoz/who_note_delayed_haemolytic_anaemi
a_oct13.pdf Accessed 16 February 2014.  
WHO (2013b). Management of severe malaria – A practical handbook. 3rd edition, Geneva, 
World Health Organization; 2013.  
References 
146 
 
WHO (2014). World Malaria Report. Geneva: World Health Organization; 2014.  
WHOPARs. World Health Organization Public Assessment Reports. 
http://apps.who.int/prequal/whopar/whoparproducts/MA051part6v1.pdf 
Winskill, P., Rowland, M., Mtove, G., Malima, R. C., & Kirby, M. J. (2011). Malaria risk 
factors in north-east Tanzania. Malar J, 10, 98.  
Wolf, L. R., Otten, E. J., & Spadafora, M. P. (1992). Cinchonism: two case reports and review 
of acute quinine toxicity and treatment. J Emerg Med, 10(3), 295-301.  
Woolhouse, M. E. (1998). Patterns in parasite epidemiology: the peak shift. Parasitol Today, 
14(10), 428-434.  
World Bank. (2013). http://data.worldbank.org/country/congo-dem-rep Accessed 04.06.2015.  
Wu, L., van den Hoogen, L. L., Slater, H., Walker, P. G., Ghani, A. C., Drakeley, C. J., Okell, 
L. C. (2015). Comparison of diagnostics for the detection of asymptomatic 
Plasmodium falciparum infections to inform control and elimination strategies. 
Nature, 528: S86–93. 
Yadouleton, A., N'Guessan, R., Allagbe, H., Asidi, A., Boko, M., Osse, R., Padonou, G., 
Kinde, G., & Akogbeto, M. (2010). The impact of the expansion of urban vegetable 
farming on malaria transmission in major cities of Benin. Parasit Vectors, 3, 118.  
Zachariah, R., Harries, A. D., Ishikawa, N., Rieder, H. L., Bissell, K., Laserson, K., 
Massaquoi, M., Van Herp, M., & Reid, T. (2009). Operational research in low-income 
countries: what, why, and how? Lancet Infectious Diseases, 9(11), 711-717.  
Zhou, G., Li, J. S., Ototo, E. N., Atieli, H. E., Githeko, A. K., & Yan, G. (2014). Evaluation 
of universal coverage of insecticide-treated nets in western Kenya: field surveys. 
Malar J, 13, 351.  
Zoller, T., Junghanss, T., Kapaun, A., Gjorup, I., Richter, J., Hugo-Persson, M., Morch, K., 
Foroutan, B., Suttorp, N., Yurek, S., & Flick, H. (2011). Intravenous artesunate for 
severe malaria in travelers, Europe. Emerg Infect Dis, 17(5), 771-777.  
 
 
 
Curriculum vitae 
147 
 
10 Curriculum vitae 
 
Giovanfrancesco Ferrari 
 
Personal Information 
Employer   Swiss Tropical and Public Health Institute (Swiss TPH) 
Profession   Biologist – PhD student 
Expertise  Molecular Biology, Biomedical Research 
Nationality   Italian 
With Swiss TPH  Since September 2009 
_________________________________________________________________________ 
Address 
Swiss Tropical and Public Health Institute (Swiss TPH) 
Health Interventions Unit 
Department of Epidemiology and Public Health 
P.O. Box  
4002 Basel/Switzerland  
Tel. business: (41) 61 284 8613  
Tel. private:  (39) 338 1986691 
Email: giovanfrancesco.ferrari@unibas.ch 
__________________________________________________________________________ 
Education/ Continued Education/ Degree 
2011 - 2015   PhD candidate in Public Health and Epidemiology (Supervisor: Christian 
Lengeler, PhD) 
2010 The price of Globalization: drug trials in resource limited settings, seminar 
(European Centre of Pharmaceutical Medicine / Swiss TPH) 
2010   Quality Assurance in Clinical Research, Kinshasa, RD Congo 
2009 United Nations Department of Safety and Security (E-courses): Basic and 
Advanced Security in the Field 
2006-2007  Postgraduate in Tropical Medicine and International Health. Prince Leopold 
Institute of Tropical Medicine, Antwerp, Belgium 
2000  University degree in Biological Sciences, Molecular Biology Major, Università 
degli Studi di Milano, 105/110 
1992  Classical High School Degree, from Liceo Classico “Alessandro Volta”, Como 
__________________________________________________________________________ 
Professional/ Work Experience 
2009-2011 Pharmaceutical Medicine Unit, Department of Medicines Research, Swiss TPH 
Research Assistant based at Swiss TPH office in Kinshasa  
Assisted in the development of the research centres of two Swiss TPH partners 
in Kinshasa, in the framework of the Alliance for Clinical Research and 
Clinical Epidemiology ARCEAU-RDC 
2009 University of Milan, Department of Clinical Sciences “L. Sacco”, Infectious 
disease Unit, Italy 
Research Assistant 
Curriculum vitae 
148 
 
Contributed to the drafting of epidemiological research projects in view of the 
Universal Exposition, EXPO’ 2015, in Milan, Italy  
Contributed to the analysis of genetic polymorphisms and lipodystrophy 
associated with antiretroviral therapy 
2008 Médecins Sans Frontières, Holland, Wardher Project, Somali region, Ethiopia.  
Lab technician supervisor 
 Organised and implemented tuberculosis laboratory activities, parasitology and 
blood transfusion unit 
2007–2008 Médecins Sans Frontières, Belgium, Gondama Referral Center, Bo, Sierra 
Leone. 
Lab technician supervisor 
Assisted in the organization and supervision of the project: Efficacy of 
Artesunate plus Amodiaquine for uncomplicated Plasmodium falciparum 
Malaria. Prospective study of children under five years in holoendemic Area 
for Malaria in Bo, Sierra Leone  
Set up of transfusion unit and the parasitology area 
2002-2006  National Neurological Institute “C. Besta”, Molecular Neurogenetics Unit, 
Milan, Italy.  
Research Assistant 
Identified and characterized nuclear disease genes responsible for 
mitochondrial disorders 
2001 University of New South Wales, Sydney, Australia. School of Biological 
Sciences.  
Research Assistant 
Conservation genetics of the Green and Golden Bell frog (Litoria aurea). 
Identified level of genetic diversity using molecular markers to develop more 
effectual strategies to preserve biodiversity 
1999-2001  Department of Physiology and General Biochemistry, Comparative 
Biochemistry, Università degli Studi di Milano 
Undergraduate student 
Dissertation project: “The effects of the deletion of the gene triosofosfate 
isomerase (TPI1) on the carbon metabolism of Kluyveromices lactis   
___________________________________________________________________________ 
Language Proficiency 
Italian   Mother tongue 
English  Fluent in spoken and written 
German  Good in spoken, basic written 
French  Good in spoken and written 
Spanish  Basic knowledge 
__________________________________________________________________________ 
Publications  
Peer Reviewed 
- A comprehensive malaria risk map in Kinshasa, Democratic Republic of 
Congo. Ferrari G, Ntuku HM, Schmidlin S, Diboulo E, Kitoto AT, Lengeler 
C, Malar J. 2016 Jan 13;15:27 
Curriculum vitae 
149 
 
- Identifying risk factors for Plasmodium infection and anaemia in Kinshasa, 
Democratic Republic of Congo. Ferrari G, Ntuku HM, Ross A, Schmidlin S, 
Kitoto AT, Lengeler C, Malar J. 2016 Jul 15;15:362 
- Feasibility and acceptability of injectable artesunate for the treatment of severe 
malaria in the Democratic Republic of Congo. Ntuku HM, Ferrari G, Burri C, 
Kitoto AT, Mitembo DK, Lengeler C, Malar J. 2016 Jan 8;15:18 
- An operational comparative study of quinine and artesunate for the treatment 
of severe malaria in hospitals and health centres in the Democratic Republic of 
Congo: the MATIAS study. Ferrari G, Ntuku HM, Burri C, Kitoto AT, 
Duparc S, Hugo P, Mitembo DK, Ross A, Ngwala PL, Luwawu JN, Musafiri 
PN, Ngoie SE, Lengeler C. Malar J. 2015 May 30;14 (1):226.  
- Delayed anaemia after treatment with injectable artesunate in the Democratic 
Republic of the Congo: a manageable issue. Burri C, Ferrari G, Ntuku HM, 
Kitoto AT, Duparc S, Hugo P, Mitembo DK, Lengeler C. Am J Trop Med Hyg 
2014, 91:821-823 
- The A467Tand W748S POLG substitutions are a rare cause of adult-onset 
ataxia in Europe. Kate Craig, G. Ferrari, W. Tiangyou, G. Hudson, C. Gellera, 
M. Zeviani and P. F. Chinnery. Brain 2007, Apr; 130POLG1 in idiopathic 
Parkinson disease.  Tiangyou W, Hudson G, Ghezzi D, Ferrari G, Zeviani M, 
Burn DJ, Chinnery PF. Neurology. 2006 Nov 14;67 :1698-700. 
- The spectrum of clinical disease caused by the A467T and the W748S POLG 
mutations: a study of 26 cases. Tzoulis C, Engelsen BA, Telstad W, Aasly J, 
Zeviani M, Winterthun S, Ferrari G, Aarseth J H Bindoff LA. Brain 2006, Jul; 
129: 1685-1692 
- Phenotypic spectrum associated with mutations of the mitochondrial 
polymerase gamma gene. Horvath R, Hudson G, Ferrari G, Futterer N, Ahola 
S, Lamantea E, Prokisch H, Lochmuller H, McFarland R, Ramesh V, 
Klopstock T, Freisinger P, Salvi F, Mayr JA, Santer R, Tesarova M, Zeman J, 
Udd B, Taylor RW, Turnbull D, Suomalainen A, Zeviani M, Chinnery PF. 
Brain 2006 Jul; 129: 1674-1684 
- Infantile hepatocerebral syndromes associated with mutations in the 
mitochondrial DNA polymerase-γA. Ferrari G, Lamantea E, Donati A, Filosto 
M, Briem E, Carrara F, Parini R, Simonati A, Santer R, Zeviani M. Brain. 2005 
Apr;128: 723-31 
- The polymorphic polyglutamine repeat in the mitochondrial DNA polymerase 
γ gene (POLG1) is not associated with oligozoospermia. Brusco A, Michielotto 
C, Gatta V, Foresta C, Matullo G, Zeviani M, Ferrari G, Dragone E, 
Calabrese G, Rossato M, Stuppia L, Migone N. J Endocrinol Invest. 2006 
Jan;29:1-4. 
- Autosomal recessive mitochondrial ataxic syndromes due to mitochondrial 
polymerase γ mutations. Winterthun S, Ferrari G, He L, Taylor RW, Zeviani 
M, Turnbull DM, Engelsen BA, Moen G, Bindoff LA Neurology. 2005 Apr 
12;64:1204-8 
- Ethylmalonic encephalopathy is caused by mutations in ETHE1, a gene 
encoding a mitochondrial matrix protein. Tiranti V, D’Adamo P, Briem E, 
Ferrari G, Mineri R, Lamantea E, Mandel H, Balestri P, Garcia-Silva MT, 
Vollmer B, Rinaldo P, Hahn SH, Leonard J, Rahman S, Dionisi-Vici C, 
Garavaglia B, Gasparini P, Zeviani M. Am J Hum Genet. 2004 Feb;74:239-52. 
- Mutations of ANT1, Twinkle, and POLG1 in sporadic progressive external 
ophthalmoplegia (PEO). Agoatino A, Valletta L, Chinnery PF, Ferrari G, 
Curriculum vitae 
150 
 
Carrara F, Taylor RW, Schaefer AM, Turnbull DM, Tiranti V, Zeviani M. 
Neurology. 2003 Apr 22; 60:1354-6 
- Microsatellite loci for the green and golden bell frog (Litoria aurea). 
Conservation Genetics. Burns, E.L., Ferrari, G. 2003. 
